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Abstract 
Chronic Myeloid Leukemia is characterised by the formation of a fusion gene bcr-
abl. The gene product BCR-ABL has deregulated tyrosine kinase activity that plays a 
direct role in the pathogenesis of the disease. Recently, use of siRNA in leukaemic 
cells has led to effective gene silencing of bcr-abl. Gene delivery systems like viral 
vectors, electroporation and lipid based vectors have showed varying efficiencies but 
are limited by their level of toxicity and immunogenicity. Developments in the field 
of Cell Penetrating Peptides have shown effective cellular uptake of nucleic acids 
and proteins by the CPPs in vitro and in vivo. Report from our lab has shown the use 
of CPP Tat along with membrane active peptide LK15 to improve the transfection 
efficiency of both Tat and LK15 peptides individually. Hence, this study will focus 
on the use of Tat-LK15 peptide to study the delivery of siRNA and shRNA plasmid 
in K562 cells and observe the BCR-ABL protein expression.  
Cellular uptake studies using Tat-LK15 based complexes of Cy5-labelled DNA and 
siRNA showed a concentration dependent uptake leading to increase in percentage 
transfected cells. Tat-LK15 based DNA complexes achieved 80% transfected cells 
(charge ratio of 2:1) while siRNA complexes resulted in a maximum of 60% (charge 
ratio of 3:1). However, Lipofectamine based DNA complexes did not show a 
concentration dependent increase in percentage transfected cells. Interestingly, Tat-
LK15 based siRNA complexes showed a similar level of uptake and percentage 
transfected cells as that of Lipofectamine based siRNA complexes.  
Cellular uptake studies using confocal microscopy 4 hours post transfection, showed 
that when 1µg of DNA was transfected, the labelled DNA was primarily localised on 
the cell membrane. Interestingly, using 5µg of DNA led to increased intracellular 
localisation of the labelled DNA, but this observation was not made with 
Lipofectamine based complexes. The observation at 24 hours post transfection of 
Tat-LK15/labelled DNA complexes was of higher intensity when compared to that of 
Lipofectamine based DNA complexes. The reason for this is however not known. 
Interestingly, the cellular uptake profile using siRNA based complexes was different. 
At 4 hours post transfection, there was intracellular localisation of labelled siRNA. 
24 hours post transfection, there was diffuse cytoplasmic localisation using lower 
concentration of siRNA whereas using higher concentration led to more high 
intensity punctate localisations within the cell. Similar observations were made for 
both Tat-LK15 and Lipofectamine based siRNA complexes. 
Gene silencing studies of Tat-LK15/shRNA plasmid complex resulted in 80% 
reduction in protein levels 96 hours post transfection for higher concentrations of 
shRNA plasmid treated. Similar level of reduction in BCR-ABL was observed with 
Lipofectamine based complex. Supporting evidence of reduction in mRNA levels 
was observed using qRT-PCR 48 hours post transfection. However, Tat-
LK15/shRNA plasmid complexes led to around 80% of protein reduction 192 hours 
post transfection while Lipofectamine based complexes resulted in only 40% of 
protein reduction. Transfection using increasing concentrations of siRNA complexed 
to Tat-LK15 and Lipofectamine led to greater than 70% reduction in protein levels 
for most concentration ranges tested. This reduction in protein levels lasted only 48 
hours post transfection. In conclusion, Tat-LK15 peptide could be used for shRNA 
plasmid and siRNA based delivery and could offer an efficient gene delivery model 
for studying RNAi. 
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Chapter 1 
Introduction 
Gene therapy is the use of oligonucleotides to correct the expression of a deficient 
gene or an abnormally expressed gene. Oligonucleotides like DNA, small interfering 
RNA (siRNA), antisense oligonucleotides can be used to target different steps of the 
gene expression. Plasmid DNA is used in general to express a particular protein to 
supplement the cell with a deficient protein expression, while in the case of highly 
expressed proteins, antisense therapy or RNA interference is used to inhibit the 
protein expression. Based on this, gene therapy has been used in clinical trials for the 
treatment of various diseases mainly geared towards the treatment of cancer 
(Edelstein et al., 2007).  The first use of a cyclodextrin based polymer to deliver 
siRNA has passed through phase I clinical trials (Davis, 2009), shows the 
possibilities of non-viral vectors for cancer gene therapy.  
 
Among the different potential targets for gene therapy Chronic Myeloid Leukemia 
(CML), characterised by the fusion gene bcr-abl which translates into the protein 
BCR-ABL, is an interesting system as it has the following features: i) BCR-ABL is 
directly associated with the leukemic condition, ii) there are established literature 
methods available for monitoring expression of BCR-ABL and iii) gene silencing of 
BCR-ABL has been documented in literature using viral and non-viral vector 
providing a platform for comparison. Even though gene therapy has been used to 
target BCR-ABL in CML cells in vitro using viral and non-viral vectors, it has led to 
only one clinical trial using SV40 viral vector carrying siRNA (Kimchi-Sarfaty et al., 
2005). However, various other viral and non-viral gene delivery vectors are currently 
being used in vitro. Of much interest to this work is the peptide based non-viral gene 
delivery vector called the Cell Penetrating Peptides (CPPs). The CPPs can be 
combined with other peptides to form multifunctional peptides. Here, we use the 
recently developed fusion peptide, Tat-LK15, which is result of the conjugation of 
Tat peptide with membrane lytic peptide LK15 (Saleh et al., 2010). This work 
focuses on the use of peptide based gene delivery system for the delivery of DNA or 
siRNA to correct the genetic abnormality associated with CML.  
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In this chapter, the CML model will be described in detail highlighting the different 
approaches that have been taken to date in relation to gene therapy. After explaining 
the physiological barriers the gene delivery systems have to overcome and the 
principles behind RNA interference, non-viral lipid and peptide based vectors will be 
reviewed with emphasis on CPPs and membrane active peptides. 
 
1.1 Chronic Myeloid Leukemia 
Chronic Myeloid Leukemia (CML) is an abnormality in the myeloid cells of the 
bone marrow leading to a high white blood cell count. Such an event can be directly 
attributed to the reciprocal translocation of the long arms of chromosomes 9 and 22. 
The resulting chromosomal abnormality, denoted as t(9:22)(q34;q11), leads to fusion 
between two genes, breakpoint cluster region (bcr) from the chromosome 22 and 
Abelson proto-oncogene (abl1) from chromosome 9, leading to the formation of bcr-
abl oncogene on the chromosome 22, as shown in Figure 1.1 (Rowley, 1973). The 
shortened chromosome 22 bearing the fusion gene is referred to as the Philadelphia 
chromosome (Ph1) (Nowell and Hungerford, 1960).  
 
 
 
Figure 1.1: Chromosomal translocation. Schematic representation of the 
Philadelphia chromosome formation. 
 
Two variants of the fusion gene sequence for bcr-abl exist, b3a2 and b2a2. The b3a2 
variant is formed by the fusion of the exon 3 of the bcr gene; similarly, the b2a2 
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variant is formed by the fusion of exon 2 of the gene. The sequences of these two 
isoforms, b3a2 and b2a2 are shown in Figure 1.2.  
 
 
Figure 1.2: Bcr-abl fusion gene sequences. a) Sequence of the b3a2 isoform of the 
bcr-abl fusion gene. b) Sequence of the b2a2 isoform of the bcr-abl fusion gene. 
Sequences obtained from the NCBI gene database. 
 
1.1.1 Mechanism of Chronic myeloid leukemia 
The abl gene encodes a non-receptor tyrosine kinase protein, ABL, which is 
ubiquitously expressed. The structure of the ABL protein encompasses for three SRC 
homology domains, SH1, SH2 and SH3. The SH1 domain has the tyrosine kinase 
activity while the SH2 and SH3 domains control the interaction with other proteins 
(Deininger et al., 2000). In particular, the SH3 domain plays a crucial role in 
controlling the kinase activity of the protein. Indeed its deletion activates a kinase 
function similar to that observed in BCR-ABL (Deininger et al., 2000). The fusion 
protein has been reported to have high tyrosine kinase activity when compared to the 
kinase activity of the parental protein c-ABL. In fact, this increased kinase function 
has been attributed to the increased cellular proliferation, a decreased apoptotic rate 
and an increase in myeloid cell numbers resulting in release of premature myeloid 
cells into the blood stream (Deininger and Druker, 2003). Due to the lack of 
knowledge on the function of BCR protein, the increase in kinase activity has been 
mainly associated with the dysfunctional ABL protein (Lugo et al., 1990). According 
to Druker (2008) the change in cellular function is due to the effect of BCR-ABL 
kinase activity on downstream substrates involved in various cellular pathways. 
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Consequently, drugs have been developed targeting the tyrosine kinase activity of the 
fusion protein as it remains key to the cause of cancer. 
 
1.1.2 Therapy for Chonic Myeloid Leukemia 
Chronic myeloid leukemia is generally treated using Interferon α (IFN-α) and 
allogenic stem cell transplantation which proved to be effective treatments 
(Milojkovic and Apperley, 2008). However, the high rate of mortality in using stem 
cell transplantation has resulted in the search for new drug molecules. After solving 
the crystal structure of ABL, drug design focused on molecules competing with ATP 
for its binding site in order to reduce the kinase activity. The result of this approach 
is Imatinib mesylate, which belongs to 2 phenyl amino pyrimidine class of drugs 
(Druker et al., 1996). This drug has been found to be most effective in killing the 
CML cells, as it inhibits BCR-ABL kinase activity by binding to the inactive 
conformation rather than the active conformation of the protein.  
 
Unfortunately, resistance to Imatinib treatment appeared and its origin is related to 
the mutations in the Imatinib binding site. Indeed some regions are more prone to 
mutations in the BCR-ABL protein and include the P-loop (ATP binding site), the 
Imatinib binding site, the catalytic domain and the activation loop: a mutation in P 
loop renders it less flexible and prevents Imatinib to bind. Additionally, Imatinib 
binding may also be hindered by the mutation T315I causing steric inhibition. 
Mutations in the activation loop results in an active (open) conformation which is 
significantly different from the inactive (closed) conformation to which Imanitib 
binds (Milojkovic and Apperley, 2008). Finally, other forms of Imatinib resistance 
have been suggested such as the efflux of Imatinib by the P-glycoprotein and over 
expression of BCR-ABL (Milojkovic and Apperley, 2008). 
 
To overcome the resistance to these mutations, a second generation of tyrosine 
kinase inhibitors have been designed: Nilotinib binds to Abl kinase in a similar 
manner as Imatinib but is 10 to 30 times more potent than Imatinib (Milojkovic and 
Apperley, 2008, Druker, 2008). Dasatinib is another type of tyrosine kinase inhibitor 
originally designed to inhibit SRC kinase but has a much larger effect on inhibiting 
BCR-ABL tyrosine kinase. In fact, Dasatinib is not a substrate of P-glycoprotein and 
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hence results in large amounts inside cells leading to effective therapy. Although 
both Nilotinib and Dasatinib are effective against most mutations causing resistance 
to Imatinib, they are still inefficient against the mutation T315I (Milojkovic and 
Apperley, 2008, Druker, 2008). Hence, the need for developing more effective 
therapy such as gene therapy for CML is required.  
 
1.2 Gene Therapy 
Gene therapy is the use of oligonucleotides in any cell that has an abnormally 
expressed gene, either low or high expression, to correct its expression (Edelstein et 
al., 2004). Gene therapy clinical trials, using viral vectors, have increased 
considerably in the recent years with most focussing on diseases such as monogenic 
diseases, cardiovascular disease and cancer. Even though non-viral vectors are 
relatively non toxic compared to the viral vectors, the clinical trials are predominated 
by viral vectors being used in more than 50% of trials. On the other hand, non-viral 
vectors including naked DNA transfer and lipofection are used in less than 25% of 
the trials due to their lower efficiency (Edelstein et al., 2007). Hence, in order to 
improve the efficiency of non viral gene delivery systems, a rational design is 
necessary to overcome problems posed by delivery barriers, nature of the vectors and 
the methods of transfection. 
 
1.2.1. In vivo gene delivery 
As gene therapy can be achieved only when the DNA has been delivered into the 
cells following injection into the body, it is important to focus on the two main ways 
to administer DNA into the body, namely localized and systemic delivery. 
 
Localized delivery 
Delivery of DNA or any drug at the site of action is called localized delivery. Such 
delivery method can be applied to organs like eye, mucus membrane, some tumours 
and skin. The main benefits of this approach are high bioavailability, less 
degradation by enzymes/nucleases, reduced non-specific delivery and also the 
benefit of reduced clearance by the renal excretion systems (Santel et al., 2006). 
Localised delivery can be divided further into subcategories depending on the site of 
injection which varies for different target tissues and disease types. The 
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classifications include intranasal, intraocular, intravitreous, intratracheal, 
intracerebral, intramuscular, intratumoral and intra-articular (Xie et al., 2006). 
Localised occular delivery of naked siRNA has been tested in vivo (Shen et al., 2006) 
and also in humans (de Fougerolles et al., 2007).  
 
Systemic delivery 
Systemic delivery is the delivery of the macromolecule to a targeted tissue which 
cannot be accessed easily for localized delivery. This involves introduction of drug 
or DNA through intravenous and intraperitoneal methods. Since the macromolecule 
is delivered through the systemic administration, it is available to travel throughout 
the body hence reducing the target specificity of the treatment and higher excretion 
by the kidney (van de Water et al., 2006, Santel et al., 2006). The inconvenience of 
systemic delivery is the increased number of physiological barriers to overcome 
(described in section 1.2.2.1). Thus, these have to be accounted for more carefully 
while designing drug molecules for systemic administration.    
 
1.2.2. Overcoming physiological barriers 
As mentioned above, physiological barriers for gene delivery play one of the most 
important roles in efficient gene therapy. A gene delivery system, when introduced 
into the body, is recognised as a foreign material by the body‟s defence mechanism. 
The immune system has developed various systemic (whole body) and cellular 
barriers in order to protect the human body from intrusion of foreign materials.  
Hence, overcoming the systemic and cellular barriers play a key role in successful 
gene delivery to its target site within the cell. 
 
1.2.2.1. Barriers for systemic gene delivery  
The main barriers for DNA delivery using systemic administration as listed by 
(Juliano et al., 2008) are: 
 Degradation by nucleases. Once in the blood circulation, the ability to resist 
serum nucleases is important as DNA and siRNA degradation may lead to 
smaller fractions which will be excreted through the kidney hence affecting 
the gene expression in cells (Kawabata et al., 1995). Degradation of pDNA 
takes place 5 minutes after intravenous injection or incubation with whole 
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blood (Houk et al., 1999). Thus one of the main role of complexation with 
non viral vectors is to protect the genetic information from degradation  
(Whitehead et al., 2009). 
 Complexation with serum proteins. The blood has negatively charged 
proteins in the serum which can electrostatically interact and bind with the 
(usually) positively charged vector/DNA complexes (Whitehead et al., 2009). 
While the positive charge on the complex favours interactions with 
negatively charged cellular surface materials such as glycosaminoglycan 
present, these vector/DNA complexes will also bind to negatively charged 
serum proteins like serum Albumin (Pack et al., 2005). Consequently the size 
of the DNA complexes is likely to increase and its apparent charge to 
decrease thus possibly affecting delivery (Zelphati et al., 1998). In vivo larger 
complexes may have problems being transported in the capillaries and 
subcapillaries where most of the exchange happens to reach the target cells. 
As these changes in physicochemical properties of the complex happen after 
systemic administration, they are difficult to control and also to predict the 
fate of these complexes. Hence, detailed study of the complex in presence of 
serum and various other conditions should be carried out and optimised 
before advancing into in vivo studies.  
 Recognition by immune system. Escaping the immune system without 
triggering it is one of the most important aspects of designing a gene delivery 
vector. Examples of material that trigger the immune system include certain 
base sequences and motifs present in DNA or siRNA that activate immune 
responses leading to being recognized by phagocytic macrophages. 
Macrophages identify macromolecules as foreign material inducing the 
release of proinflammatory cytokines. Avoiding certain DNA motifs can help 
reduce the risk of activating the immune response (Nishikawa and Huang, 
2001). The exposure of these motifs to the immune cells can also be 
minimised by complexation to a gene delivery vector which masks the 
nucleotide residues.  
 Excretion by kidney. The size of the molecules plays a critical role in 
filtration through the kidney. Indeed, excretion by kidney is observed within 
minutes of injection into the system for low molecular weight (less than 
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50kDa) macromolecules (van de Water et al., 2006). Consequently, 
unprotected siRNA (approximately 14 kDa) would face this problem. 
However, its complexation with a gene delivery vector increases its size 
considerably thereby prevents early excretion by the kidney (Whitehead et al., 
2009).  
 
The systemic barriers discussed in this section are mainly relevant for gene delivery 
in CML cells. However, for gene delivery to other target sites, systemic barriers like 
extravasation play an important role. Subsequently, once the gene delivery system 
overcomes the systemic barriers in the body and reaches the target cell, cellular 
barriers posed by individual cells prevent the entry of gene delivery systems. These 
cellular barriers are discussed below. 
 
1.2.2.2. Barriers for cellular delivery 
Once in the proximity of the target cells and before reaching the target organelle, the 
non viral gene delivery vector will have to overcome specific cellular barriers. These 
include plasma membrane (endocytosis), cytoplasm and nucleus. 
 
1.2.2.2.1. Plasma membrane 
The plasma membrane is a key cellular barrier preventing the entry of foreign 
molecules into the cells. The plasma membrane is a bilayer composed of mainly 
phospholipids, having a hydrophilic head group and two hydrophobic tails, which 
arrange in a bilayer exposing the hydrophilic head groups on the outside and the 
hydrophobic tails facing inwards. Consequently, the presence of hydrophobic groups 
on the inside of the cell membrane restricts the entry of hydrophilic molecules. Most 
drugs or drug delivery systems are designed to have a certain degree of 
hydrophilicity to enable easy interaction with the water present in the body. The only 
routes of entry for hydrophilic drugs across the cell membrane include use of 
channels or transporters on the cell membrane. On the other hand, hydrophilic 
macromolecules require different routes of entry possibly involving negatively 
charged cell membrane macromolecules such as negatively charged phosphate 
groups of the proteoglycans, phospholipids such as phosphatidylserine and/or cell 
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receptors. This uptake of macromolecules across the cell membrane takes place 
widely through different types of endocytosis.   
 
1.2.2.2.2. Endocytosis 
Endocytosis is the mechanism of uptake of macromolecules present on or in the near 
vicinity of the cell membrane. The uptake is facilitated by the formation of 
protrusions or invaginations by the cell membrane. Mostly, endocytosis is triggered 
by the macromolecule by either binding to a receptor leading to receptor mediated 
endocytosis or is non-receptor mediated. Three well known types of endocytosis 
have been described here:   
 Macropinocytosis is a non-specific form of endocytosis caused by the 
rearrangement of actin filaments inside the cell, causing protrusions of the 
plasma membrane. These protrusions then engulf the macromolecules and 
encapsulate large portion of the extracellular fluid by dropping onto and 
fusing with the plasma membrane forming an endocytic vesicle called 
macropinosome (Conner and Schmid, 2003). Macropinocytosis is likely be 
exhibited in macrophages and dendritic cells. The size of the macropinosome 
ranges up to 1 to 2 µm thereby able to encapsulate large cargoes and/or large 
volume of fluid. The fate of the macropinosomes varies with cell types where 
in some cells it matures into the endosomes, later fusing with the lysosome 
destroying the engulfed macromolecule.  
The formation of actin protrusions, called ruffles, plays an important role in 
triggering the endocytosis of the macromolecule. Recent reports suggest that 
the formation of protrusion is also induced by the activation of some 
receptors like the Epidermal growth factor receptor (EGFR) and Platelet 
derived growth factor receptor (PDGFR) in the presence of high amounts of 
the respective ligands (Doherty and McMahon, 2009). The activation of these 
receptors (EGFR and PDGFR) leads to an increase in the formation of ruffles 
(Kerr and Teasdale, 2009).  
 
 Caveolae mediated endocytosis is characterised by the flask shaped 
invaginations of the plasma membrane found widely on the surface of 
endothelial cells. This method of endocytosis is used by the endothelial cells 
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to transport nutrients across the endothelial layer (Doherty and McMahon, 
2009). Caveolae are also characterised by cholesterol-binding proteins called 
caveolin which forms the basis of caveolae mediated endocytosis. The 
internalization appears to be triggered by tyrosine phosphorylation of 
caveolin (Conner and Schmid, 2003). The dimeric caveolin clusters form 
caveolae coated pits leading to the invagination and later pinching off from 
the plasma membrane to form vesicles by the GTPase dynamin. Interestingly, 
caveolae coated vesicles are postulated not to traffic into the endosomes and 
lysosomes resulting in the delivery of cargoes into organelles like the golgi or 
the endoplasmic reticulum (Pelkmans and Helenius, 2002). Hence, the cargo 
taken up by the cells through caveolae mediated endocytosis does not result 
in degradation by the lysosome, making it an attractive target for drug 
delivery systems (Sahay et al., 2010). However, further studies are required to 
confirm these reports. Finally, caveosomes are characterised by a much 
smaller size (50 to 100nm) than macropinosomes and their slow rate of 
uptake (Hillaireau and Couvreur, 2009).  
 
 Clathrin mediated endocytosis (CME) is the most common type of 
endocytosis found in mammalian cell types or at least the most studied; it has 
been shown to be involved in the uptake of nutrients into the cells from the 
extracellular medium. Clathrin mediated endocytosis takes place mainly 
through receptor-mediated and non-receptor mechanisms, however the 
receptor mediated mechanim is well understood. CME originates on the 
surface of the cell membrane with high density of clathrin, a cytosolic coat 
protein, which then polymerizes to form Clathrin Coated Pits (CCPs). 
Binding of the ligand to the receptor triggers the polymerization of clathrin 
units and the pit containing the receptor-ligand deepens and is then pinched 
off from the plasma membrane (Doherty and McMahon, 2009) forming a 
Clathrin Coated Vesicle (CCV) (Khalil et al., 2006). The clathrin present on 
the CCV now depolymerises leading to the sorting of the contents in the 
vesicle, while the receptors present in the vesicles generally get recycled back 
to the plasma membrane. Moreover, the ligands often get trafficked into the 
early endosomes maturing into the late endosomes and finally reaching the 
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lysosome where the ligands face drop in pH followed by degradation (Khalil 
et al., 2006).  
CME also takes place through a receptor independent mechanism (Bareford 
and Swaan, 2007). The receptor independent variant is also called fluid phase 
endocytosis. The internalisation involves the same clathrin-coated pits taking 
up liquid along with solute present in the near vicinity (Hillaireau and 
Couvreur, 2009). This method of uptake could be involved in the uptake of 
positively charged molecules or complexes that lie in the near vicinity of the 
cell membrane due to its interactions with the negative charges of the 
membrane (Bareford and Swaan, 2007).  
 
After entering the cell through various types of endocytosis as discussed above, 
DNA or DNA complexes escape the endosome (see section 1.4.4.1.3) and reach the 
cytoplasm where it faces another important cellular barrier, the cytoplasm. 
 
1.2.2.2.3. Cytoplasm 
Gene delivery vectors, after release from endosomal vesicles, are released into the 
cytoplasm. In some cases, the cargo, mainly DNA or siRNA, are also released into 
the cytosol. Naked DNA may be released into the cytosol through different ways: 
Firstly, while using naked DNA or siRNA for direct delivery into the cells. Secondly, 
when using fusogenic lipids for gene delivery that fuses with the cell membrane or 
endosomal membrane leading to release of naked DNA into the cytosol. Thirdly, 
when the vector is displaced from the DNA due to its interactions with various 
proteins, it results in DNA being released into the cytoplasm. Wading through the 
cytoplasm is a challenging task as the cytoplasm is composed of a dense network of 
microfilaments, microtubules and other subcellular organelles. This overcrowding of 
the cytosol with proteins and organelles strongly slows down the movement of DNA 
or DNA complexes across the cytosol to its target site (Lechardeur et al., 2005). 
Naked DNA released into the cytosol especially faces a problem due to its size and 
negative charge. Indeed larger the DNA, slower the transport across the cytoplasm 
(Wagstaff and Jans, 2007). Additionally, the negative charge of the DNA also 
attracts positively charged DNA binding proteins which on binding severely impede 
the movement of DNA across the cytoplasm, hence underlining the need for a gene 
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delivery vector to protect the DNA until the target organelle is reached. These 
cationic delivery vectors also mask the negative charges of DNA thereby preventing 
the binding of cytosolic proteins leading to faster transport across the cytoplasm and 
delivery to its target site (Lechardeur et al., 2005).    
 
To conclude on this barrier, another major obstacle facing the naked DNA when 
released in the cytosol, is its very low stability due to the degradation of DNA in the 
cytoplasm. Lechardeur et al., (1999) found that the half life of DNA injected into the 
cytosol is 90 minutes in Cos and HeLa cells. This degradation takes place due to the 
activity of numerous nucleases present in the cytosol. On the other hand, the 
degradation of naked DNA is reduced when complexed with vectors such as cationic 
lipids, polymers and peptides.  
 
1.2.2.2.4. Nuclear Membrane  
The nucleus encompasses the machinery required for transcription of the plasmid 
DNA. Hence, the delivery of plasmid DNA reaches its destination only when 
delivered to the nucleus leading to transcription of the gene of interest. Thus, nuclear 
membrane is one of the major barriers for gene delivery. There are different ways of 
crossing the nuclear membrane and the most common one for non-viral gene 
delivery systems seems to be during mitosis when the cell‟s nuclear membrane 
disintegrates thereby allowing DNA molecules to interact with the transcription 
machinery of the cell. However, for non-dividing cells, DNA or the DNA/vector 
complex may only be able to enter the nucleus by interaction with channels present 
on the nuclear membrane called Nuclear Pore Complexes (NPCs) (Wagstaff and Jans, 
2007, van der Aa et al., 2006). The NPCs are very stringent in transportation of 
molecules across the nuclear membrane. Indeed only macromolecules with a 
molecular weight smaller than 50 kDa may traverse the nuclear membrane through 
passive diffusion. Larger macromolecules may require the presence of a Nuclear 
Localisation Signal (NLS) to help in crossing the nuclear membrane through the 
NPC by active diffusion (Escriou et al., 2003). NLSs are recognition sequences 
involved in complex formation with the Importin family of proteins in NPC e.g. NLS 
from SV40-T antigen is KKKRK. Peptides with NLS sequence complexed with 
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DNA have been shown to increase nuclear DNA uptake resulting in higher 
transfection efficiency (Yang et al., 2009, Lindgren et al., 2000).  
 
Before discussing the relevance of these barriers for siRNA and shRNA plasmid it is 
important to discuss the mechanism of gene silencing using these cargoes. 
 
1.3. RNA interference (RNAi) 
RNAi, discovered by Fire et al. in 1998 in Caenorhabditis elegans (Fire et al., 1998), 
is the process of suppressing or inhibiting the expression of a protein by using double 
stranded RNA (dsRNA) in a sequence specific manner (Fire et al., 1998). This work 
on RNA interference led to the 2006 Nobel Prize in Physiology and Medicine.  
 
There are three main ways by which siRNA can be introduced into cells (see Figure 
1.3): The two main ways to induce RNAi in cells involves using short hairpin RNA 
(shRNA) plasmid and small interfering RNA (siRNA), as discussed below. The third 
way involves introducing long dsRNA. shRNA and long dsRNA when introduced 
into the cell is then recognised by Dicer and gets cleaved to form siRNA, which then 
enters the RNAi pathway thereafter.  
 
 
Figure 1.3: A diagrammatic representation of the different ways of introducing a 
siRNA into a cell. 
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Of much importance and relevance here is the use of siRNA and shRNA plasmid. A 
schematic representation of the mechanism of RNAi is presented below (Figure 1.4). 
 
1.3.1. Short interfering RNA (siRNA) 
RNAi pathway involves the recognition of dsRNA molecules by a group of proteins 
in the cell resulting in the degradation of the target mRNA. One of the most 
important proteins involved in the RNAi pathway is Dicer, which cleaves the long 
dsRNA including shRNA molecules into small RNA molecules. These small RNA 
are 21-23 nucleotides long, have 2-3 base overhang at the 3‟ end and are called small 
interfering RNA (siRNA). The protein Dicer along with the RNA induced silencing 
complex (RISC) group of proteins, help in assembling the guide strand on the 
endogenous target mRNA. Here, the guide strand bonds to the site of 
complementarity on the target mRNA. The RISC further processes the mRNA to 
cleave it into smaller fragments resulting in the suppression of target protein 
synthesis (Meister and Tuschl, 2004). The RNAi pathway can be achieved using 
siRNA and short hairpin RNA (shRNA): a schematic representation of the 
mechanism of RNAi is presented below (Figure 1.4). 
 
 
Figure 1.4: RNAi mechanism. Schematic representation of shRNA plasmid and 
siRNA delivery into the cell and mechanism of RNAi. 
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1.3.2. Short hairpin RNA (shRNA) 
Short hairpin RNA is produced from plasmid DNA in which the transcription of the 
insert is driven by a promoter. This insert sequence is designed in such a way that 
when transcribed, the mRNA folds back on itself, due to the high complementarity of 
the sequence, to form a hairpin like structure, as shown in Figure 1.5. Here, the 
sequence of the sense strand is followed by the loop sequence, sequence of the 
antisense strand and finally the terminator sequence for the promoter. Hence, when 
the mRNA of this insert is synthesised and the first half the sequence being similar to 
the second, it folds back on itself to form the hairpin. This hairpin double strand is 
then recognized by the Dicer and processed into siRNA: the resulting siRNA is then 
processed by RISC complex as described above. 
 
RNAi offers great potential for gene therapy where an overexpressed oncoprotein 
could be targeted. However, like any other gene delivery systems, delivery of siRNA 
in vivo also has its own limitations and barriers. 
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Figure 1.5:  Design of shRNA plasmid vector. a) Diagrammatic representation of 
the design of the insert to be used for vector based approaches. It has the sequence of 
the sense strand followed by the loop sequence and then the sequence of the antisense 
strand followed by the termination sequence of the promoter. b) Representation of the 
formation of shRNA from the mRNA of the inserted sequence. Both images have been 
taken  from Applied Biosystems handbook (AppliedBiosystems, 2008). 
 
1.3.3. Considerations for siRNA and shRNA plasmid delivery in vivo 
There are various important additional issues to be considered when delivering 
siRNA for in vivo studies. Among these the protection of siRNA against enzymes, 
side effects such as the induction of type I interferon and off-target effects are key 
concerns. 
 
a 
b 
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The use of naked siRNA delivered systemically is not the most sensitive approach 
due to rapid degradation by enzymes, rapid renal excretion and electrostatic repulsion 
from the cell surface and lack of cell selectivity. In contrast,  localized delivery of 
naked siRNA offers a more feasible approach (de Fougerolles et al., 2007), as it 
ensures that siRNA is delivered into rapidly dividing cells. Ocular delivery of naked 
siRNA targeting the VEGF pathway in patients suffering from wet AMD has shown 
considerable success in the clinical trials and has completed Phase I and Phase II 
trials (de Fougerolles et al., 2007). The localised delivery of naked siRNA to eye, 
lung etc, are feasible due to the relatively low concentration of nucleases present in 
these organs compared to the serum. Direct injection into the eye avoids side effects 
caused due to systemic administration, while inhalation of naked siRNA ensures 
localisation in the lung epithelial cells making these organs suitable for delivery of 
naked siRNA.  
 
Noticeably, undesired side effects can also be triggered using siRNA which include 
induction of type 1 interferon response and saturation of RNAi machinery which can 
lead to cell cytotoxicity. Type 1 interferon response is triggered when certain 
immunostimulatory sequence motifs are present in the siRNA (Kim and Rossi, 2007). 
Another important trigger is the use of dsRNA longer than 30bp. Proteins present on 
the surface of endosomes also recognise certain specific ssRNA and dsRNA eliciting 
immune response. However, this can be avoided using shRNA vector instead of 
chemically synthesized siRNA. Additionally, the selection of a wrong target may also 
trigger non specific responses leading to shut down of cell‟s protein machinery 
resulting in cell death (Kim and Rossi, 2007). 
 
Off Target Effects (OTE) can be triggered due to various reasons, one of which 
includes the use of siRNA targeting the 3‟ Untranslated Region (UTR) of mRNA 
since this region is usually the target for the cell‟s endogenous miRNA pathway. This 
issue can be avoided by designing siRNA to target the Open Reading Frame (ORF) of 
the mRNA away from the 3‟UTR (Castanotto and Rossi, 2009, Kim and Rossi, 2007). 
 
Another major obstacle of using siRNA therapeutics is the use of shRNA vector 
leading to synthesis of large amount of shRNA for a long duration thereby saturating 
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the RNAi machinery resulting in toxicity (Grimm et al., 2006). One of the most 
important proteins which play a crucial role is the Exportin family of proteins which 
help in the translocation of the shRNA and miRNA from the nucleus to the cytoplasm 
(Grimm et al., 2006, Snove and Rossi, 2006). Hence, synthesis of large amounts of 
shRNA can lead to saturation of the Exportin protein and results in limited 
availability for use by the cell‟s endogenous miRNA pathway leading to toxicity. 
Consequently to avoid saturation and toxicity two possibilities exist: i) the use of a 
weak promoter e.g. H1 instead of strong one such as U6 should lead to a reduction of 
shRNA synthesis or ii) use of chemically synthesized siRNA at low concentrations to 
avoid saturation of RNAi machinery (Castanotto and Rossi, 2009). 
 
Similar to DNA  many  issues such as charge and size can be addressed by 
complexing  the siRNA or shRNA plasmid with gene delivery vectors to mask the 
negative charge and obtain favourable sizes of the complex (Xie et al., 2006) leading 
to enhanced gene delivery properties. In addition, other methods which are currently 
in use to improve transfection efficiencies could be potentially useful for siRNA and 
shRNA plasmid delivery as detailed below. 
 
1.4. Current methods of improving gene delivery 
To aid the delivery of DNA to its target site, various methods of gene delivery 
including physical methods have been developed to carry, protect and enhance the 
intracellular delivery of DNA or siRNA. In fact, an excellent gene delivery system 
should overcome systemic and cellular barriers without external action to silence 
gene expression in CML. Widely used gene delivery methods for CML like 
electroporation, viral and non-viral vectors will be discussed in the following 
sections.   
 
1.4.1. Physical methods of gene delivery 
Various techniques have been used to enhance gene delivery but all of them have 
pitfalls; the simplest form of gene delivery is naked DNA injection. This process 
involves the injection of DNA in the near vicinity of the cell or target organ and the 
DNA enters the cells possibly during cell division. However, the method is limited 
by various factors like half life of naked DNA, nuclease degradation and clearance 
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by immune cells (Nishikawa and Huang, 2001). The ultimate refinement of this 
approach is the so-called gene gun which involves rapid introduction of the plasmid 
DNA directly into the cells or target tissue. One of the main advantages of using this 
method is the delivery of DNA directly into the cytoplasm but a disadvantage would 
be the limited penetration into the tissues (Nishikawa and Huang, 2001). Overall the 
main disadvantage of injections is the invasiveness and, consequently the possibility 
of not reaching the target site.  
 
1.4.1.1 Electroporation mediated gene delivery 
More relevant to the study of RNAi in CML is electroporation. Electroporation is the 
process of gene transfer into the cell using short electric pulses which opens transient 
pores facilitating the uptake of macromolecules surrounding the cell. This method of 
gene transfer has increased cellular gene delivery several fold when compared to 
naked DNA injection (Nishikawa and Huang, 2001). While it is relatively efficient, 
the use of electroporation has to be optimized for each target organ. However, the 
application of electroporation in vivo is limited due to its invasive nature and also by 
the toxicity associated with it.  
 
siRNA delivery using electroporation 
Electroporation has also been used for the delivery of siRNA into CML cell line 
K562. However, due to the long half life of BCR-ABL, repeated electroporation was 
performed 24 hours after the first transfection. Electroporation achieved around 80% 
transfection efficiency and resulted in bcr-abl gene silencing of around 90% 12 hours 
post second transfection, increasing in expression thereafter (Rangatia and Bonnet, 
2005). Varying gene silencing has been reported to be from 25% to 60% from 24 
hours to 48 hours (Scherr et al., 2003b). Alternatively, other cell lines like 32D and 
M07 have been transformed with BCR-ABL using viral vectors. The expression of 
BCR-ABL is then targeted using siRNA by electroporation which resulted in 
efficient gene silencing of 80% (Wohlbold et al., 2003).   
 
1.4.2. Viral gene delivery vectors 
Viruses have been widely used in gene delivery due to their ability to infect a wide 
range of cells and translocate across the cell membrane. Among them, some are able 
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to integrate the viral genome into the host genome thus resulting in a stable 
expression of the viral proteins. These proteins are involved in viral replication 
resulting in the production and release of numerous viral progenitors. The viral 
infection also elicit a very strong immune response from the host which mostly result 
in the death of the cell infected (Thomas et al., 2003).  Hence, there could be many 
advantages and disadvantages in using the viral vectors as gene delivery vectors.  
 
Based on these inherent properties, many viral gene delivery vectors have been 
designed utilizing their high efficiency of viral infection while deleting the genes 
responsible for viral replication: the result of this approach is vectors with high gene 
delivery efficiency but a reduced infectious ability. However, viral vectors still pose 
the risk of triggering an immune response and lead to fatality. Nevertheless the next 
subsections will present the most common viral vectors. 
 
1.4.2.1. Retrovirus 
Retroviral vectors are RNA viruses with DNA intermediates. They have the ability to 
integrate into the host genome which allows for stable expression of the gene of 
interest. The therapeutic gene of interest is inserted in place of viral genes gag, pol 
and env thus ensuring continuous synthesis of the therapeutic gene in the cells. 
Another advantage is the location of viral genes in close proximity enables the 
replacement of therapeutic genes up to 8 kbp in size (Kay et al., 2001). However, as 
retroviral vectors lack the ability to infect non-dividing cells (Lundstrom, 2003) and 
since a very low percentage of cells undergoing mitosis, this becomes a major 
disadvantage (El-Aneed, 2004).   
 
Among retroviruses, lentiviral vectors offer distinct advantages over the other 
retroviral vectors as they can penetrate dividing and non-dividing cells. However, 
lentiviral vectors pose a greater risk which could be caused due to their origin, the 
human immunodeficiency virus (HIV) (El-Aneed, 2004). 
 
1.4.2.2. Adenovirus 
Adenoviruses, double stranded DNA viruses, are amongst the most effective gene 
delivery vectors. Adenovirus derived vectors can infect both dividing and non-
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dividing cells. Viral genes E1 and E2 are deleted to insert therapeutic genes of choice. 
However, adenoviral vectors cannot integrate into the host genome thereby 
producing only a transient gene expression. Hence, the viral DNA exists as an 
episome which gets diluted in number as cell division progresses resulting in a major 
disadvantage (Atkinson and Chalmers, 2010). Indeed, determining the longevity of 
expression of the therapeutic gene is a difficult task due to the very different rate of 
cell division for various cells and tissues. The overall consequence is the need for 
repetitive treatments using the adenoviral vectors at carefully determined dosage and 
repeated intervals. It is noteworthy to remember that adenoviral vector administration 
has also led to the first fatality in clinical trials due to immunological responses 
elicited by the host (Kay et al., 2001).  
 
1.4.2.3. Herpes simplex virus 
Herpes simplex virus type 1 (HSV-1) based vectors are some of the most studied. 
The HSV has an impressive linear 152 kbp dsDNA allowing the integration of 
foreign DNA ranging in size of 30 to 40 Kb, providing a large capacity for one or 
more therapeutic genes to be inserted (Latchman, 2001). Interestingly, HSV DNA 
may exist latently in cells i.e. episomally in the nucleus of the cell providing an 
advantage when the expression of therapeutic gene is required for the entire lifetime 
of the cell or organism. It is worth mentioning that it also raises some safety concerns 
since it causes infection in the human eye and sensory neurons in the brain 
(Lundstrom, 2003). However, the possibility of infection can be tackled by the 
deletion of viral genes rendering them non-toxic (Latchman, 2001).   
 
1.4.2.4. Adeno associated virus 
Adeno associated virus (AAV) based viral vectors are formed by deleting the viral 
genes like rep and cap thereby allowing the insertion of therapeutic genes for 
expression in cells. AAVs are able to infect both dividing and non-dividing cells and 
integrate the viral DNA into the host genome thus providing continuous expression 
of the therapeutic gene (Atkinson and Chalmers, 2010). In some forms of the viral 
vector, the integration also takes place at a particular position on the chromosome 19 
preventing the speculation of any insertional mutation in any vital gene in the host 
organism (El-Aneed, 2004). Additionally this vector does not cause any immune 
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response or infection. Nevertheless, these single stranded DNA vectors have a low 
capacity (less than 5 kb) and need helper viruses to aid in replication of the virus 
(Atkinson and Chalmers, 2010). Hence, large scale production of the virus may 
become tedious and may introduce contamination due to other viruses. However, the 
problem of contamination can be overcome by the use of radiation, chemicals or heat 
shock to induce viral replication (El-Aneed, 2004). Many of the above vectors have 
been used to deliver siRNA & shRNA plasmid.  
 
1.4.3. Delivery of siRNA and shRNA plasmid using viral gene 
delivery vectors 
Viral gene delivery vectors have been used to deliver siRNA in various cell lines 
with high efficiency. However, they deliver shRNA expression plasmid instead of 
chemically synthesized siRNA. For CML, lentiviral vectors have been used 
extensively to study gene silencing of bcr-abl. Introduction of plasmid expressing 
shRNA using lentiviral vectors offers the advantage of inducing stable reduction of 
the BCR-ABL protein in K562 cells, BCR-ABL positive hematopoietic stem cells 
and also CD34+ primary cells (Scherr et al., 2005, Futami et al., 2008). This 
reduction in protein levels lasts for several weeks and also induces apoptosis of cells 
treated with bcr-abl specific siRNA. Here, the use of lentiviral supernatants were 
found to be more efficient in inducing stable reduction in protein levels than plasmid 
constructed based on the lentiviral backbone or conventional plasmid that were 
transfected using electroporation. Lentiviral vectors are preferred for siRNA transfer 
due to their ability to integrate the DNA into non-dividing cells. This includes 
hematopoietic stem cells and terminally differentiated cells (Scherr et al., 2003a). 
Other vectors like retroviral vectors have shown efficiency in transfecting BCR-ABL 
positive hematopoietic stem cells for the delivery of plasmid DNA but not specific in 
targeting of bcr-abl using siRNA.  
Viral vectors have a great potential to deliver shRNA plasmid and siRNA, but the 
major issue of toxicity has not been satisfactorily addressed despite the intense 
research investigation. 
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1.4.4. Non-viral gene delivery systems  
Increasing concerns on the toxicity of viral vectors and immunogenicity together 
with economical aspects lead to the development of non-viral gene delivery 
strategies. Nevertheless these novel approaches although based on synthetic 
polymers or macromolecules, try to retain or mimic certain key features used by viral 
vectors for gene delivery: the most important ones are detailed below. 
 
1.4.4.1. Properties of non-viral gene delivery vectors 
Most of the non-viral gene delivery vectors share some important features, mostly 
adopted from viral vectors. Properties like net positive charge aids in both binding to 
DNA as well as influencing cellular uptake through interactions with negatively 
charged groups present on the surface of the cell membrane. Cellular uptake can also 
be made specific by the addition of ligands to bind to receptors selectively expressed 
on certain groups of cells. These non-viral gene delivery vectors also share similar 
obstacles in reaching the target site inside the cell like trapping inside the endosomal 
compartment. An ideal gene delivery vector should have the following characteristics. 
It should form a complex with DNA, be able to target specific cells and have built in 
endosomal escape mechanism. These basic properties will be considered for the 
development of non-viral vectors. 
  
1.4.4.1.1. DNA complexation 
Based on the observation of the role of histones in the nucleus or viral vectors, the 
formation of condensates or compact DNA particles was described by Bloomfield 
(1997): DNA condensation is the process of reducing DNA volume into small 
toroidal particles under the action of polycations (initially multivalent ions were used) 
by up to 1000 fold (Bloomfield, 1997). As DNA is negatively charged, electrostatic 
interactions play a key role in the interactions with polycations and in the formation 
of vector/DNA complexes (Bloomfield, 1996). Similar electrostatic interactions are 
used by histones, a group of proteins that condense DNA in the nucleus of the 
eukaryotic cell (Berg et al., 2007). Apart from electrostatic interactions, hydrophobic 
interactions between the condensing agent (like cationic peptides) and the DNA play 
a role in the formation of DNA complexes (Niidome et al., 1997). It is noteworthy to 
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remember that condensation is different from complexation: two aspects often 
mistaken. Indeed the addition of polycations may lead to the formation of possibly 
large complexes. Nevertheless complexes and condensates protect DNA from 
enzymes recognition and degradation.  
 
1.4.4.1.2. Cellular targeting 
Cellular targeting is nowadays a routine in vitro and in vivo approach, to improve 
gene delivery to specific cells. The reason lies in the fact that cells express different 
surface receptors and these receptors may vary with the disease state (e.g. cancer). 
Additionally, different types of cells (e.g. hepatocytes) and organs can also be 
targeted. Proteins are often used as ligands as well as short peptides sequences which 
are specifically recognised by the surface receptors. Examples of ligands which fall 
into three categories are discussed below:  
 
 Proteins as ligands. Tumour cells express certain receptors at a different 
level than the normal cells. For instance, the large amounts of iron required 
by the rapidly proliferating cancer cells result in a marked increase in the 
expression of transferrin receptors on their surface while lower levels are 
observed in cells such as blood cells, hepatocytes and intestinal cells. Thus 
attaching transferrin to a gene delivery system has been shown to increase 
significantly the uptake and the expression in cancer cells (Daniels et al., 
2006a, Daniels et al., 2006b). Similarly, epidermal growth factor receptors 
(EGFR) are over-expressed in certain types of cancers like the breast cancer 
and prostate cancer. Attaching an EGF to the cationic vector like 
Polyethylenimine significantly enhanced the gene delivery efficiency (Ogris 
and Wagner, 2002).  
 
 Short peptide sequences as ligands. Although targeting cells specifically 
based on the expression of various receptors using ligands (protein or 
antibodies) makes an efficient gene delivery vector, it posed a downside of 
considerable increase in molecular weight of the complex due to the 
attachment of a protein to the vector. Hence to counteract this problem, cell 
surface receptors have also been targeted using short peptides that act as 
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ligands. These short peptides are obtained by narrowing down and identifying 
the unique binding sequence of the protein with the receptor. This paves the 
way for smaller and more compact gene delivery vectors. A fine example for 
this model would be use of RGD ligand to target integrin receptors. These 
receptors are made of α and β subunits which form heterodimers. Of specific 
interest is the αvβ3 which are over-expressed during tumour angiogenesis. 
Ligands like laminin, fibronectin, vitronectin, proteolysed collagen and 
fibrinogen have been identified for various integrin receptors: They have a 
common peptide sequence motif (RGD) facilitating receptor recognition and 
binding. However, using RGD peptide alone to aid gene delivery reduces the 
half life of the RGD peptide/DNA complex. As a result, RGD motif has been 
used along with other gene delivery vectors like PEI to increase the efficiency 
of the gene delivery as well as increase in specificity (Wang et al., 2010). 
RGD peptide conjugated with Chitosan nanoparticle when complexed to 
siRNA showed three fold higher localisation in tumour tissues that over 
express αvβ3 receptors, compared with Chitosan nanoparticle lacking the 
RGD motif (Han et al., 2010). 
 
Other cell surface receptors like the laminin receptors are also expressed at 
different levels in various cancerous cells. In fact, the binding of Laminin 
with the receptors has been found to play a key role in tumour metastasis. 
Narrowing down on the peptide recognition sequence of laminin involved in 
the interaction with the receptor has led to several key sequences like IKVAV 
on the α-chain, RYVVLPR on the β-1 chain and CDPGYIGSR on the β-1 
chain. Further working on the CDPGYIGSR sequence, it was found that 
YIGSR was sufficient to induce cell adhesion, migration and binding to the 
laminin receptor. Recent report from our group (Saleh et al., 2008) has found 
the attachment of this pentapeptide, YIGSR, to cell penetrating peptide Tat 
increased the cellular uptake and gene expression in cells over-expressing 
laminin receptor when compared to cells expressing low levels of laminin 
receptors.  
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 Small molecules as ligands. As mentioned earlier, the hepatocytes express a 
high level of asialoglycoprotein receptors. Hence to target the liver, galactose 
residues may be attached to a gene delivery system to increase uptake by 
hepatocytes (Yan and Tram, 2007). Similarly, folic acid has been used to 
target folic acid receptors. These folic acid receptors are found to be over-
expressed in a range of tumours like the non-mucinous ovarian carcinomas, 
uterine carcinomas, testicular choriocarcinomas, ependymomas, and pleural 
mesotheliomas, and less frequently in breast, colon, and renal cell carcinomas, 
which is otherwise expressed at low levels. Conjugation of various non-viral 
gene delivery vectors like liposomes and PEI to folic acid have been found to 
improve the gene and drug delivery efficiencies (Zhao et al., 2008). 
Liposomes, loaded with siRNA targeting mycn oncogene, were attached to 
folic acid targeting neurobalstoma LA-N5 cells that over express folate 
receptors. The study showed that siRNA targeting mycn gene resulted in 80% 
reduction in mycn mRNA levels in vitro and approximately 53% inhibition of 
mRNA expression in mice tumours (Feng et al., 2010), an efficiency found to 
be higher than that observed with liposome that does not target folate 
receptors. 
 
1.4.4.1.3. Endosomal escape 
Gene delivery systems are likely to enter the cells through different endocytosis 
routes as described earlier (section 1.2.2.2.2). For some endocytotic routes, the 
endosome will be trafficked through an acidic route and may finally fuse with the 
lysosomes. When the cargo (gene delivery system) is not able to evade the endosome 
it will most likely be degraded in the lysosomes. Consequently as it appeared 
important to evade degradation, some non viral vectors which include endosomal 
escape mechanisms can offer additional benefit. There are number of ways to 
encourage endosomal esacape which are described below. 
 
Lysomotropic agents help in crossing the endosomal membrane and releasing the 
cargo into the cytoplasm. A good example of lysomotropic agent is Chloroquine 
which is a weak base that gets protonated at acidic pH and accumulates in the 
endosome. It acts in two different ways , depending on concentration, to mediate the 
Chapter 1 
46 
 
release of the cargo from the endosome (Wattiaux et al., 2000). Firstly at low 
Chloroquine concentration, it prevents the acidification of the endosome thereby 
delaying or preventing endosome maturation (El-Sayed et al., 2009). Secondly at 
high Chloroquine concentrations it causes swelling of the endosome due to 
accumulation of counterions after protonation. The resulting influx of counter ions 
further leads to the bursting of the endosome. Consequently the cargo along with the 
non-viral vector is released into the cytoplasm. Addition of Chloroquine along with 
the vector/DNA complexes in the medium has been shown to increase the expression 
levels of the pDNA. For instance, addition of Chloroquine along with the gene 
delivery vector Tat peptide-NLS peptide-Dendrimer showed a significant increase in 
DNA uptake as well as increase in transfection efficiency (Yang et al., 2009). In 
some instances, Chloroquine is also postulated to enhance transfection efficiency by 
displacing the oligonucleotides from the vector and enhancing nuclear localisation 
(Cheng et al., 2006). Due to the non-specificity in rupturing the endosomes of all the 
cells and toxicity associated with the use of high concentrations of Chloroquine, the 
widespread use of this approach is limited and therefore applications of Chloroquine 
in vivo (El-Sayed et al., 2009) has not been forthcoming.  
 
Proton sponge effect is the buffering induced by the reduction in pH inside the 
endosome leading to additional pumping of protons, along with the concurrent influx 
of chloride ions to maintain charge neutrality. This consequently increases the ionic 
strength inside the endosome (Akinc et al., 2005). An important example of a vector 
exhibiting the proton sponge effect is Polyethylenimine (PEI) (Akinc et al., 2005). It 
is a highly cationic gene delivery vector that has shown high efficiency in mediating 
gene delivery into the cytoplasm of cells after escaping the endosome (Boussif et al., 
1995). PEI is made up of high amount of primary, secondary and tertiary amines that 
can get protonated and cause buffering at varying pH ranges. The protonation of PEI 
leads to transport of large number of ions (positive and negative) into the vesicle. 
Consequently, this is then thought to cause osmotic swelling and physical rupture of 
the endosome, resulting in the escape of the vector from the degradative lysosomal 
trafficking pathway (Pack et al., 2005, El-Sayed et al., 2009). PEI has been used for 
the delivery of siRNA in vivo resulting in 75% to 90% reduction in expression of 
firefly luciferase gene in mouse lungs (Thomas et al., 2005).  
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Membrane fusion is the ability of lipid bilayers to fuse to each other creating a 
uniform bilayer. Membrane fusion occurs naturally in cells in case of exocytosis. 
Some liposome formulations have been designed to fuse with the cell membrane as 
an important mean to encourage endosomal escape thereby  releasing the trapped 
cargo into the cytoplasm (Hafez and Cullis, 2001). For example: addition of neutrally 
charged helper lipids such as DOPE (dioleoylphosphatidylethanolamine), is known 
to improve the gene transfection efficiency primarily by mediating escape from the 
endosome through membrane fusion. The change in the conformation of the lipid 
from lamellar phase to an inverted hexagonal phase can be triggered by decreasing 
pH which then helps in protecting the DNA from degradation and also induces 
fusion with the endosomal membrane releasing the cargo into the cytoplasm (Morille 
et al., 2008).  Several studies have been carried out to increase the bioavailability of 
the vector/DNA complexes during systemic administration by the addition of 
hydrophilic PEG (Polyethyleneglycol) and Tat peptide bound to DOPE. However the 
results did not match the expectations as a decrease in efficiency was observed due to 
the steric hindrance caused by the PEG during interaction with the endosomal 
membrane. Change in the linkage between the PEG and DOPE to an acid degradable 
bond, increased the endosomal escape. Such a linkage between PEG and DOPE 
degrades releasing the liposome/R8 complex. Consequently, the cationic charges on 
peptide interact with the negative charges on the endosome membrane bringing the 
complex in close proximity to the endosomal membrane which leads to increase in 
the membrane fusion efficiency of DOPE (El-Sayed et al., 2009).     
 
Another important way to escape the endosome involves the use of membrane active 
peptides to either disrupt membranes or induce fusion between membranes. Both pH 
sensitive and pH insensitive membrane active peptides have been used. The 
composition and mechanism of endosomal escape utilised by these peptides will be 
discussed in detail in section 1.4.7.2. 
  
Many of the currently used non-viral vectors are expected to include some or all of 
the above mentioned properties. In particular lipid, polymer and peptide based 
vectors have attracted considerable attention. 
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1.4.5. Lipid mediated gene delivery 
Lipid mediated gene delivery can be performed in two different ways: liposomes and 
lipoplexes. Liposomes are vesicles formed by lipids with a hydrophilic core where 
the drug molecule/ DNA/ siRNA can be loaded during the preparation of liposomes. 
Lipoplexes are formed by a complex of lipids with DNA or siRNA. These lipids are 
often commercially available like Lipofectin, Lipofectamine etc. Cationic lipids like 
N-[1[(2,3-dioleyloxy)]-N-N-N trimethyl ammonium propane (DOTAP) and N-[1-
(2,3-dioleyloxy) propyl]-N,N,N- trimethylammonium chloride (DOTMA) 
electrostatically interact and condense DNA/siRNA efficiently (Schroeder et al., 
2009). Lipoplexes are thought to initiate cellular uptake using two main mechanisms: 
i) relying on positive charges on the lipids to help interacting with the cell membrane 
thereby leading to fusion of the lipids with the membrane releasing the cargo into the 
cytosol (Schroeder et al., 2009). ii) Lipoplexes induce uptake by endocytosis, where 
neutral lipids like DOPE facilitates endosomal escape as described earlier (El-Sayed 
et al., 2009). Although cationic lipoplexes are widely used for their increased 
transfection efficiency, they are severely limited by their toxicity (Lv et al., 2006).  
 
1.4.5.1. Lipid mediated siRNA delivery  
Lipoplexes have been widely used for the delivery of DNA and siRNA (Schroeder et 
al., 2009). Of specific interest are cationic lipids like DOTAP for delivery of DNA 
and other lipids like DOTMA, DOTAP, and DOPC (dioleolyphophatidylcholine) for 
delivery of siRNA (Morille et al., 2008). Neutral lipids like DOPC complexed to 
siRNA targeting EphA2 in mice have led to significant reduction in expression of 
target protein as well as reduction in size of the tumour (Landen et al., 2005).  
 
Recently, one study used lipoplexes in vivo, where Lipofectamine 2000 was 
complexed to siRNA targeting lamin A/C endogenous gene for delivery through 
intravaginal administration (Zhang et al., 2006b). They showed that Lipofectamine 
2000/siRNA reduced the expression of lamin A/C up to 86%, while naked siRNA 
injection did not result in significant decrease. Another example of lipoplex mediated 
siRNA delivery is the use of formulation called RPR209120/DOPE complexed with 
siRNA which resulted in 60% reduction in expression of tumor necrosis factor (TNF-
α) in mouse macrophage cell line J774.1, comparable to that achieved using 
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Lipofectamine (Khoury et al., 2006). Interestingly, results obtained in a mouse model 
for arthritis, showed 32% reduction in levels of TNF-α with RPR formulation 
complexed with siRNA, but there was no incidence of arthritis when complexed with 
a combination of DNA and siRNA (Khoury et al., 2006).   
 
An example of in vivo application of siRNA encapsulated within liposomes, is the 
use of liposome made of 50% DDAM and 50% cholesterol with siRNA targeting 
caveolin-1 in mice (Miyawaki-Shimizu et al., 2006). The study showed that using 1 
mg/kg and 1.3 mg/kg of siRNA encapsulated with the liposomes when injected 
through mouse tail vein led to 90% reduction in expression of caveolin-1 in 96 hours 
(Miyawaki-Shimizu et al., 2006).  
 
Moreover, various lipid formulations are being tried in clinical trials targeting 
tumour growth in cancer patients (Schroeder et al., 2009). A lipid formulation called 
LNP01, constituting 98N12-5(1): cholesterol: PEG in mole ratio of 42:48:10, proved 
successful in the delivery of siRNA to the liver in mice targeting Factor VII (Akinc 
et al., 2009). This formulation is now being tested in the phase I clinical trials. 
Lipoplex, AtuPLEX, mediated siRNA delivery targeting Protein Kinase N3 that gave 
promising results in vivo studies in monkeys, has now progressed to phase I clinical 
trials (Aleku et al., 2008).  
 
More relevant to the present study, commercially available lipoplex formulations like 
Lipofectamine, Oligofectamine, siPORT along with siRNA  have been used to target 
BCR-ABL in K562 cells and CML primary cells (Wilda et al., 2002, Withey et al., 
2005, Merkerova et al., 2007). In these cases, reduction in protein levels and mRNA 
levels were observed from 26% to 90% for different concentrations of siRNA used. 
Oligofectamine based siRNA complex reduced BCR-ABL to undetectable levels 
(Wilda et al., 2002) in K562 cells, while another study on CML primary cells using 
Oligofectamine and siPORT with 50 nM siRNA showed only reductions up to 26% 
of untreated controls (Merkerova et al., 2007). However, the issues of toxicity 
associated with delivery of siRNA using liposomes limits its usage while other 
options for other non-viral vectors like polyplexes are considered.   
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1.4.6. Polyplex 
Complexes formed with polymers and DNA are also called polyplexes. Cationic 
polymers have been used in gene delivery extensively due to their ability to pack 
DNA efficiently, a key reason leading to effective gene delivery. Some of the most 
used polymers are off-the shelf polymers, not specifically designed for gene delivery, 
but were later found to be very efficient in gene delivery. They include polylysine 
and polyethylenimine (PEI) (Pack et al., 2005). Polylysine, as the name suggests, is 
made of single amino acid repeats of lysine. The positive charge of lysine aids in the 
electrostatic interactions with DNA leading to DNA complexation. Since lysine is a 
natural amino acid, this polymer has increased biocompatibility compared to other 
synthetic polymers like PEI (Morille et al., 2008). Nevertheless polylysine polymers 
are limited by their capacity to enhance endosomal escape (Lv et al., 2006). 
  
PEI, the polymer previously mentioned has shown efficient gene delivery. PEI is rich 
in primary, secondary or tertiary amines having different pKa, hence offers buffering 
at different pH conditions. PEI provides a good example of proton sponge effect as 
discussed earlier in the chapter (see section 1.4.4.1.3) where the protonation of 
amines at low pH results leads eventually into endosome rupture. PEI exists both as 
linear and branched polymers. The latter has the higher DNA condensation ability 
and thus protects DNA against nucleases (Kim and Kim, 2009). However, one of the 
main disadvantages of high molecular weight PEI is its high toxicity due to the high 
density of positive charges and the large molecular weight. On the other hand, lower 
molecular weight PEIs have been used, which show efficient gene delivery as well as 
low toxicity (Pack et al., 2005).  
 
siRNA delivery using polymers has given very promising results. Indeed, 
cyclodextrin based polymers have shown significant activity in mouse and humans 
(Davis, 2009). In this study, a polymer based on β-cyclodextrin, a seven sugar ring 
molecule, conjugated with transferin ligand and PEG has reached the phase I clinical 
trials. This polymer was electrostatically complexed to siRNA targeting 
ribonucleotide reductase subunit 2, that inhibits proliferation of cancer cells (Davis, 
2009).  PEI has also been investigated extensively for siRNA delivery in vitro and in 
vivo (Thomas et al., 2005, Kim and Kim, 2009). However, significant toxicities due 
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to high concentrations of PEI used has led to the investigation into less toxic forms 
of polymeric gene delivery (Whitehead et al., 2009). The other group of polymers 
used for gene delivery involve the use of membrane translocating peptides. Since 
membrane translocating peptides form the focus of this thesis, a detailed section on 
them has been included.  
 
1.4.7. Membrane translocating peptides 
Membrane translocating peptides, as the name suggests, have the ability to cross the 
lipid bilayer of the cell. They can be broadly classified into Cell penetrating peptides 
(CPPs) based on Protein Transduction Domains (PTDs) and membrane active 
peptides. CPPs have the ability to translocate across the cell membrane while the 
membrane active peptides, further divided into pH sensitive and pH insensitive 
peptides, penetrate the lipid bilayer by forming secondary structures. Multifunctional 
peptides are formed by using a combination of peptide motifs each having different 
properties. Such properties include cell penetration, nuclear localisation, endosomal 
escape, cellular targeting etc.  
 
1.4.7.1. Protein transduction domain based cell penetrating peptides 
Some proteins are involved in the translocation across the cell membrane to perform 
various functions like trans-activation of genes etc. Mutational studies have helped in 
narrowing down the sequence of these proteins and peptides responsible for the 
translocation ability (Derossi et al., 1994). These peptides in general are called the 
Cell Penetrating Peptides (CPPs). They usually comprise a stretch of less than 30 
amino acids with a net positive charge and have the ability to cross the cell 
membrane and enter the cell (Heitz et al., 2009). The earliest identified CPPs include 
Tat peptide, Penetratin and VP22. Further developments in the field of CPPs saw the 
use of very short cationic peptides like octaarginine (R8) (Futaki, 2005). The 
mechanism of cell uptake of CPPs is however under constant debate: both energy 
dependent and energy independent pathways have been reported and found to depend 
on various factors including size of the peptide/cargo complex, type of cargo used as 
well as cell type. Moreover, diverse range of cargoes such as DNA, siRNA, 
liposomes, proteins to name a few have also been used along with CPPs to enhance 
their cellular uptake (Heitz et al., 2009). Three of the most commonly studied CPPs 
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for gene delivery (Table 1.1) i.e. VP22 (Normand et al., 2001), penetratin (Davidson 
et al., 2004)and Tat (Chiu et al., 2004) will be discussed in the following sections. 
 
Name Sequence 
VP22 DAATATRGRSAASRPTERPRAPARSASRPRRPVD 
Penetratin RQIKIWFQNRRMKWKK 
Tat RKKRRQRRR 
 
Table 1.1: Sequence of protein transduction based cell penetrating peptides 
VP22, Penetratin and Tat peptide. 
 
1.4.7.1.1. Herpes simplex virus type 1 (HSV-1) protein VP22 
The herpes simplex virus protein VP22 exhibits the unusual property of intercellular 
transport. After being synthesised in a subpopulation of cells largely in the cytoplasm, 
VP22 then penetrates and localises in the neighbouring cells (Elliott and O'Hare, 
1997). Additionally, after being transported to adjacent cells, the protein accumulates 
mainly in the nucleus. The C-terminus of VP22 was found to be essential to the 
transport of the native protein: a fusion protein consisting of GFP linked to the N-
terminal 1-192 residues of VP22 failed to transport between cells (Elliott and O'Hare, 
1997, Elliott and O'Hare, 1999). VP22 protein with the ability to transport cargo 
proteins between cells thus has a significant potential in the field of gene therapy. 
VP22 appears to be involved in different functions such as intercellular transport, 
binding to and bundling of microfilaments, inducing cytoskeleton collapse, nuclear 
translocation during mitosis, and binding to chromatin and nuclear membrane. 
Moreover, these functions are controlled by specific regions in the polypeptide: 
intercellular transport by amino acid region 81-195; binding and reorganisation of 
cytoskeleton by region 159-267; nuclear targeting, inhibition of cytoskeleton collapse, 
81-121; and nuclear targeting and facilitation of intercellular transport, 267-301 
(Aints et al., 2001). Hence, the 34 amino acid peptide (267-301) tagged to GFP has 
shown nuclear targeting and intercellular transport. The C terminal of VP22 (amino 
acids 159-301) complexed to short oligonucleotides exhibited gene delivery in HeLa 
and other cell types (Normand et al., 2001). However, the fluorescence associated 
Chapter 1 
53 
 
with the oligonucleotides remained confined in specific regions of the cells which 
became diffuse after exposure to light.  
 
1.4.7.1.2. Penetratin 
Homeodomains, members of the class of trans-activating factors discovered in 
Drosophila, were found to be involved in many physiological functions of the cell. 
They exist in the form of three alpha helices with one ß turn between helix 2 and 3 
and bind to DNA over a length of 60 amino acids (Derossi et al., 1994). The 
Antennapedia homeodomain is capable of translocating across the lipid bilayer and 
finally localises in the nucleus (Joliot et al., 1991).  
 
Initial mutational studies have revealed that the translocating property of the peptide 
was localised to the third helix (amino acids 41-60) of the Antennapedia 
homeodomain (Derossi et al., 1994).  Further mutational studies have helped in 
identifying the amino acids responsible for translocation (Derossi et al., 1994). In 
particular, peptides 43-58 and 41-60 were found to localize in the nucleus of the cell 
whereas deletions at the N and C terminal of these peptides had poor or no nuclear 
localisation properties. Hence, the 16 amino acids long sequence (43-58), considered 
the minimal sequence required for translocation is called Penetratin I. Furthermore, 
the peptide 43-58 FF, where the Tryptophan residues at position 48 and 56 were 
mutated to Phenylalanine, lost its translocating properties (Derossi et al., 1994) 
indicating that the translocating property depends on both the hydrophobic residues 
and on the Tryptophan residues at these positions. Derossi et al. (1996) showed that 
the peptide made of the same amino acids with the order reversed (58-43 instead of 
43-58) was able to translocate across the cell membrane indicating the lack of 
receptor mediated uptake (Derossi et al., 1996). Studies were also performed to show 
the effect of chirality and helical conformation on the translocation property of the 
peptide. To demonstrate this, firstly, experiments were performed with D forms of 
the same amino acids and secondly, a peptide with Proline, which disrupts the helical 
conformation, was used. Both these peptides showed good membrane translocation. 
Consequently, none of the properties like the chirality or the helicoid conformation 
are crucial for the translocation activity of the peptide.  
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Finally, detailed studies of the mechanism of CPPs by Derossi et al. (1994) found that 
the peptides 43-58 and 41-60 showed very little or no inhibition at 4ºC, whereas the 
internalization of the shorter peptides 41-55 and 43-60 was completely abolished, 
suggesting energy independent internalization of peptides 41-60 and 43-58 (Derossi 
et al., 1994). However, this energy independent mechanism was later contradicted 
and found to be an artefact of cell fixation during imaging and also insufficient 
removal of cell membrane-bound labelled peptides (Richard et al., 2003).  
Various reports have used Penetratin peptide covalently conjugated to siRNA and 
showed efficient internalisation into range of cell lines (Davidson et al., 2004, 
Lundberg et al., 2007). However, Lundberg et al. achieved higher transfection and 
gene silencing efficiency when Penetratin peptide was modified to escape the 
endosome (Lundberg et al., 2007), indicating Penetratin based complexes are limited 
by their endosomal escape capabilities. 
 
1.4.7.1.3. Trans-activating transcriptional activator (TAT) 
Frankel and Pabo (1988) demonstrated that the human immunodeficiency virus type-I 
TAT protein translocated across the cell membrane and the nucleus to trans-activate 
viral promoters in vitro (Frankel and Pabo, 1988). The protein sequence found to be 
responsible for the translocation ability of the protein was narrowed down to residues 
37-72 (Fawell et al., 1994). This region could be divided into two main regions, 
amino acids 37-49 involved in α-helix formation due to its amphipathic 
characteristics and amino acids 49-58, a region composed of basic amino acids. 
Further investigation into the residues responsible for translocation found that the N–
terminal amphipathic region was not significant for the transduction property of the 
protein (Vives et al., 1997). Whereas, the basic region, composed of six arginine and 
two lysine residues, was mainly involved in the translocation property (Vives et al., 
1997). This region (amino acids 49 to 57) is called the minimal protein transduction 
domain (PTD) which contains the Nuclear Localisation Sequence (NLS). Mutational 
studies in the basic region led to the loss of translocation activity. Thus the minimum 
Tat peptide is composed of residues from 49 to 57 (Gupta et al., 2005). The Tat 
peptide was successfully used for the delivery of DNA (Ignatovich et al., 2003) and 
siRNA (Chiu et al., 2004).  
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1.4.7.2. Membrane active peptides 
Membrane active peptides are primarily amphipathic peptides which have 
hydrophobic residues and hydrophilic residues alternatively. These membrane active 
peptides are usually less than 30 amino acids long and often imitate the viral vectors 
in enhancing endosomal escape by membrane fusion (Wharton et al., 1988). This can 
be performed by for instance, forming α helical structure either in response to pH or 
under normal physiological conditions. Therefore, they can be classified into pH 
sensitive and pH insensitive peptides based on their response to different pH 
environments with the cell. Some of important types of membrane active peptides 
include GALA, KALA, HA2, Melittin and LK15 will be explained in detail.  
 
Peptide Amino acid sequence 
HA2 peptide GLFGAIAGFIENGWEGMIDGWYG 
GALA WEAALAEALAEAHLAEALAEALEALAA 
KALA WEAKLAKALAKALAKHLAKALAKALKACEA 
Melittin GIGAVLKVLTTGLPALISWIKRKRQQ 
LK15 KLLKLLLKLLLKLLK 
 Table 1.2:  List of amino acid sequences of the membrane active peptides. 
 
1.4.7.2.1. HA2 derived peptide  
The influenza virus hemaglutinin protein, which has two vital functions, membrane 
receptor binding and membrane fusion (Steinhauer et al., 1995), consists of a trimer 
of identical subunits, each subunit consisting of peptides HA1 and HA2 connected by 
disulphide bond (Wharton et al., 1988). These peptides are formed by the cleavage of 
the parent peptide HAo, the N-terminal domain of which contains the signalling 
sequence while the C-terminal contains the membrane binding sequence. HAo 
cleavage, critical for membrane fusion activity, results in the localisation of 
membrane anchor sequence in the HA2 peptide (Skehel et al., 2001). Therefore, HA2 
peptide sequence which can mediate endosomal escape through membrane fusion is 
also known as fusion peptide. HA2 derived peptide becomes protonated in acidic pH 
thereby results in the extrusion of the fusion peptide from its buried state into the lipid 
bilayer, causing strain on the endosomal membrane resulting in the destabilization of 
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the membrane (Steinhauer et al., 1995). Thus HA2 peptide has been extensively 
studied pH sensitive membrane active peptide that has shown a 100 fold increase in 
transfection efficiency when used in conjunction with poly Lysine peptide and 
Transferrin to deliver DNA compared to only polylysine-Transferin complex 
(Wagner et al., 1992). Another study using Tat-HA2 fusion peptide observed higher 
transfection efficiency compared to Tat peptide presumably by influencing increase 
in endosomal escape. Indeed, the study shows that Tat peptide is limited by its 
endosomal escape properties (Wadia et al., 2004). 
 
1.4.7.2.2. GALA  
GALA is a synthetic pH sensitive membrane active peptide, with a repeat sequence of 
glutamic acid-alanine-leucine-alanine (Table 1.2) that gives the peptide its 
amphipathic characteristics (Cho et al., 2003). At physiological pH, the peptide 
remains in a random coil conformation due to charge repulsion of the glutamic acid 
residues. However, when the pH lowers from 7.5 to 5, the conformation changes to 
an α-helix due to the neutralization of glutamic acid residues (Subbarao et al., 1987). 
Then the α-helices aggregate and form a pore or channel through the membrane, 
destabilising and disrupting the endosome membrane (Li et al., 2004). Although 
GALA peptide, in its α-helix conformation is efficient at evading the endosome, it 
cannot complex DNA due to the large number of negative charges on the peptide 
(Cho et al., 2003). Hence, GALA has to be used in combination with other cationic 
peptides to aid in oligonucleotide delivery (Li et al., 2004).  
 
1.4.7.2.3. KALA 
To overcome inability of GALA to complex DNA, KALA peptide was designed 
having both membrane activity and ability to condense DNA, where glutamic acid 
residues were primarily replaced with lysine residues (Table 1.2) (Wyman et al., 
1997). Additionally, the number of glutamic acid residues is reduced and the some 
alanine residues were replaced with lysine residues. Hence, this gives the KALA 
peptide positive charges to interact electrostatically with DNA, thus to complex DNA 
(Martin and Rice, 2007). Further studies revealed that the peptide exists as an α-helix 
and changes to a mixture of α-helix and random coil with decrease in pH. 
Interestingly, the peptide exhibits membrane activity over the whole the physiological 
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pH range (from 4.0 to 8.5) (Wyman et al., 1997). KALA exhibits 100% leakage of 
negatively charged liposomes in the pH range of 4.0 to 8.5 indicating membrane 
activity of KALA at endosomal pH. This effect could be an influence of the positive 
charges of the peptide interacting and binding to negative charges of the liposomes 
(Cho et al., 2003, Wyman et al., 1997). A study reporting the conjugation of KALA 
peptide to Penetratin for DNA delivery (Min et al., 2010) showed that Penetratin-
KALA increased the transfection efficiency by 400 fold and 8 fold compared to 
Penetratin and KALA peptides respectively.  
 
1.4.7.2.4. Melittin  
Another well known endosomolytic peptide is Melittin, a 26 amino acid peptide that 
displays lytic activity (Dempsey, 1990). Such an activity is the result of its 
amphipathic nature while forming an α helix in presence of lipid bilayers. Due to the 
absence of acidic groups in the peptide sequence, Melittin is not pH sensitive. The 
positive charges and the presence of NLS sequence „KRKR‟ (see Table 1.2) on the 
peptide allow it to be utilised as a gene delivery vector. However, Melittin used by 
itself did not show efficient gene delivery properties probably due to its higher 
toxicity (Legendre and Szoka, 1993). On the other hand, use of PEI conjugated to 
melittin exhibited increased transfection efficiency when compared to PEI/DNA 
complexes (Ogris et al., 2001a).  
 
1.4.7.2.5. LK15 
LK15 is a synthetic membrane active peptide based on amphipathic antimicrobial 
peptides which destabilise and penetrate lipid membranes. LK15 is constructed with 
the two amino acids lysine and leucine, in which the former is hydrophilic and the 
latter hydrophobic. Initially, the peptide was constructed using amino acids leucine 
and lysine at ratio of 1:1, which exhibited membrane lytic activity by changing the 
conformation to α-helix on contact with lipid bilayer (Blondelle and Houghten, 1992). 
In the studies by Cornut et al. (1994), the peptide was built using the formula Li K j 
where i=2j, where the peptides of length 15, 20 and 22 were found to have a higher 
lytic activity than melittin, another efficient membrane active peptide (Cornut et al., 
1994). Further investigation into the optimum length required to cause maximum 
lytic activity, found that this can be achieved using 15 residues, hence resulting in 
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peptide LK15 (Castano et al., 1999). Consequently, LK15 peptide was sufficient to 
form α-helix having hydrophilic residues on one side and hydrophobic residues on the 
other side. This amphipathic nature of the peptide ensures stable helix conformation 
and membrane destabilization induced by the peptide. Since LK15 is not pH sensitive 
peptide, the membrane activity can take place on most lipid bilayer irrespective of the 
pH. This property could influence higher cellular uptake and also higher endosomal 
escape. Due to the cationic nature of LK15, the peptide is able to complex DNA 
(Dufourcq et al., 1998). However, transfection efficiency was poor in HCT 116 
tumour cells (Perry et al., 2008). To overcome this poor performance, Tat peptide 
(49-57) fused to LK15, to form a multifunctional peptide, discussed in detail in 
section 1.4.7.3.5 (Saleh et al., 2010), has been used.  
  
1.4.7.3. Multifunctional CPPs 
To overcome the relatively poor transfection efficiency of CPPs and in some cases 
toxicity, it may be worthwhile to combine two or more peptide sequences to form a 
single vector with multiple properties thus rationally designing an efficient gene 
delivery system. Most CPPs are faced with trapping in the endosome leading to 
inefficient release into the cytosol for nuclear delivery although CPPs like HIV-1 Tat 
peptide and Penetratin appeared initially promising tools (Endoh and Ohtsuki, 2009). 
Hence, complexation with membrane active peptides appears to be the logical 
solution to this problem. Two examples are Tat-LK15 (Saleh et al., 2010) and Tat-
HA2 (Wadia et al., 2004) peptides. Other ways of obtaining multifunctional peptides 
include cases where membrane active peptides are modified to have DNA or siRNA 
binding abilities. Conversely, in some cases, well known CPPs are further modified to 
gain endosomal escape properties. Examples of these include CADY and EB1 
respectively. 
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Peptides Amino Acid sequence 
CADY Ac-GLWRALWRLLRSLWRLLWRA-cysteamide 
MPG 
∆NLS
 Ac-GALFLGFLGAAGSTMGAWSQPKSKRKV-cysteamide 
EB1 LIRLWSHLIHIWFQNRRLKWKKK-amide 
Tat-LK15 RKKRRQRRRGGGKLLKLLLKLLLKLLK-COOH 
 
Table 1.3: List of amino acid sequences of membrane active peptides. 
 
1.4.7.3.1. CADY 
CADY is an amphipathic CPP designed based on a model peptide called ppTG1. The 
peptide ppTG1 is in itself a modified form of fusion peptide JTS1 where the glutamic 
acid residues are replaced with Lysine or Arginine (Rittner et al., 2002). Further 
changes in ppTG1 were made to increase the interaction of the peptide with the 
siRNA and lipid bilayer: Phe (at position 3), Leu (at position 7 and 18) were changed 
to Trp, while Lys at positions 4,8 and 11 were replaced with Arg (Crombez et al., 
2008). The resulting peptide, CADY (Table 1.3), forms an α-helix with charged 
residues on one side for interaction with siRNA and hydrophobic residues including 
Tryptophan residues on the other side which aides in cellular uptake. Further changes 
in the peptide composition include a cysteamide group on the C-terminal which 
removes the negative charge and aids in forming stable siRNA complexes and also 
improve cellular uptake efficiency. Consequently, CADY peptide was efficient at 
complexing siRNA providing protection against serum nucleases and at delivering 
siRNA into cells targeting gene knockdown at subnanomolar concentrations of 
siRNA. Furthermore, determination of the secondary structure indicated that CADY 
exists in a random coil conformation and changes to a α-helical conformation in the 
presence of lipids (Konate et al., 2010). It is noteworthy that this helical conformation 
is not affected by the complexation with siRNA. Finally, cellular uptake studies have 
shown a non-endocytotic mechanism to be involved in the uptake of CADY/siRNA 
complexes.  
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1.4.7.3.2. MPG based peptides 
MPG is an amphipathic peptide derived from the fusion between HIV-1 gp41 fusion 
domain and NLS region of SV-40 large T antigen (Morris et al., 1997). The HIV-1 
gp41 fusion domain and the NLS region constitute the hydrophobic and hydrophilic 
regions respectively. The resulting peptide, MPG, was shown to be efficient in 
delivery to the cell nucleus (Morris et al., 1999). The nuclear localisation occurs 
within one hour of transfection indicating a mechanism other than endocytosis to be 
involved in the cellular uptake of the MPG/DNA complexes (Morris et al., 1997). On 
the other hand, since siRNA requires cytoplasmic localisation for its activity, a 
mutation in the NLS region (MPG
∆NLS
), where a lysine residue is mutated to serine 
(Table 1.3), led to increase in the delivery of the siRNA into the cytosol. Such a 
mutation led to a more significant down regulation of the target gene (Simeoni et al., 
2003). Even though the NLS region was also found to be involved in electrostatic 
interaction with the DNA (Simeoni et al., 2003), a single amino acid mutation in the 
NLS region did not affect the DNA interaction ability of the peptide. Moreover, 
further modifications on the MPG parent peptide led to the shorter peptide MPG-8 
(Crombez et al., 2009b) which showed 30 to 60 fold higher siRNA mediated 
silencing of cyclin B1 when compared to MPG
∆NLS
.  
  
1.4.7.3.3. EB1 
EB1, a variant of Penetratin, has been formed by replacing some of the amino acids in 
Penetratin with Histidines (Lundberg et al., 2007). This variation was proposed to 
increase endosomal escape using a pH induced conformational change of the peptide 
into an α-helix induced by low pH of the endosome. As a result, EB1 showed higher 
cellular uptake as well as higher gene silencing efficiency of the target gene 
compared to its parent peptide Penetratin. Interestingly, the fusion of HA2 peptide to 
Penetratin did not result in gene silencing efficiency equivalent to EB1, indicating 
EB1 could be contributing to other factors for improved cellular uptake. For example, 
the interaction between EB1 and siRNA depends both on electrostatic interactions 
and also on the hydrophobic interactions between the nucleic acids of the siRNA and 
Histidine residues of EB1. Another possible reason for higher cellular uptake is that 
EB1 has six additional amino acids compared to Penetratin, that leads to an α- helical 
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conformation which would span the entire lipid bilayer resulting in effective 
penetration (Lundberg et al., 2007).  
 
1.4.7.3.4. PTD-DRBD 
Cationic charges on CPPs play an important role in its cellular uptake. However, 
when complexed electrostatically with negatively charged DNA or siRNA, most of 
the cationic charges are masked leading to inefficient gene expression or gene 
silencing. To avoid this problem, Eguchi et al. (2009) have used a double stranded 
RNA binding domain (DRBD), a 62 amino acid domain which has high binding 
efficiency to siRNA, leading to PTD-DRBD fusion protein (Eguchi et al., 2009). 
Hence, this results in free cationic charges on the TAT-PTD available to interact with 
the cell membrane and influence complex uptake. This strategy has led to efficient 
siRNA uptake as well as effective gene silencing as early as 6 hours indicating 
efficient siRNA delivery in the cytosol. Additionally, cellular uptake was also 
observed in the entire cell population indicating very effective delivery strategy.  
 
1.4.7.3.5. Tat-LK15 
Cationic membrane active peptide LK15 showed high efficiency of DNA 
complexation but exhibited poor transfection efficiency (Perry et al., 2008). To 
address the issue, Saleh et al. (2010) synthesized and studied the covalently linked 
LK15 peptide with CPP Tat (49-57) peptide. The resulting peptide, Tat-LK15, 
showed efficient DNA complexation and higher cellular uptake compared to Tat and 
LK15 peptides alone. However, the mean fluorescence intensity of labelled DNA 
inside the cells was found to be lower than that of PEI and Lipofectin. Nonetheless, 
the percentage of cells which have the labelled DNA is greater than 75% and is the 
same as that observed with PEI and Lipofectin. On the other hand, the transfection of 
Tat-LK15/DNA complexes was higher than that of Tat and LK15 peptides alone but 
found to be lower than Lipofectin and PEI. These studies indicate that while Tat-
LK15 shows cellular uptake (percentage of positive cells) comparable to PEI and 
Lipofectin, it leads to lower transfection efficiency. The cellular uptake by a large 
population of cells could be due to the lytic activity of the LK15 peptide. Tat-LK15 
retains almost 80% of the lytic activity even when complexed to DNA. Studies using 
chloroquine, showed an increase in transfection efficiency in HT29 cells while no 
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change was observed in HT1080 cells, indicating that the endosomal entrapment is 
not the problem in both HT29 and HT1080 cell lines. Since chloroquine might also 
influence various other factors like DNA protection and enhanced DNA expression in 
cells, it is difficult to conclude that the increase in transfection efficiency observed is 
only due to the release of entrapped complexes in the endosome. Nevertheless, 
attachment of LK15 helps in increasing the transfection efficiency of Tat peptide.  
 
1.4.7.4. Delivery of siRNA using CPPs 
Two methods of CPP/siRNA delivery strategies are currently being used: non-
covalent strategy and covalent strategy (Morris et al., 2008). Non-covalent strategy 
utilises the electrostatic interactions between the negative charges of the siRNA and 
the positive charges of the peptide. Most of the CPPs used until recently were 
designed to deliver DNA to the nucleus of the cells. However, for the delivery of 
siRNA, the CPPs need to be modified to aid in the delivery of siRNA to the 
cytoplasm. Simeoni et al. have modified the peptide MPG, originally designed to 
deliver oligonulceotides in the nucleus, to deliver siRNA into the cytoplasm (Morris 
et al., 1999, Simeoni et al., 2003). In fact a single amino acid mutation in the NLS 
region has shown to improve the siRNA delivery to the cytoplasm significantly 
(Simeoni et al., 2003). Moreover, the gene silencing observed by delivering MPG 
∆NLS
/siRNA was also higher than that delivered using MPG peptide. MPG/siRNA at a 
molar ratio of 10/1 and siRNA concentration of 50nM led to 75 to 85% luciferase 
silencing while MPG 
∆NLS
/siRNA exhibited 90 to 95% silencing (Simeoni et al., 
2003). MPG-8 peptide, modified from the MPG peptide, showed 30 to 60 fold 
increase in gene silencing in Hela cells when compared to MPG 
∆NLS 
(Crombez et al., 
2009b). Additionally, MPG-8 showed very efficient inhibition of tumour growth in 
human prostate carcinoma cell PC-3 xenografted mice. In this study, 5µg of 
siRNA/MPG-8 showed complete inhibition of tumour growth compared to 7 to 10% 
inhibition of tumour growth using 5µg of siRNA/ MPG 
∆NLS 
(Crombez et al., 2009b).   
 
The cationic amino acids on the CPPs are not only instrumental in the formation of 
non-covalent peptide/siRNA complexes but also helps in internalisation of the 
complex which also takes place mainly through electrostatic interactions. Masking of 
all the positive charges of the CPP could result in little or no positive charges left to 
Chapter 1 
63 
 
interact with the cell membrane thereby reducing the efficiency of uptake. To avoid 
this problem, Ishihara et al. have used cationic peptide along with the CPP connected 
through by disulfide bonds (Ishihara et al., 2009). The presence of these bonds 
ensures that the cationic oligopeptide interacts and forms non covalent complexes 
with the siRNA, while the CPP helps in transduction across the cell membrane. Here, 
the disulfide bond between the cationic peptide and the CPP gets reduced in the 
cytoplasmic environment thereby releasing the cationic peptide/siRNA complex. This 
study shows that covalent conjugation of Transportan with K6 (TP-K6) and TP-H6K6 
showed 30 and 40% luciferase gene silencing respectively at a 60nM siRNA 
concentration and 60/1 molar ratio, while Penetratin-K10 resulted in 15% luciferase 
gene silencing in FRCK cells. Nevertheless, there was significant difference between 
the gene silencing observed between Transportan and Transportan conjugated to K6 
and H6K6, indicating that the conjugation of a stretch of cationic peptide to a CPP 
could increase the cellular uptake as well as the gene silencing efficiency (Ishihara et 
al., 2009).  
 
Eguchi et al. (2009) have used another approach to counteract this problem. Double 
stranded RNA binding domain (DRBD) was used to bind with the siRNA, while 
protein transduction domains (PTDs) were used to give a net positive charge to the 
complex (Eguchi et al., 2009). This method ensures that the PTDs or CPPs are not 
involved in electrostatic interactions with the siRNA, but are more involved in the 
transduction across the cell membrane, leading to better transfection efficiencies. 
Eguchi et al. (2009) showed that using siRNA at a concentration of 400nM 
complexed to TAT PTD-DRBD led to 90% gene silencing. In vivo studies in mice 
expressing luciferase showed that PTD-DRBD luciferase siRNA led to 50% 
reduction in luciferase expression from 24 hours following treatment which lasted for 
almost 2 weeks (Eguchi et al., 2009). Another study using the TAT PTD-DRBD 
complexed to siRNA in mice, expressing human U87MG-EGFR vIII glioblastoma, 
showed significant reduction in the size of the tumour and greater than 10 fold 
decrease in mRNA levels (Michiue et al., 2009). Hence, the fusion of TAT PTD and 
DRBD has shown significant potential in vivo studies for siRNA delivery.  
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The second strategy used to deliver siRNA in the cytoplasm of the cell is the covalent 
strategy. Here again, the covalent bond can be reversible or irreversible. The 
irreversible bond can be formed during chemical synthesis of CPP with a N terminal 
cysteine and siRNA strand with a 3‟ amino group with a heterobifunctional 
crosslinker (Chiu et al., 2004). Here, Tat peptide was covalently conjugated to siRNA 
which exhibited efficient cellular uptake in Hela cells. The complex was also able to 
reduce the expression of EGFP to 70% using 300nM siRNA and the expression of 
cdk9 to 54% using 200nM siRNA (Chiu et al., 2004). Although this strategy induces 
rapid cell uptake and cytoplasmic localisation, the irreversible bond between the CPP 
and siRNA could disrupt the functionality of siRNA (Endoh and Ohtsuki, 2009). An 
alternative method is the reversible covalent strategy which involves the formation of 
disulfide bond between the peptide and the 5‟ end of the sense strand. The disulfide 
linkage gets reduced in the cytoplasmic environment, thereby releasing the cargo in 
the cytoplasm of the cell in its active form (Davidson et al., 2004). However, the 
difficulty involved in this procedure is the need for purification after the formation of 
disulfide bonds to remove any traces of free unbound peptide and also bears the risk 
of altering the biological activity of the cargo (Morris et al., 2008, Deshayes et al., 
2008). Hence, due to these limitations, non-covalent complexation of peptide and 
siRNA seems to be a more attractive option mainly due to the simplicity of the 
complex preparation.  
 
CPPs have a considerable potential in delivering siRNA in various cell types in vitro 
and in vivo. Use of multifunctional peptides has only enhanced their cell penetration, 
target specificity and endosomal escape of the complex. Tat-LK15 has produced 
higher transfection efficiency when compared to Tat and LK15 peptides alone. Hence, 
this multifunctional peptide could prove to be an efficient gene delivery vector for 
targeting BCR-ABL in chronic myeloid leukemic cells studied here. 
 
 
Chapter 2 
65 
 
Chapter 2 
Aims and Objectives 
Chronic Myeloid Leukemia is characterised by the presence of bcr-abl fusion gene 
that translates into BCR-ABL protein. BCR-ABL has deregulated tyrosine kinase 
activity that is directly involved in the pathogenesis of the disease. Hence, the 
expression of BCR-ABL is an attractive therapeutic target. RNA interference is the 
use of shRNA plasmid or siRNA to target the expression of a protein by degrading 
the target mRNA, thereby inhibiting the expression of the protein. The potential of 
RNA interference has made it possible to target the expression of several proteins 
including BCR-ABL in CML cells.  
The widely used shRNA plasmid or siRNA delivery methods for CML include the 
use of viral vectors. Even though viral vectors are widely used in the clinical trials, it 
still poses certain risks like integration into the host genome and immunogenic 
reactions leading to toxicity. Other widely used methods include physical methods 
like microinjection, gen gun and electroporation. However, these methods are also 
limited due to their invasiveness and hence are a less attractive option for in vivo 
applications.   
The limitations associated with the viral and physical methods widen the scope for 
alternative methods including gene delivery using the non-viral vectors to be 
considered. Non-viral methods like Cell Penetrating Peptides (CPPs) represent a 
promising field that offer the advantage of cellular delivery of cargo as well as low 
cytotoxicity. CPPs have shown the ability to transfect wide range of cell lines and 
delivery of various cargoes. Even though CPPs are efficient at cell penetration, they 
are limited by their poor endosomal escape. To counteract this problem, various 
multifunctional peptides have been recently developed which combine some of the 
key properties namely DNA complexation, cell penetration, endosomal escape, 
nuclear or cytoplasmic localisation. Recent studies have shown the potential of 
multifunctional peptides to deliver various cargoes in vivo as well with very little or 
no toxicity. Therefore, this makes the use of CPPs modified to attain certain features 
a more attractive option. One such example of a multifunctional peptide that was 
recently reported from our lab is Tat-LK15, fusion of CPP Tat peptide and 
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membrane lytic LK15 peptide. Tat-LK15 has shown the ability to complex and 
delivery DNA in adherent cell lines like HT29 and HT1080. Tat-LK15 also showed 
increased transfection efficiency when compared to parent peptides Tat and LK15.   
2.1 Hypothesis 
Consequently, it was hypothesized that efficient and long lasting silencing of the 
protein BCR-ABL expressed in chronic myeloid leukemia cells could be achieved by 
using a non-viral gene delivery system based on an appropriate siRNA or shRNA 
plasmid complexed to the multifunctional peptide Tat-LK15. 
2.2 Aims 
More specifically this project aimed at: 
1) producing non toxic, well characterised non-viral gene delivery systems 
based on electrostatic interactions between the vector and DNA or siRNA 
2) Demonstrating the ability of these non viral gene delivery systems to be taken 
up by cells, transfect them and finally silence protein expression. 
3) Establishing differences between siRNA and shRNA plasmid based 
complexes in terms of silencing. 
  
2.3 Objectives 
The above mentioned aims of the project will be achieved through the following 
objectives: 
1. Assessment of i) the ability of Tat-LK15 and Lipofectamine (used as positive 
control vector) to form complexes with DNA and siRNA: this point will be 
studied using YO-PRO-1 displacement assay; ii) the physico-chemical 
properties of the peptide based complexes by determining the size and zeta 
potential of the complexes. 
2. Determination of the toxicity of peptide and complexes by MTT assay 
3. Evaluation of the transfection efficiency mediated by Tat-LK15 and 
Lipofectamine using pEGFPLuc plasmid: the expression of luciferase in 
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K562 cells will be measured. Subsequently we will be able to determine the 
optimum (+/-) charge ratios for both Tat-LK15 and Lipofectamine based on 
the luciferase assay and cytotoxicity study. 
4. Characterisation of cellular association of Tat-LK15 and Lipofectamine by 
flow cytometry and confocal microscopy: quantitative evaluation of uptake 
by flow cytometry will be carried out using fluorescently labelled DNA and 
siRNA at increasing concentrations of DNA and siRNA. Confocal 
microscopy will be used to observe the cellular localisation of the complexes 
in K562 cells. 
5. Evaluation of the ability of the shRNA plasmid complexed to Tat-LK15 to 
silence the expression of the protein BCR-ABL (compared with 
Lipofectamine/shRNA plasmid complexes) for a range of shRNA plasmid 
concentrations. The gene silencing of bcr-abl will be evaluated by 
determining the expression of the protein using western blot and mRNA 
levels using qRT-PCR. 
6. Determine the variation in shRNA plasmid mediated reduction in protein 
levels over time. 
7. Evaluation of the ability of the siRNA complexed to both Tat-LK15 and 
Lipofectamine to silence protein expression: western blotting will be used to 
determine the expression levels of the BCR-ABL protein. 
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Chapter 3 
Materials and Methods 
 
Materials 
3.1 Reagents for cell culture  
Cell culture reagents like RPMI 1640 (without L-Glutamine and Phenol Red), OPTI-
Mem, Penicillin-Streptomycin, L-Glutamine, Foetal bovine Serum (FBS) were 
purchased from Invitrogen, UK.  Cell line K562 was obtained from ATCC. 
Lipofectamine™ (#18324-012) was purchased from Invitrogen, UK. MTT (#M5655) 
was purchased from Sigma Aldrich, UK. 
 
3.2 Reagents for shRNA plasmid and siRNA  
pSilencer 2.1 U6 hygro shRNA expression plasmid (#27104) was purchased from 
Ambion Inc (Applied Biosystems, UK). siRNA targeting b3a2 isoform was 
purchased from Dharmacon, UK. Cy5 Nucleic acid labelling Kit was purchased from 
Mirus Bio (LabelIT, USA). Negative control siRNA was purchased from Sigma (All 
Stars Negative Control siRNA). 
 
3.3 Reagents for cloning  
pSilencer 2.1 U6 hygro siRNA expression vector (Ambion, UK), Bam HI and 
HindIII (Roche, UK), Tryptone, NaCl, Yeast Extract, LB agar, DH5 alpha, 
Ampicillin, T4 DNA Ligase, 10X T4 DNA Ligase buffer, Oligonucleotides 50 nmole 
synthesis scale (Invitrogen, UK), DNA sequencing primers (Invitrogen, UK), 
Annealing solution (Ambion, UK). 
 
3.4 Reagents for western blot analysis  
Primary Antibody for BCR-ABL targeting the N-terminal region of BCR (N-20 
#sc:885) was purchased from Santa Cruz Biotechnology Inc, USA. Primary antibody 
for α-Tubulin (#ab4074) and β-Actin (#ab8226) was purchased from Abcam. 
Secondary antibody for Rabbit IgG, HRP-Linked Whole Ab (from donkey) (#NA934) 
was purchased from GE Life Sciences. SuperSignal West Pico Chemiluminescent 
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Substrate (#34077) was purchased from Thermo Fisher Scientific, UK. PageRuler™ 
Plus prestained protein ladder (Fermentas, UK), Immobilon-P transfer membranes 
(Millipore, UK).  
 
3.5 Reagents for lysis buffer  
Reagents for TNN cell lysis buffer: Trizma Base (#T1503), Sodium Chloride 
(#S9625), Ethylenediaminetetraaceticacid (EDTA) (#E6758), Sodium Orthovanadate 
(#S6508), β Glycerol Phosphate (#G9891), Sodium Pyrophosphate (#P8010) and 
Protease Inhibitor (P8340) were all purchased from Sigma Aldrich, UK. Nonidet P-
40 (#74385), Dithiothereitol (DTT) (#43819) and Phenylmethanesulfonyl fluoride 
(PMSF) (#78830) were purchased from Fluka. 
 
3.6 Reagents for luciferase assay   
Luciferase assay kit was purchased from Promega, UK. 5X cell culture lysis reagent 
was supplied along with the kit, which was later diluted to 1X dilution. 
 
3.7 Reagents for quantitative real time PCR  
SYBR® Green JumpStart™ Taq Ready-Mix™ was purchased from Sigma, oligo-dT 
primer from ABgene, Bioscript™ Reverse Transcriptase (Bioline, UK) 10X Reverse 
Transcriptase buffer and dNTP (Bioline, UK). 
 
3.8 Buffer preparation 
3.8.1. Bacterial cell growth buffers  
3.8.1.1 TB buffer   
PIPES 1.62 g, 125 mL of 1 M KCl and 7.5 mL of 1 M CaCl2 were mixed. The pH 
was adjusted to 6.7 with KOH. The volume was made up to 500 mL using water and 
5.45 g Mn(II)-Tetrahydrate was added. The buffer was filtered with 0.22 µm filter 
and stored at 4ºC. 
 
3.8.1.2 SOB  
Super optimal broth (SOB) was prepared using the following constituents: Bacto 
tryptone 20 g, Bacto yeast extract 5 g, NaCl 0.5 g and water was added to 950 mL. 
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10 mL of 250 mM KCl (1.86 g KCl/100 mL H2O) was added and the pH was 
adjusted to 7.0 with 0.2 mL 5 N NaOH. The volume was made up to 1 L with water 
and sterilized by autoclave. Just before use, 5 mL of 2 M MgCl2 (19 g MgCl2 in 100 
mL H2O) was added to the broth. 
 
3.8.1.3 SOC  
SOC was prepared by supplementing Super optimal broth with glucose (SOB + 20 
mM glucose).  Sterilized 20mL of 1M glucose was added to 1 L of SOB.  
 
3.8.2. Agarose gel electrophoresis buffers  
3.8.2.1 TAE buffer   
TAE buffer (50X) was prepared by adding the following: Tris Base 142 g, glacial 
acetic acid 57 g, 50 mL of 0.5 M EDTA pH 8.0 and water was added to a final 
volume of 1L.   
 
3.8.2.2 DNA loading buffer  
DNA loading buffer (6X) was prepared by adding the following: 0.25% w/v 
bromophenol blue, 0.25% w/v xylene cyanol, 30% v/v glycerol, 50 mM EDTA.  
 
3.8.3 Non-denaturing polyacrylamide gel electrophoresis  
TBE buffer   
10X TBE buffer was prepared by adding 0.89 M Tris, 0.89 M boric acid, 20 mM 
EDTA and pH was adjusted to 8.3. 
1X TBE buffer   
89 mM Tris, 89 mM boric acid, 2 mM EDTA.  
 
3.8.4 Western blot buffers  
3.8.4.1 High salt lysis buffer  
50 mM Tris HCl pH 7.4, 240 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40 
supplemented with freshly added 1 mM DTT, 1mM Phenylmethanesulfonyl fluoride, 
and approximately 1 g of protease inhibitor per cell lysate. 
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3.8.4.2 Sample buffer  
Sample buffer (3X) was prepared by adding the following constituents at the given 
strength: 187 mM Tris pH 6.95, 30% glycerol, 15% β mercaptoethanol and 6 mg/mL 
of SDS and 0.01% bromophenol blue. 
 
3.8.4.3 SDS buffer  
30 g Trizma buffer, 144 g glycine, 10 g SDS, final volume of water to 1L was added 
to obtain 10X SDS buffer. 1X SDS buffer was used in Western blot.   
 
3.8.4.4 Western blot transfer buffer  
66 g Trizma buffer, 225 g glycine, final volume of water to 1L was added to obtain 
10X transfer buffer. To obtain 1X transfer buffer, 100 mL of 10X transfer buffer was 
mixed with 200 mL methanol and 700 mL water. The 1X transfer buffer was directly 
used in Western blot.  
 
3.8.4.5 PBS buffer  
14.8 g NaCl, 6.49 g NaH2PO4.H2O and 50.07 g Na2HPO4.H2O made up to 2 L with 
water to obtain 10X PBS buffer.  
  
3.8.4.6 PBS-Tween 
1X PBS buffer was mixed with Tween 20 (final concentration of 0.1%).  
 
3.8.4.7 Resolving gel  
The resolving gel for a 7.5% SDS polyacrylamide gel was prepared with the 
following composition: 13.3 mL of water, 7 mL of acylamide, 7 mL of 1.5 M Tris 
pH 8.95, 280 µL of 0.2M EDTA, 280 µL of 10% SDS, 157 µL of Ammonium 
persulphate, 17 µL of TEMED. This mixture is sufficient to prepare three resolving 
gels. 
 
3.8.4.8 Stacking gel  
The stacking gel for a 7.5% SDS polyacrylamide gel was prepared with the 
following composition: 6.73 mL of water, 1.67 mL of acrylamide, 1.25 mL of 1 M 
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Tris pH 6.95, 100 µL of 0.2 M EDTA, 100 µL of 10% SDS, 100 µL of 10% 
Ammonium persulphate, 10 µL TEMED. The mixture is sufficient to prepare three 
stacking gels. 
 
Methods   
3.9 Tat-LK15  
CPP HIV-Tat (49-57) (RKKRRQRRR) was fused to membrane active peptide LK15 
(KLLKLLLKLLLKLLK) using the linker GGG between the two sequences. Tat-
LK15 peptide (RKKRRQRRRGGGKLLKLLLKLLLKLLK-CONH2) having a net 
positive charge of +13 was synthesized by Advanced Biomedical (UK) with >95% 
purity. 
 
3.10 Cell culture techniques  
3.10.1 Cell lines  
Chronic Myeloid Leukemic cell line K562, a suspension cell line, was used in this 
study. K562 cells were cultured using RPMI complete medium which was 
supplemented with FBS (10% v/v), Pen-Strep (1% v/v) and L-Glutamine (2 mM) at 
37º C in a 5% CO2 incubator. The complete medium was then stored at 4º
 
C and was 
pre-warmed in a 37º
 
C water bath before use. The shelf life of the complete medium 
is around 6 weeks. 
 
3.10.2 Cell counting and subculturing   
K562 cells were subcultured by centrifuging for 3 minutes at 1000 rpm; the 
supernatant was then aspirated and the pellet resuspended in 1 mL of fresh complete 
medium. A 10 µL sample was pipetted and added on a haemocytometer. Following 
this step, a sterilized cover slip was placed over it to spread the culture by capillary 
action to cover the entire grid. The haemocytometer, as shown in Figure 3.1, contains 
4 main squares each of which is further divided into 64 small squares each measuring 
1 mm x 1 mm with a depth of 0.1mm. The number of cells in each of the four 
squares and the number of cells in 1 mL was calculated as follows:  
factordilution  x 2500 x squares 4in count  cell of Sum  mLcount /  Cell   
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Figure 3.1: A schematic representation of a haemocytometer. The numbers 
represent the boxes where the cells are counted. These boxes have an area of 1 mm
2
. 
 
3.10.3 Cell cryopreservation  
Cryopreservation of cells is performed to prepare stocks of cells and to prevent the 
need to have all the cell lines in culture at all times and to work with cells in log 
phase of growth. Some of the other advantages of cell cryopreservation are: 
 
 Reduce risk of contamination in culture, 
 Reduce cross contamination from other cell lines, 
 Reduce risks of morphological changes, 
 Work constantly with healthy cells having higher cell division. 
 
This method was performed on cells in the log phase of growth, which essentially 
was taken before confluency was reached. The media used for freezing the cells was 
made using 45% v/v serum (essentially >20%), 10% DMSO (cryoprotectant) and 
RPMI. DMSO is a cryoprotectant which preserves the cell wall from rupturing due to 
the formation of ice crystals. 1 mL of the culture was then added to 500 µL of the 
freezing medium in a cryovial (Nalgene) and kept at -80º
 
C overnight after which it 
was transferred to a liquid nitrogen tank.  
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3.10.4 Cell resuscitation  
Cells resuscitation involves rapid thawing to enable efficient revival of cells. 
Immediately after taking cells from the liquid nitrogen tank cells were half immersed 
into a water bath maintained at 37º
 
C for 2-3 minutes until the culture was 
completely thawed. Then they were transferred to a culture flask containing pre-
warmed complete medium and allowed to grow in a 37º
 
C incubator maintained with 
5% CO2. Cell survival was checked the next day and fresh medium added. 
 
3.11 Cloning  
3.11.1 Plasmid DNA vectors  
Two plasmid DNA vectors were used in this study. One was the pEGFPLuc (6.4kbp) 
which expresses both luciferase gene and enhanced green fluorescence protein (GFP). 
The other plasmid DNA used was pSilencer hygro expression vector (4.8Kbp) 
(Ambion, Applied biosystems), as shown in Figure 3.2, which was used to express 
shRNA in mammalian cells.  
 
 
Figure 3.2: Map of Ambion’s pSilencer 2.1 U6 hygro shRNA expression vector. 
This image has been adopted from the Ambion handbook (AppliedBiosystems, 2008).  
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pSilencer plasmid DNA has a Col E1 origin for expression in bacterial cells, 
followed by Ampicillin resistance gene. The plasmid also has a human U6 RNA 
polIII promoter for expression in mammalian cell lines. The promoter sequence is 
then followed by the shRNA insert sequence and the RNA polIII termination 
sequence (poly T). The shRNA insert site is flanked by restriction enzymes BamHI 
and HindIII on either side.   
 
 
 
Figure 3.3: Design of shRNA insert. Diagrammatic explanation of the concept of 
hairpin loop structure formed when the insert from the pSilencer hygro vector is 
expressed in mammalian cells. This picture was obtained from the Ambion 
instruction manual (AppliedBiosystems, 2008). 
 
3.11.2 Oligonucleotide synthesis  
In order to form a hairpin-like conformation having a loop region after synthesis of 
mRNA, the shRNA insert to be synthesized should follow the guidelines given by 
the manufacturer. The oligonucleotides were designed as shown in the Figure 3.3 
shown above having the sequence of the sense strand (same sequence as target 
mRNA) followed by the loop sequence (CCTAAGAGA), the sequence of the 
antisense strand and, finally the polIII termination sequence (polyT), see Table 3.1. 
These oligonucleotides were synthesized with restriction sites of BamHI and HindIII 
flanking on either side, so that they could be inserted into the pSilencer2.0 hygro 
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vector. The oligonucleotides were synthesized on a 50 nmole scale by Invitrogen, 
UK, and the concentrations are shown in Table 3.2. 
 
Name  Oligonucleotide sequence 
B3A2 Sense 5' GATCCGCAGAGTTCAAAAGCCCTTCTCAAGAGAAAGGGCTTTTGAACTCTGC 
TTTTTTGGAAA 3'  
B3A2 Antisense 5' AGCTTTTCCAAAAAAGCCGAGTTCAAAAGCCCTTTCTCTTGAGAAGGGCTTTT 
GAACTCTGCG 3' 
 
Table 3.1: The sequences of the oligonucleotides synthesized for the cloning purpose.  
 
Oligonucleotides Molecular weight 
 (µg/µmole)  
Weight  
in µg 
Volume 
 of water 
Final  
concentration 
B3A2 sense 19420.6 1224.47 1.2ml 1µg/µl 
B3A2 Antisense 19356.6 931.60 900µl 1µg/µl 
 
Table 3.2: Stock concentrations of oligonucleotides. This table shows the weight of 
the oligonucleotides obtained from Invitrogen and the dilutions made with water. 
 
As the oligonucleotides were obtained in vials in a lyophilised form, they were given 
a quick spin on the microcentrifuge to settle the oligonucleotides. Sterile water was 
added to them to make their final concentration to 1 µg/µL. The oligonucleotides 
were then stored at -20º
 
C until further use. 
 
3.11.3 Annealing of oligonucleotides  
The synthesized oligonucleotides have to be annealed to enable stability of double 
stranded oligonucleotides as it results in higher efficiency of ligation and helps 
cloning into the vector. The annealing reaction was set up according to the volumes 
specified in Table 3.3. The sample was placed in a heating block at 90º
 
C for 3 
minutes and then the heating was turned off and allowed to cool down to 37º
 
C which 
takes usually about 2 hours. Then, the sample was either ligated to the vector using 
the protocol given below or stored at -20º
 
C for future use. While storing at -20º
 
C is 
feasible, it is recommended to proceed with the ligation reaction on the same day as 
the annealing is more efficient.  
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Volume of Oligonucleotides Component 
2µl Sense siRNA template oligonucleotide 
2µl Antisense siRNA template 
46µl 1XDNA Annealing solution 
 
Table 3.3: Volume of the constituents in the annealing reaction.  
 
3.11.4 Ligation of vector and insert  
The following protocol was used for ligation of the annealed oligonucleotides 
containing the BamHI and HindIII overhangs into the pSilencer plasmid DNA vector. 
5 µL of the annealed solution was further diluted to 50 µL with sterile water. The 
ligation reaction setup is shown in Table 3.4. The reaction samples were either left 
overnight in a PCR machine at 16º
 
C or left at room temperature overnight. The 
minus insert sample is a negative control in which no annealed oligonucleotide was 
added. The ligated plasmid was then transformed into DH5α competent cells.  
 
Plus-Insert Minus-Insert Component 
2µl -- Diluted annealed insert 
-- 2 µl 1XDNA Annealing solution 
5 µl 5 µl Sterile water 
1 µl 1 µl 10X T4 DNA ligase buffer 
1 µl 1 µl pSilencer hygro vector 
1 µl 1 µl T4 DNA ligase (5U/ µl) 
 
Table 3.4: Volume of constituents of Plus-insert and Minus-insert ligation 
reactions. 
 
3.11.5 E.coli competent cell preparation  
Ampicillin stock solution  
A stock solution of Ampicillin (50 µg/µL) was prepared and aliquoted in 1.5 mL 
microcentrifuge tubes before being stored at -20º
 
C. 
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Competent cell preparation  
Competence, the property of a bacterial cell to take up DNA from the environment, 
can be artificially induced to enable the bacteria express the DNA of interest. To 
make competent cells, an overnight culture, which has an absorbance of 0.1 at 
600nm, was inoculated in a 250 mL SOB (section 3.8.1.2) in a 2 L flask. It was 
grown at 18º
 
C till the absorbance reached 0.6, which takes about 18-24 hours. 
Having reached the correct absorbance, the culture was kept on ice for 10 minutes 
and centrifuged at 6000 rpm for 30 minutes. After discarding the supernatant, the 
pellet was resuspended in 80 mL of TB buffer (prepared as described in Materials 
section 3.8.1.1), kept on ice for 10 minutes and spun down. The pellet was again 
resuspended in 20 mL of TB buffer and 1.4 mL of DMSO and kept on ice for 10 
minutes. The suspension was then aliquoted in centrifuge tubes and flash frozen with 
liquid nitrogen and then maintained at -80º
 
C.   
 
3.11.6 Transformation  
Competent cells were thawed at room temperature (RT). 5 µg of plasmid DNA was 
added to pre-cooled 1.5 mL microcentrifuge tubes containing 200 µL of competent 
cells. The mixture was kept on ice for 10 minutes, then given a heat shock at 42º
 
C 
for 45 seconds and kept on ice immediately for 2 minutes. 0.8 mL of SOC medium 
(section 3.8.1.3) was added and the resulting mixture was shaken for 1 hour at 37º
 
C. 
200 µL of sample was then plated on to a LB agar plate containing 50 µg/mL of 
Ampicillin or any other antibiotic based on the resistance gene present on the 
plasmid DNA introduced. The agar plate was then incubated at 37º C overnight and 
the number of colonies grown was counted. 
 
3.11.7 Plasmid DNA preparation   
Plasmid DNA was extracted from the bacterial cells using Qiagen‟s QIAprep 
miniprep kit. The colonies were picked and inoculated into tubes containing 5 mL 
LB broth mixed with the antibiotic (50 µg/mL of Kanamycin for pEGFPLuc, and 50 
µg/mL of Ampicillin for pSilencer shRNA plasmid) and grown overnight in a 37º
 
C 
shaker at 250 rpm. 1.5 mL of the culture was then taken in a microcentrifuge tube 
and centrifuged at 6000 rpm for 10 minutes. The supernatant was discarded and the 
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pellet was then resuspended in 250 µL of solution P1 (RNAase and Lyseblue 
solution was added to P1 and stored at 4º
 
C until future use. The Lyseblue solution is 
an indicator for cell lysis and protein precipitation). 250 µL of solution P2 was added 
and mixed by inverting the tube 4-6 times (efficient lysis should be indicated by blue 
colour). 350 µL of solution N3 was added and it was also mixed by inverting the 
tube 4-6 times. After turning white indicating precipitation of SDS from the lysis 
solution, the solution was centrifuged at 13,000 rpm for 10 minutes. The supernatant 
was then added to the QIAprep spin columns, which were centrifuged for 60 seconds 
and the flow-through was discarded. 750 µL of buffer PE was added to the spin 
column which was centrifuged again for 1 minute and the flow through was 
discarded. An additional quick spin was done to remove any residual PE. The 
QIAprep column was placed in a sterile microcentrifuge tube and 50 µL of elution 
buffer was added to elute the DNA. After one minute, the solution was centrifuged 
for one minute. The presence of DNA was checked by running an agarose gel 
electrophoresis along with 1 kb DNA ladder. DNA was then stored at -20º
 
C for 
future use.  
 
3.11.8 DNA gel electrophoresis  
1% (w/v) agarose gel with 0.5X TAE (section 3.8.2.1) was used to resolve fragments 
of DNA under a particular electric field in presence of ethidium bromide, a DNA 
intercalating dye, which is excited with UV using a UV illuminator (Ex 302nm / Em 
595nm). An agarose solution was obtained by heating (about 90ºC) the required 
amount of agarose and the buffer. After disappearance of the crystals, the solution 
was cooled down, 3 µL of Ethidium bromide (5 µg/mL) added and the resulting 
solution was poured onto the gel casting plate. After 30 minutes, the resulting gel 
was placed in the electrophoresis tank filled with 1X TAE buffer. DNA samples 
mixed with gel loading buffer (section 3.8.2.2) were loaded into the wells. Then the 
gel was run for 30 minutes at (6.6 V/cm). The gel was then carefully taken and 
imaged under a UV illuminator.  
 
3.11.9 Restriction digestion  
Double-digest using Restriction Endonucleases (RE) was performed to cut the 
circular plasmid DNA at two different sites to excise out a particular fragment of 
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DNA potentially used as a confirmatory test to verify the DNA fragment insertion. 
The chosen two REs were BamHI and HindIII as the restriction sequences were 
present in the plasmid DNA. Interestingly for the experiment, they have a common 
Buffer B (10X). A solution containing 5 µL of the DNA sample, 1 µL of each of the 
enzymes, 3 µL of Buffer B (1X final concentration) and 20 µL of water (total 
reaction volume 30 µL) was prepared and incubated in a 37º C water bath for 3 hours. 
After digestion, 5 µL were taken and loaded on an agarose gel to check the bands of 
the DNA fragment.  
 
3.11.10 Non-denaturing polyacrylamide gel electrophoresis  
Non-denaturing polyacrylamide gels may be used for the separation of small double 
stranded DNA molecules, ideally which are less than 1000 base pairs. Thus, these 
gels are of interest to separate the approximately 60 bases pairs DNA. A 12% w/v 
non-denaturing polyacrylamide gel, which is ideal for resolving bands of sizes from 
50 to 200 bp, was used (Russell and Sambrook, 2001). The gel solution was prepared 
by mixing 20 mL of 29:1 acrylamide/bisacrylamide solution with 5 mL of 10X TBE 
buffer (section 3.8.3) and making it up to almost 50 mL with sterile water. Then, 250 
µL of 10% w/v Ammonium persulfate and 25 µL of NNN‟N‟-
Tetramethylenediamine (TEMED) were added to initialise and catalyse the gel cross-
linking reaction. The solution was then immediately poured into the SDS-PAGE 
cassette and the gel was allowed to cast for at least 30 minutes. Once the 
polymerization was complete, the comb was removed and the wells were rinsed with 
water. The lower tank was filled with 1X TBE buffer and DNA samples mixed with 
DNA gel loading dye were loaded into the wells. 1X TBE was then used to fill the 
entire tank till the brim of the gel plates covering the wells. The gel was then run for 
about 45 minutes at 6.6V/cm. At the end of the run, the gel was separated from the 
plates carefully, and then stained with ethidium bromide 0.5 µg/mL for 30 minutes. 
The gel was then viewed under the UV illuminator. 
 
3.11.11 Gene sequencing  
DNA sequencing was performed to confirm the precision of the cloning process. The 
plasmid was sequenced at the DNA sequencing facility at the Stopford Building, 
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University of Manchester. The cloned plasmid was sequenced using the following 
primers: 
 
T7 forward primer: 
5‟ TAATACGACTCACTATAGGG 3‟ 
Reverse Primer: 
5‟ AGGCGATTAAGTTGGGTA 3‟ 
 
3.12 siRNA 
The siRNA was synthesized by Dharmacon (UK) that matched the B3A2 target 
region as covered by the shRNA. The siRNA sequence used was: 5‟ 
GCAGAGUUCAAAAGCCCUU 3‟. The negative control siRNA was purchased 
from Sigma (All stars negative control, Sigma, UK). 
 
3.13 Vector/oligonucleotide complex preparation 
 Peptide/DNA and Peptide/siRNA complex formation  
Peptide and DNA complexes were formed at increasing peptide/DNA charge ratios. 
A 1:1 charge ratio is defined as the theoretical electroneutrality i.e. the number of 
positive charges on the peptide is the same as the number of negative charges on the 
DNA. The number of positive charges required for Tat-LK15 (MW 3282.19) at a 
particular charge ratio is detailed below: 
 
1µg of DNA has 9.71 x 10
14 
basepairs 
As each base pair bears two negative charges, 1µg of DNA has 1.942 x 10
15
 negative 
charges. 
On the other hand, Tat-LK15 has 13 positive charges 
Thus to reach electroneutrality, one needs: 
 
peptide LK15-Tat of molecules 10493.1
13
10942.1 14
15


 
(or) 
required LK15-Tat of moles 1048.2
10023.6
10493.1 10
23
14



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Finally, the amount of Tat-LK15 peptide to reach electroneutrality is  
 
:weightmolecular  average  peptide of moles ofNumber   
 
g81.019.32821048.2 10    
  
Similarly, for 2:1 charge ratio of Tat-LK15/DNA, 1.62 µg of Tat-LK15 is required. 
To prepare a particular charge ratio peptide/DNA complexes solution, the correct 
amount of peptide was dissolved in 50 µL of HEPES-buffered saline (10 mM 
HEPES, 150 mM NaCl, pH 7.4). 1 µg of oligonucleotide (DNA or siRNA) was 
resuspended using 10 mM HEPES buffer pH 7.4 to a final volume of 50 µL. The 
peptide solution was then added to the oligonucleotide solution, agitated for a few 
seconds and left to incubate at room temperature for 30 minutes. This solution was 
then added to 900 µL of OptiMEM (Invitrogen, UK) containing cells in a 6 well 
plate. Peptide/siRNA complexes were formed using the same method.  
 
 Lipofectamine and nucleotide complexes  
Complex formation for Lipofectamine was based on weight ratio rather than 
charge ratio. The complex formation between Lipofectamine and oligonucleotide 
was prepared according to the manufacturer‟s instruction (Invitrogen). For a 1:1 
weight ratio, 1µg of Lipofectamine was diluted in 50 µL of Opti-MEM-1. The 
Lipofectamine solution was then mixed with 1 µg of DNA or siRNA previously 
diluted in Opti-MEM: the resulting solution was incubated for 15 minutes at room 
temperature. The Lipofectamine based complexes were then added to cells 
maintained in Opti-MEM in a 6 well plate. 
 
3.14 YO-PRO-1 displacement assay 
DNA was labelled using YO-PRO-1 fluorescent dye (Invitrogen, UK) at a ratio of 
50:1 dye/base pairs and at a ratio of 5:1 for siRNA. The methodology to determine 
the amount of dye required to label DNA and siRNA is presented below: 
 
As previously, 1µg of DNA has 9.71 x 10
14 
basepairs 
To reach a theoretical number of one dye every 50 base pairs, one need to have:  
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requiredpair  baseper  moleculaes 1-YOPRO of molecules 10942.1
50
1071.9 13
14


 
 
On the other hand, a 0.1mM solution of YO-PRO-1 was prepared by diluting a 1mM 
solution using DMSO. 
Number of YO-PRO-1 molecules in 1L of 0.1 mM solution is 
molecules 10023.610023.6101 19234    
Thus for the labelling one needs: 
L322.0
10023.6
100010942.1
  needed dye of Volume
19
13



   
 
Consequently to fluorescently label 1µg of DNA, 0.322 µL of the 0.1mM solution of 
dye was used to achieve a 50:1 DNA bp: dye ratio. Effectively, 3µg of DNA were 
diluted to a volume of 60 µL by addition of 10 mM HEPES buffer (pH 7.4). The 
required amount of YO-PRO-1 to label these 3 µg of DNA was diluted to 60 µL. The 
two solutions were mixed and incubated at 4º C overnight. The methodology to label 
siRNA is similar except that a higher dye: base pair ratio of 5:1 was used.  
 
The formation of peptide/DNA complexes was followed by adding increasing 
amounts of vector to the YO-PRO-1 DNA solution as described in the 
vector/oligonucleotide complexes formation section 3.18. The fluorescence intensity 
was measured using the count rate by fluorescence correlation spectroscopy, a highly 
sensitive technique (Zeiss Confocor 2).  
 
3.15 Size and zeta potential measurement  
Dynamic light scattering (DLS) is a technique used to measure the size of the 
particles, by determining the Brownian motion of particles and correlating it with 
their size. Light is used to illuminate the samples and the intensity of light scattered 
due to the Brownian motion of particles is measured using an optical arrangement. 
Smaller particles move more rapidly due to collision with the fluid medium and 
hence scatter more light. Whereas, the larger particles are relatively less disturbed by 
the fluid medium and hence scatter less light. The velocity with which these particles 
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move can be defined using the translational diffusion coefficient, from which the size 
of the particles is calculated. The Stokes Einstein equation is as follows: 
 
d(H) = kB T/ 3πηD 
 
Where, d(H) is the hydrodynamic diameter, D - translational diffusion coefficient, k - 
Boltzmann‟s constant, T - absolute temperature and η – viscosity. 
 
Tat-LK15/DNA or Tat-LK15/siRNA complexes were prepared as described above 
(section 3.18). The complexes were prepared in 10 mM HEPES buffer (pH 7.4) and 
the final concentration of DNA or siRNA in the cuvette was 10 µg/ml. The size of 
the particles was measured using Zetasizer 3000 HS (Malvern Instruments, UK) and 
the temperature was equilibrated to 37°C.  
 
Zeta potential  
Zeta potential is the potential that exists between the dispersion medium and the 
stationary layer of the fluid that is attached to the dispersed particle. Zeta potential 
provides information on the stability of the particles in suspension. Particles with 
high zeta potential tend to repel each other and hence are less likely to aggregate. 
However, particles with low zeta potential tend to aggregate due to little or no 
repulsion between the particles. Samples for measuring the zeta potential were 
prepared in the same way as mentioned above for size measurement using DLS. 
DNA or siRNA complexes were dissolved in 10 mm HEPES buffer (pH7.4) at a 
concentration of 10 µg/ml and the zeta potential measured using Zetasizer 3000 HS 
(Malvern Instruments, UK).  
 
3.16 Transfection 
K562 cells were plated at a cell density of 1.5x10
6 
cells in 900 µL of reduced serum 
Opti-MEM I in a 6 well plate (Corning, UK). 100 µL of Peptide/DNA complexes 
were added to the cells and incubated in a 37° C incubator for 4 hours. After 4 hours, 
the medium was removed and the cells washed with PBS. The cells were then 
resuspended in 2 mL of RPMI supplemented with 10% FBS without any antibiotics 
and incubated for 96 hours or 192 hours for shRNA plasmid based transfection and 
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48 hours for siRNA based transfection. The cells were replaced with fresh complete 
medium every 72 hours. 
 
3.17 Determination of transfection efficiency  
The transfection efficiency was determined using Luciferase assay, flow cytometry 
and confocal microscopy studies. For the luciferase assay, pEGFPLuc (BD 
Bioscience Clontech, UK) was complexed to Tat-LK15 peptide and Lipofectamine 
as described previously (section 3.18) to study the uptake of complexes in cells. For 
the flow cytometry and confocal microscopic studies, the plasmid DNA was labelled 
using Cy5 to quantify the cellular uptake. 
 
3.17.1 Luciferase assay  
For efficient DNA transfection, DNA needs to be delivered into the nucleus and 
result in efficient transcription of the gene. The protein‟s synthesis from the plasmid 
can be quantified by different methods. One method is to use a reporter plasmid e.g. 
pEGFPLuc that expresses both the firefly luciferase and enhanced green fluorescent 
protein (GFP). Although luciferase assay is destructive to the cells, it provides an 
easy way to quantify the expression. The Promega luciferase assay kit was used to 
quantify luciferase which oxidises the substrate (luciferin) producing light. This light 
can be detected and measured using a luminometer (Flurostar Optima, BMG).  
 
Cells were treated with pEGFPLuc at 2:1 and 3:1 (+/-) peptide/DNA charge ratios 
for 4 hours after which cells were washed with PBS and replaced with fresh RPMI 
containing 10% FBS. For Lipofectamine, as mentioned earlier weight ratios were 
used and 2:1 and 3:1 weight ratios of Lipofectamine/DNA were used. 24 hours after 
treatment cells were washed with PBS, resuspended in 80 µL of 1X lysis buffer 
(Promega,UK) and kept on a rocker at 4
o
C for 30 minutes. Then, the mixture was 
vortexed for 15 seconds and centrifuged at 12000 rpm for 15 minutes in a 
microcentrifuge maintained at 4ºC. From the supernatant stored on ice, 20 µL 
samples were added into a 96 well plate in triplicate. The luciferase substrate was 
then thawed and dispensed at a volume of 50 µL per well by the luminometer 
(Flurostar Optima, BMG) and the luminescence was recorded.  
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3.18 Determination of oligonucleotide uptake 
3.18.1 Cy5 nucleic acid labelling 
DNA was covalently labelled using Cy5 nucleic acid labelling kit (Mirus Bio, USA). 
Labelling ratios, dye concentration or incubation time can be amended depending on 
the level of sensitivity required. Here, the plasmid DNA (pcDNA3 and pEGFPLuc) 
was labelled at a 1:10 dye to DNA (v/w) ratio using the Cy5 nucleic acid labelling kit 
according to manufacturer‟s instructions with slight modifications. Briefly, 20 µg of 
DNA was added to a microcentrifuge tube containing 2 µL of the Label IT reagent, 5 
µL of 10X labelling buffer with molecular biology grade water used to make up to 
50 µL of sample. After 2 hour incubation at 37° C, the samples were purified using 
the G50 microspin columns provided. The empty microspin column was, first, 
centrifuged for 1 minute at 735 x g and the buffer collected was discarded. Then, the 
labelled DNA sample was applied to the bed of the microspin column, which was 
again centrifuged for 2 minutes. The purified labelled DNA collected at the bottom 
of the microspin column was then used directly for various applications like studying 
uptake using flow cytometry and confocal microscopy. 100% recovery of labelled 
DNA was assumed as per manufacturer‟s instructions. B3A2 siRNA was labelled 
using the same procedure but at a 1:2 (v/w) ratio. Transfection was performed using 
the Cy5 labelled DNA and siRNA as mentioned above. 
 
3.18.2 Flow cytometry 
Flow cytometry is used to study the uptake of fluorescently labelled products into 
cells while measuring the properties of individual cells. When cells are injected into 
the flow cytometry machine, they flow in parallel with the sheath fluid. This fluid 
then streamlines the cells into a single file of cells called hydrodynamic focussing 
(Rahman, 2006). The cells in a single stream pass through lasers, which excite them 
at particular wavelength. The light scattered from the cell at an angle of 20º is called 
the forward scatter and gives details on the size of the cell. The light scattered from 
the cell at an angle of 90º is called side scatter and provides information about 
granular content of the cells (Rahman, 2006). The forward and side scatters are 
unique to different cell types and also help distinguish live from dead cells. Forward 
scatter helps in identifying cellular debris and clumps that can be distinguished from 
single cell size information. Dead cells have lower forward scatter and higher side 
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scatter than living cells. Hence, these cells can be eliminated while gating the cells 
for analysis. The fluorescence measurements from the cells are collected by the 
detectors like photomultiplier tubes. The photodetector then translates the amount of 
light reaching it into electrical signals, which is processed into the final data that is 
plotted.    
 
For the experiments, cells were plated at a density of 1.5x10
6
 cells in 900 µL of Opti-
MEM in a 6 well plate. The desired vector/labelled nucleic acid complex was then 
added to the cells and incubated for 4 hours. After 4 hours, the cells were rinsed 
twice with PBS and then cells were trypsinised using 0.1% v/v trypsin/EDTA in PBS 
for 5 minutes at 37°C to remove any membrane-bound complexes and then washed 
again twice with PBS. RPMI supplemented with 10% v/v foetal calf serum (FCS) 
was then added to each well and the cells were centrifuged at 1,000 rpm for 5 
minutes. The supernatant was discarded and 0.5 mL of ice-cold PBS was used to 
resuspend the cell pellet. Fluorescence analysis was performed immediately at a 
minimum of 10,000 events/sample using fluorescence-activated cell sorter (FACS) 
(Becton Dickinson, UK) set up to detect red fluorescence (Ex 650 nm, Em 670 nm). 
Cell viability was determined based on live cells being gated using forward and 
sideward scatter. 
 
3.18.3 Confocal microscopy  
The uptake of Cy5 labelled DNA or siRNA complexed to Tat-LK15 and 
Lipofectamine was also studied using confocal laser scanning microscopy (CLSM). 
In confocal microscopy, a particular focal plane of a sample is illuminated or excited 
instead of the whole sample (Semwogerere and Weeks, 2005). Hence only receives 
signal from a particular focal plane, thereby reducing most of the background 
fluorescence by rejecting the light returning from the other layers of the sample by a 
pinhole aperture (Semwogerere and Weeks, 2005). This light is then collected by a 
detector e.g. the photomultiplier tube which sends the signals to the computer. The 
computer then assembles the data collected from the different points of a sample to 
form the final image. Confocal microscopy also enables construction of a 3D image 
using a process called sectioning where each section of the sample is imaged 
individually and then a 3D image is constructed from a stack of 2D images.   
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In the present study, K562 cells were transfected with Tat-LK15 and Lipofectamine 
complexed to Cy5 labelled siRNA (Em 647nm/Ex 670nm) for 4 hours. Cells were 
then washed with PBS twice and then incubated with Syto-16 (Em 488nm/Ex 518nm) 
at a concentration of 500 nM in the 37°C incubator for 5 to 10 minutes. The cells 
were then washed again with PBS and diluted with Opti-MEM to a required cell 
number. Approximately 400 µL of the sample was added to an 8-well Nunc plate and 
imaged by CLSM with a 20x objective lens. Cy5 was excited using the 633 He-Ne 
laser and Syto-16 was excited using a 488 Argon laser.  
 
3.18.4 Confocal image analysis  
Fluorescence intensities associated with the cells obtained by confocal imaging were 
quantified using Image J (NIH, USA). The image was first converted into a 16 bit 
gray scale image. The image was thresholded and a mask created dividing the image 
into objects and the background. The threshold was then adjusted till the background 
was dark against the fluorescence intensity of the bright regions. The fluorescence 
intensity associated with each cell was then measured and averaged by the number of 
cells in the image.   
 
3.19 Determination of protein expression  
3.19.1 Western blot 
Western blot is used to detect the presence of proteins by resolving the proteins in a 
denaturing condition and detecting those using antibodies. Briefly, the SDS PAGE 
gels are set using a particular concentration of polyacrylamide based on the size of 
the proteins to be resolved as the gel pore size is function of the gel concentration. 
Hence, a larger pore size may be used to resolve higher molecular weight proteins 
better while the smaller proteins migrating rapidly would not be resolved. As the 
present study mainly involves studying two proteins BCR-ABL (210 KDa) and α-
Tubulin (56 KDa), a 7.5% w/v polyacrylamide gel was used. The resolving gel 
(section 3.8.4.7) was first poured and allowed to set, followed by the stacking gel 
(section 3.8.4.8) set with the combs inserted. Once the gels have been set, they were 
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fitted into the gel running tank filled with 1X SDS buffer (section 3.8.4.3). 
Meanwhile, the protein samples were harvested and prepared as described below. 
 
Transfected cells were scrapped from the 6 well plate and centrifuged. After being 
washed with PBS, K562 cells were harvested using high salt lysis buffer (section 
3.8.4.1). Then, the cells were lysed for 25 minutes at 4°C and the cell debris removed 
by centrifugation at 13,000 rpm at 4°C for 15min. Protein concentration was 
estimated using the Bradford assay and the absorbance was measured at 595nm. 
Protein samples were mixed with a third volume of 3X sample buffer (section 3.8.4.2) 
and denatured by boiling at 95°C for 5 minutes.  
 
Equal amounts of proteins were loaded on a 7.5% w/v polyacrylamide gel alongside 
a PageRuler™ Plus prestained protein ladder (Fermentas, UK). Samples were run on 
a 7.5% w/v polyacrylamide gel placed in 1X SDS buffer (section 3.8.4.3) at 14.4 
V/cm till the proteins in the marker have reached a desired level. The samples were 
then transferred onto a Immobilon-P transfer membrane (Millipore, UK), placed in a 
1X transfer buffer (section 3.8.4.4) by transferring at 0.8 Amps for 2 hours. After the 
transfer, the membrane was blocked using 5% w/v milk for an hour and probed using 
anti-BCR-ABL primary antibody (Santa Cruz Biotechnology Inc, USA) (1:1000) and 
anti-α-Tubulin primary antibody (Abcam, UK) (1:10000) by incubating at 4°C 
overnight. Membrane was washed 5 times for 5 minutes each using PBS-Tween 
(section 3.8.4.6). Anti-rabbit secondary antibody conjugated to horseradish 
peroxidise (GE Life Sciences, UK) was diluted 10000 times using PBS-Tween and 
incubated with the membrane for 1 hour. After the incubation with the secondary 
antibody, the membrane was again washed 5 times for 5 minutes each using PBS-
Tween. Finally, the membrane was flushed with West Pico chemiluminescent 
substrate (Thermo Fisher Scientific, UK) for 2 minutes and visualized on a Fujifilm 
Super RX. 
 
3.19.2 Densitometric analysis 
Intensities of the bands obtained from the western blot were analyzed using the 
Image J software (NIH, USA). First, the background of the image was converted into 
a gray scale image. Bands in a single vertical lane were selected using the rectangular 
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selection tool and box of the same dimensions was used for the remaining lanes. 
Then, the lanes were plotted and the area of each peak corresponding to each band 
was determined after eliminating the background intensity. Finally, the intensities of 
BCR-ABL bands were divided by the intensity of the housekeeping protein α-
Tubulin.  
 
3.20 Determination of mRNA expression  
3.20.1 RNA extraction and reverse transcription  
K562 cells were washed with PBS and pelleted. RNA was extracted according to 
manufacturer‟s instruction (RNeasy Kit, Qiagen). Briefly, cells were lysed and 
homogenised using a buffer rich in highly denaturing guanidine-isothiocyanate. This 
inactivates the RNases present in the sample and ensures protection of RNA released 
from the cells. The lysate was then passed through a gDNA eliminator column, 
which efficiently removes genomic DNA using a high salt lysis buffer. Then the 
RNA was bound to the membrane in the columns using ethanol based solutions 
which was used to wash the column. This ensures that the impurities were washed 
away. RNA was then eluted in a small volume (50 µL) and the concentration was 
determined using the Nanodrop (Thermo Scientific, UK). 
  
During reverse transcription, the RNA was reverse transcribed into cDNA. This was 
done using Reverse Transcriptase. 1 mg/mL of RNA was reverse transcribed 
according to the two-step protocol (ABgene, UK) using an oligo-dT primer 
(ABgene). Briefly, 1 µg of RNA was used for each reverse transcription reaction. 1 
µL of Anchored Oligo was made up to 14 µL using molecular biology grade water 
(Fisher Scientific, UK) and incubated at 70º C for 5 minutes. Then Reverse 
Transcriptase buffer was added to a final concentration of 1X, followed by 0.5 mM 
dNTP (Bioline, UK) and 1 µL of Reverse Transcriptase (200 Units/µL). The 
resulting mixture was then incubated at 47º
 
C for 30 to 60 minutes. It was further 
incubated at 75º C for 10 minutes. The cDNA concentration was then measured 
using the instrument Nanodrop, which helps determine concentration of 
oligonucleotides. 
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3.20.2. Quantitative real time reverse transcriptase PCR  
The cDNA was diluted 4-fold with RNAse free water. qPCR analysis was performed 
using SYBR® Green JumpStart™ Taq Ready-Mix™ (Sigma). The expression of 
B3A2 mRNA was measured using the following primers: forward primer 5′ CAT 
CGT CCA CTC AGC CAC T 3′ and reverse primer 5′ ACG AGC GGC TTC ACT 
CAG 3′. The following primers were used to measure Rpl19: forward primer 5′ ATG 
TAT CAC AGC CTG TAC CTG 3′ and reverse primer 5′ TTC TTG GTC TCT TCC 
TCC TTG 3′. The PCR protocol mentioned in Table 3.5 was used on an Eppendorf 
Realplex realtime PCR machine. The protocol has 4 key steps; step 1 consisting of 
denaturation of double stranded nucleotide, step 2 consisting of denaturation, 
annealing and extension, step 3 consisting of annealing and step 4 involving the 
melting curve. The data was analysed using the Realplex software. The signal 
obtained from the B3A2 primers were normalised using the values obtained from the 
Rpl19 primers. 
 
 Temperature Time Number of cycles 
Step 1 95º C 2 minutes 1 cycle 
Step 2 
95º C 15 seconds 
44 cycles 50º C 30 seconds 
72 º C 30 seconds 
Step 3 72 º C 10 minutes 1 cycle 
Step 4 
95 º C 15 seconds 
Melting Curve 
72 º C 30 seconds 
Gradient 1 º C  
95 º C 30 seconds 
 
Table 3.5: Quantitative real time PCR reaction parameters. The protocol has 4 
main steps as elaborated in the section above.  
 
Chapter 3 
92 
 
3.21 Cytotoxicity studies 
 Vector cytotoxicity  
Vector cytotoxicity was determined using the colorimetric (3-[4,5-Dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay as described by (van de 
Loosdrecht et al., 1994). K562 cells were transfected as described earlier (section 
3.16) and incubated with the vector (Tat-LK15 or Lipofectamine) at a desired 
concentration for 4 hours at 37°C. Then MTT was added at a final concentration of 
0.5 mg/mL and incubated for 4 hours. The supernatant was then removed without 
disturbing the purple formazan crystals and 150 µL of DMSO was added. The plate 
was kept on a shaker at 150 rpm for 5 minutes at room temperature. The absorbance 
was measured using a plate reader at 550 nm. The percentage of cell viability of a 
test sample was calculated using the equation: 100
control
test
A
A
 
 Vector/Oligonucleotide cytotoxicity 
The procedure for determining the vector/nucleotide cytotoxicity was same as that 
described above except for the incubation time. The cells containing the complexes 
was washed with PBS and then returned to the plate for 24 hour incubation. This 
helps in determining the effect of oligonucleotide complexation to the vector and 
hence provides the toxicity of the complex itself. MTT solution was then added at a 
final concentration of 0.5 mg/mL. The remaining procedure was same as that 
described for vector cytotoxicity.  
 
3.22. Statistical analysis  
Differences between groups were calculated using Student t-test and a P value of less 
than 0.05 was considered significant. 
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Chapter 4 
Characterization of vector/nucleotide complexes and 
studying nucleotide uptake 
 
4.1 Introduction  
Leukemic cells, for instance, K562, have in the past been transfected by a number of 
means. One of the widely used methods is the viral vectors (Rangatia and Bonnet, 
2006), but they are limited by their high cytotoxicity and pose the risk of viral gene 
being integrated into the host genome (Hatefi and Canine, 2009). Another 
extensively used method is electroporation (Wohlbold et al., 2004) that also faces the 
problem of being impractical for use in vivo conditions (Meng et al., 2009). On the 
other hand non-viral vectors like lipid based transfection vectors have also been used 
successfully (Zhelev et al., 2004) (Wilda et al., 2002). Hence, it is necessary to 
consider other vectors for transfection of leukemic suspension cell lines. 
 
An alternative to these approaches is the non-viral gene delivery method based on 
peptides, in particular cell penetrating peptides (CPPs), which have limited 
cytotoxicity when compared to the viral vectors and physical methods. The CPPs are 
usually short cationic peptides (~30 amino acids) have been widely used to transfect 
a range of cell lines. Commonly used CPPs include Tat (Frankel and Pabo, 1988), 
Penetratin (Derossi et al., 1994) and VP22 (Elliott and O'Hare, 1997). However, the 
CPPs are limited by poor endosomal escape resulting in reduced transfection 
efficiency (Endoh and Ohtsuki, 2009). Thus the challenge lies with modifying and 
designing vectors with enhanced transfection efficiency without increasing the 
cytotoxicity. Recent studies from our group have utilised CPP HIV-Tat (49-57), to 
aid in cell penetration, and membrane active peptide LK15, likely to aid in 
endosomal escape by forming alpha helices, resulting in the formation of 
multifunctional peptide Tat-LK15 (Saleh et al., 2010). The resulting peptide 
increased the transfection efficiency more than 16 fold compared to Tat and LK15 
peptides alone without significantly affecting the cytotoxicity (Saleh et al., 2010). 
However, the ability of Tat-LK15 to transfect suspension cells has never been tested. 
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Hence, we have used Tat-LK15 peptide to study its potential to transfect the K562 
suspension cell line bearing the bcr-abl fusion gene.  
 
4.2 Aim of the chapter  
The aim of the chapter was to assess the ability of Tat-LK15 peptide at forming 
complexes with both DNA and siRNA. Thus, the specific objectives are as follows: i) 
to characterise the formation of complexes between the vectors and DNA or siRNA 
at different charge ratios or weight ratios by fluorescence displacement assay and 
determine their physico-chemical properties, ii) to assess the transfection ability of 
the resulting complexes and iii) to ascertain whether transfection efficiency 
correlated with the DNA/siRNA uptake using flow cytometry and confocal 
microscopy. 
 
4.3 Characterisation of vector/DNA complexes  
Cationic gene delivery vectors like CPPs interact with DNA using electrostatic 
interaction between the positive charges of the peptide and negative charges on the 
phosphate backbone of the DNA. Hence, the positive charges on the peptides play a 
vital role in the complexation with the oligonucleotides. Therefore, the ability of the 
vector to form complexes with the DNA or siRNA was determined since it is one of 
the most important factors to consider while designing a gene delivery vector. 
Additionally, physicochemical characterisation of the complexes like size and net 
charge of the complexes reveals key aspects of the complexes that might play an 
important role in the determination of transfection efficiency. 
 
4.3.1 DNA and siRNA complexation studies  
To study the complex formation of DNA and siRNA with the vector (Tat-LK15 and 
Lipofectamine), the nucleotides were labelled with YO-PRO-1, an intercalating dye, 
at dye:DNA base pair ratio of 50:1 and dye:siRNA base pair ratio of 5:1. YO-PRO-1 
is interesting as its levels of fluorescence when bound compared to the unbound are 
orders of magnitudes apart: YO-PRO-1 appears to fluoresce only when bound to the 
nucleotide with an increase in fluorescence quantum yield of 1000 fold when bound 
to DNA (Dähne et al., 1997). Figure 4.1 a and b shows the addition of increasing 
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amounts of peptide or Lipofectamine leads to a decrease in fluorescence intensity. As 
a displacement/quenching assay, these results indicate that competition takes place 
between the dye and the vector to bind to DNA i.e. the ability of a vector to complex 
DNA is assumed to be  function of its ability to displace the dye.  
 
More specifically, Figure 4.1a suggested efficient binding of the vectors as the 
fluorescence intensity was reduced rapidly when Tat-LK15 and Lipofectamine were 
added to YO-PRO-1 labelled DNA. Indeed at a (+/-) charge ratio (hereafter referred 
to as charge ratio) of 1:1 for Tat-LK15 and at a weight ratio of 1:1 for Lipofectamine, 
fluorescence levels were less than 5% of the DNA/YO-PRO-1 fluorescence intensity. 
As the fluorescence intensity remains similar at higher ratios, it can be regarded as 
residual fluorescence intensity. Thus Tat-LK15 and Lipofectamine appear to form 
complexes with DNA starting from charge ratios of 1:1 and weight ratio of 1:1 
respectively by displacing or quenching the dye from the DNA to form complexes. 
The decrease in YO-PRO-1 intensity could also be due to quenching of the dye 
formed as a result of dye molecules coming in close proximity during complexation 
(Murayama and Sano, 2005). 
 
On the other hand, when this assay is used to study siRNA complexation, Tat-LK15 
and Lipofectamine seem to have an apparently reduced ability to displace YO-PRO-1 
or quench its fluorescence. Indeed, Tat-LK15/siRNA at a charge ratio of 2:1 there is 
less than 10% of the initial fluorescence intensity. Lipofectamine/siRNA at a weight 
ratio of 1:1 has fluorescence intensity less than 20% compared to the initial 
fluorescence intensity levels, after which weight ratio residual fluorescence intensity 
is observed.  
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Figure 4.1: YO-PRO-1 displacement assay. a) DNA was labelled with YO-PRO-1 at 
a basepair:dye ratio of 50:1. Initially, the fluorescence of labelled DNA was 
measured and then increasing amounts of vector (Tat-LK5 or Lipofectamine) was 
added to YO-PRO-1 labelled DNA according to increase in charge ratio for Tat-
LK15/DNA and weight ratio for Lipofectamine/DNA complexes. The fluorescence 
intensity was calculated relative to the YO-PRO-1 labelled DNA without the addition 
of any vector. b) siRNA was labelled with YO-PRO-1 at a basepair:dye ratio of 5:1. 
Initially, the fluorescence of labelled siRNA was measured and then increasing 
amounts of vector, Tat-LK5 or Lipofectamine, was added to YO-PRO-1 labelled 
siRNA and the drop in fluorescence intensity was observed. The fluorescence 
intensity was calculated relative to the YO-PRO-1 labelled siRNA without the 
addition of any vector. The values represent mean ± SD, n=10. 
 
 
4.3.2 Size and zeta potential measurements  
The peptide/DNA complexes were further characterised by determining the size and 
zeta potential of the complexes. Experiments were performed as described in 
Materials and Methods chapter (section 3.15). In brief, based on Figure 4.1, charge 
ratios were chosen and complexes prepared as described by (Saleh et al., 2010). As 
they only observed very large micrometer size particles at 1:1 charge ratios while the 
fluorescence intensity was already residual, we chose to study Tat-LK15/DNA 
complexes at charge ratio of 2:1 and Tat-LK15/siRNA complexes at charge ratio of 
3:1. Table 4.1 shows that the size of the resulting complexes is rather large as sizes 
of 850 ± 141 nm and 663 ± 256 nm were determined for 2:1 charge ratio of Tat-
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LK15/DNA and for 3:1 charge ratio of Tat-LK15/siRNA respectively. On the other 
hand, the net positive charge of the Tat-LK15/siRNA complexes was higher than that 
of Tat-LK15/DNA complexes, +10 mV and +4 mV for the siRNA and DNA based 
complexes respectively. Comparisons between the two complexes (DNA and siRNA) 
can be made only considering two main points: i) the difference in structure between 
DNA and siRNA (flexible chain and rigid rod respectively) and ii) different charge 
ratios used to form complexes (2:1 for Tat-LK15/DNA complex and 3:1 for Tat-
LK15/siRNA complex), hence one does expect to see variations in the size and 
charge of the complexes. The smaller size and higher net charge of the Tat-
LK15/siRNA complexes can be explained by the increase in amount of peptide 
added leading to higher complexation of siRNA resulting in complexes of higher net 
charge. Consequently higher net charge leads to repulsion between the complexes 
leading to smaller size particles. The lower net charge of the Tat-LK15/DNA 
complexes is likely to aid in aggregation of the complexes resulting in large size of 
the complexes.  
  
 
Table 4.1: Physicochemical characterisation of peptide/DNA complexes. Particle 
size and zeta potential of Tat-LK15/DNA at charge ratio of 2:1 and Tat-LK15/siRNA 
at charge ratio of 3:1. The complex was formed in 10 mM HEPES NaCl buffer (pH 
7.4) and incubated at room temperature for 30 minutes. DNA (pSilencer 2.1 U6 
hygro 4.8Kbp) and B3A2 siRNA (21 bp) was used at a concentration of 10 µg/mL. 
The measurements are presented as the average value of three independent 
experiments.  
 
Tat-LK15/oligonucleotide 
(+/-) Charge ratio 
Size of Complex 
(nm) 
Zeta Potential (mV) 
2:1 Tat-LK15/DNA 850 ± 141.4 +4.09 ± 0.834 
3:1 Tat-LK15/siRNA 663.4 ± 256.1 +10.55 ± 2.61 
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4.4 Determination of DNA transfection efficiency using luciferase 
assay 
4.4.1 Effect of dose and charge ratio on transfection efficiency and 
toxicity 
To assess the ability of vector/DNA complexes to transfect cells, it is essential to 
follow the synthesis of a protein and for this purpose expression of luciferase protein 
was assessed as an indicator of transfection efficiency. Figure 4.2a shows that, for 
both 2:1 and 3:1 charge ratios, Tat-LK15/DNA transfection resulted in luciferase 
expression in a DNA dose dependent manner. Although the 3:1 charge ratio of Tat-
LK15/DNA complexes were expected to display a higher net positive charge than 
2:1 as observed by (Saleh et al., 2010), a higher expression of luciferase was 
observed for 2:1 charge ratio of Tat-LK15/DNA complexes than for 3:1 charge ratio 
of Tat-LK15/DNA complexes in K562 cells (Figure 4.2a). This result is surprising as 
Saleh et al. suggested that 3:1 Tat-LK15/DNA charge ratio was the most effective for 
HT29 and HT1080 cells (Saleh et al., 2010). Although unexpected, the optimum 
charge ratio appears to be 2:1 for K562 cells transfection and, as a consequence, 
appears to depend on the cell type. Additionally, cytotoxicity studies on the 
vector/DNA complexes showed that Tat-LK15 based complexes were found to be 
not toxic to K562 cells irrespective of the charge ratios (2:1 and 3:1) or the amounts 
of DNA used (1 and 5 g) as presented in Figure 4.2 b. 
 
On the other hand, comparing the toxicity of Lipofectamine based complexes 
prepared at a weight ratio of 2:1 and 3:1 indicated that at a 3:1 weight ratio 
complexes were toxic to cells even though it had a higher luciferase expression at 3:1 
than at 2:1 (Figure 4.2 b and d). The higher and DNA dose dependent cytotoxicity of 
Lipofectamine based complexes at 3:1 (Figure 4.2 d) does not make it a very 
attractive option in the event of DNA dose dependent gene silencing studies. Hence, 
a weight ratio of 2:1, exhibiting low cytotoxicity, was selected for Lipofectamine 
based complexes. 
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Figure 4.2: Determination of transfection efficiency and toxicity of DNA 
complexes. a) Luciferase expression (section 3.17.1) of K562 cells transfected using 
Tat-LK15/DNA at a (+/-) ratio of 2:1 and 3:1 with 1 µg and 5 µg of pEGFPLuc. 
Luciferase expression was checked 24 hours post transfection. b) MTT cell viability 
assay (section 3.21) performed on K562 cells treated with Tat-LK15/DNA at a 
charge ratio of 2:1 and 3:1 with 1 µg and 5 µg of pEGFPLuc. MTT assay was 
performed 24 hours post transfection. c) Luciferase expression of K562 cells 
transfected using Lipofectamine/DNA at a weight ratio of 2:1 and 3:1 with 1 µg and 
5 µg of pEGFPLuc. Luciferase expression was checked 24 hours post transfection. d) 
MTT cell viability assay performed on K562 cells treated with Lipofectamine/DNA at 
weight ratio of 2:1 and 3:1 with 1 µg and 5 µg of pEGFPLuc. MTT assay was 
performed 24 hours post transfection. The experiment was performed in triplicate 
and repeated three times.  
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4.4.2 Comparison of vectors efficiencies 
Figure 4.3 shows luciferase expression data at the optimum charge ratio (in case of 
Tat-LK15 based complexes) or weight ratio (in case of Lipofectamine based 
complexes) of 2:1 as a function of the amount of DNA incubated with the cells. The 
data indicates the difference between Lipofectamine and Tat-LK15 mediated 
transfection efficiency decreases from Lipofectamine being 18 times higher than Tat-
LK15 at 1µg DNA to 3 times higher at 5 g of DNA. In contrast, at 2 g of DNA 
complexed to Tat-LK15 mediated higher luciferase expression than Lipofectamine‟s. 
Hence, the amount of DNA used might affect the uptake of the vector/DNA 
complexes resulting in variability in transfection efficiency.  
 
 
 
Figure 4.3: Comparison between transfection efficiency of Tat-LK15 and 
Lipofectamine. Graph showing the expression of luciferase quantified using the 
luciferase assay normalised to the amount of protein. K562 cells were transfected 
using pEGFPLuc using Tat-LK15 and Lipofectamine using 2:1 charge and weight 
ratio respectively and incubated for 4 hours with the complex in Opti-MEM. Cells 
were then incubated with complete medium at 37ºC and luciferase assay was 
performed after 24 hours. Luciferase assay was performed in triplicate and the 
experiment was repeated three times.  
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4.5 DNA uptake studies by FACS   
Based on previous section‟s optimal transfection efficiencies of Tat-LK15 and 
Lipofectamine based systems (section 4.4), DNA uptake was quantified using flow 
cytometry (section 3.18.2). The experiments were carried out to clarify the relation 
between DNA cell association to the transfection efficiency obtained from the 
luciferase assay (Figure 4.3). The experiment would also help determine if the 
difference between transfection efficiencies (as determined by luciferase assay) and 
the cellular uptake (as determined by flow cytometry) may be related to cellular 
barriers such as endosomal escape or nucleus entry. The efficiency of DNA uptake 
by Tat-LK15 and Lipofectamine was studied using Cy5 covalently labelled pcDNA3 
plasmid at a dye:base pair ratio of 10:1 (as recommended by the manufacturer).  
 
Tat-LK15/DNA uptake  
In this section, only the optimum 2:1 charge ratio was studied (see section 4.4.). Tat-
LK15/Cy5-DNA complexes were prepared and added to cells in Opti-MEM and 
incubated at 37C for 4 hours and analysed using flow cytometry (section 3.18.2). 
Figure 4.4a presents a typical uptake histogram for Tat-LK15/DNA complexes at a 
2:1 charge ratio in K562 cells. The uptake profile in Figure 4.4a shows a wide 
distribution indicative of heterogeneous uptake of labelled DNA complexed to Tat-
LK15 for the different amounts of DNA studied (1 g, 2 g and 5 g). The mean 
fluorescence intensity (MFI) of the Tat-LK15/DNA complexes increase with 
increasing amount of DNA used, indicating a dose dependent uptake profile as seen 
in Figure 4.4 c. There are very high fluorescent intensity peaks almost at the end of 
the histogram contributes significantly to the MFI values. These peaks could likely 
be dead cells. Finally, at low DNA amounts (1 g and 2 g), the percentage of cells 
that have internalised DNA is approximately the same i.e. about 60% and 55% 
respectively, which then increases to reach a maximum of 80% positive cells at 5 g 
DNA.  
 
Lipofectamine/DNA uptake  
Similar to the DNA uptake studies above, flow cytometry experiments were carried 
out with cells that were previously incubated with the optimum 2:1 weight ratio of 
Lipofectamine/DNA complexes using increasing amounts of DNA. Unlike the 
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histogram obtained using Tat-LK15/DNA, the representative Lipofectamine/DNA 
histogram (Figure 4.4 b) has narrow well defined peaks at lower intensity range and 
very high peaks at higher intensities, indicative of narrower distribution. These very 
high fluorescent intensity peaks almost at the end of the histogram contributes 
significantly to the MFI values. When quantitatively analysed (Figure 4.4 c), the MFI 
of Lipofectamine mediated DNA uptake appears to increase with increase from 1 µg 
to 2 µg of DNA. The percentage of positive cells was found to be variable depending 
on the amount of DNA used varying from 20% to 50% positive cells in a non-dose 
dependent manner (Figure 4.4 d). 
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Figure 4.4:DNA uptake measured by flow cytometry. Representative histogram 
obtained from the flow cytometry showing the uptake of DNA in K562 cells using : (a) 
Tat-Lk15 and (b) Lipofectamine. pcDNA3 was labelled using Cy5 nucleic acid 
labelling kit at a ratio of 0.1:1 as described in materials and methods section 3.18.1. 
Flow cytometry was performed 4 hours after treatment with the vector/DNA 
complexes (section 3.18.2). Samples were gated initially for viable cells based on 
forward and side scatter. Samples were then gated with respect to untreated control 
cells in such a way that the gate (R6) has less than 1% of the control cells. (c) Graph 
showing the mean fluorescence intensity of labelled DNA uptake by Tat-LK15 and 
Lipofectamine with increasing amounts of DNA. (d) Graph showing the percentage 
of positive cells having the Cy5 labelled DNA calculated based on the gate (R6). The 
bars represent mean ± S.D, n=3.  
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4.6 siRNA uptake study using FACS  
In the case of siRNA based transfection, the determination of optimum transfection 
efficiency is feasible only through the observation of gene silencing. Therefore, the 
siRNA uptake study was performed with the vector/siRNA ratio that yielded the 
minimum residual fluorescence intensity in the YO-PRO-1 displacement assay 
(Figure 4.1 b). In this case a charge or weight ratio of 3:1 for Tat-LK15 and 
Lipofectamine based siRNA complexes was chosen as the decrease in intensity of 
YO-PRO-1 stabilises after 3:1. Similar to the previous section uptake was studied 
with Cy5 covalently labelled siRNA. 
 
The histogram of Tat-LK15/siRNA (Figure 4.5 a) shows a different behaviour from 
that observed for the Tat-LK15/DNA (Figure 4.4a). Indeed, using 1 µg of siRNA 
leads to a bell shaped histogram skewed towards the lower intensity on the graph 
(left side) indicating that majority of cells that take up siRNA have lower intensity of 
siRNA labelling. However using 2 µg and 5 µg of siRNA the histograms indicate 
large number of cells have high fluorescence intensity with a more heterogeneous 
distribution (Figure 4.5 a). Consistently, the quantification of the Cy5 fluorescence 
intensity in cells shows the MFI for Tat-LK15/Cy5-siRNA at a charge ratio of 3:1 
clearly increases in a dose dependent manner (see Figure 4.5d). Additionally, the 
percentage of positive cells also increases with siRNA amounts for Tat-LK15 based 
siRNA complexes up to around 60% positive cells at the highest amount of siRNA (5 
µg) used.  
 
On the other hand, for the cells treated with Lipofectamine based siRNA complexes, 
the histogram (Figure 4.5b) shows a relatively heterogeneous distribution pattern for 
all the amounts of siRNA tested (1 µg, 2 µg and 5 µg). The MFI showed no apparent 
change in intensity of Cy5-siRNA for 1 µg and 2 µg of siRNA treated (Figure 4.5 c), 
but increases 3 fold in intensity using 5 µg of siRNA. Similar behaviour is also 
observed in the case of percentage of positive cells at both 1 µg and 2 µg of siRNA 
(Figure 4.5 d) which again increases with higher amount of siRNA (5 µg) and 
reaches a maximum of 55% of positive cells. These results are indicative of dose 
dependent uptake only for high amounts (above 2 µg) in the case of Lipofectamine 
based siRNA complexes. Furthermore, they are consistent with the DNA uptake 
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observed earlier (Figure 4.4 and Figure 4.5). Comparison between the uptakes of 
Lipofectamine based DNA and siRNA complexes shows that the MFI remains stable 
when using lower amounts of DNA or siRNA (1 µg and 2 µg) (Figure 4.4 c and 
Figure 4.5c respectively), and increases with 5 µg of DNA or siRNA. Further 
inspection of the data reveals that the actual pattern of percentage positive cells that 
uptake DNA or siRNA varies between the two complexes. Lipofectamine based 
DNA complex shows a dose independent uptake in number of cells while for siRNA 
based complex, it remains unchanged in the low amounts (1 µg and 2 µg) of siRNA 
used but increases with higher amount (5 µg) of siRNA. Comparing the siRNA 
uptake pattern between the two vectors namely Tat-LK15 and Lipofectamine shows 
a dose dependent uptake for all the doses of siRNA tested using Tat-LK15 vector, 
while Lipofectamine based siRNA also exhibits dose dependent uptake but only for 
high doses tested (2 g and 5 g). 
 
The flow cytometry experiments have shown that the DNA and siRNA complexed to 
the vectors have been taken up into the cells. It is worth stressing that since 
trypsinisation was performed before FACS to eliminate cell bound complexes, 
interference from non-internalised complexes can be disregarded or at least 
minimised. Reaching the destination, nucleus in case of plasmid DNA and cytoplasm 
in case of siRNA, is vital for achieving the full potential and functionality of the 
cargo (DNA or siRNA). It was therefore important to determine the cellular 
localisation of the complexes using confocal microscopy.  
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Figure 4.5:siRNA uptake measured by flow cytometry. Representative histogram 
obtained from the flow cytometry showing the uptake of siRNA in K562 cells using: 
(a) Tat-Lk15 and (b) Lipofectamine. siRNA was labelled using Cy5 nucleic acid 
labelling kit at a ratio of 5:1 as described in materials and methods section 3.18.1. 
Flow cytometry was performed 4 hours after treatment with the vector/siRNA 
complexes (section 3.18.2). Samples were gated initially for viable cells based on 
forward and side scatter. Samples were then gated with respect to untreated control 
cell such that less than 1% of control cells lie within the gate (R2). (c) Graph 
showing the mean fluorescence intensity of labelled siRNA uptake by Tat-LK15 and 
Lipofectamine with increasing amounts of siRNA. Note that the MFI of Tat-LK15 
using 1µg of siRNA is very low to appear as a bar. (d) Graph showing the 
percentage of positive cells having the Cy5 labelled siRNA calculated based on the 
gate (R2). The bars represent mean ± SD, n=3.  
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4.7 DNA uptake studies using confocal microscopy  
DNA uptake was further studied using confocal laser scanning microscopy (CLSM) 
(section 3.18.3) to determine the localisation of the Cy5 labelled DNA at 4 hours and 
24 hours post treatment of K562 cells with the vector/DNA complexes. As a first 
step, 2:1 charge ratio of Tat-LK15 and 2:1 weight ratio of Lipofectamine based 
complexes with Cy5-DNA were observed by CLSM after 4 hours incubation at two 
different doses of DNA (1 µg and 5 µg). Unlike the FACS experiment where the 
cells are treated with trypsin (0.1% v/v) to remove any cell bound complex, the cells 
for the confocal experiment were not trypsinised due to the following reasons. Firstly, 
trypsinisation was not used for transfection procedure, considering the in vivo 
conditions where only the complexes that are not cell bound would be cleared from 
the circulation and a harsh treatment like trypsinisation would be absent. Secondly, 
since the objective is to follow cellular localisation over several hours, trypsinisation 
may hence have an inhibitory effect by removing the membrane bound complexes 
which are yet to internalise. Hence, to determine the localisation of the complex 4 
hours after treatment with the DNA/siRNA complexes, it was important to observe 
them under the same conditions as transfections.   
 
4.7.1 Intracellular localisation of Cy5 DNA at 4 hours   
When treated with 1 µg DNA (Figure 4.6a), Tat-LK15 based complexes appear to be 
localised mainly on the cell membrane as indicated by an arrow. However, when 
treated with 5 µg of DNA (Figure 4.6 c) intracellular localisation of DNA (arrow 1) 
along with membrane localisation (arrow 2) is observed. Interestingly, for 
Lipofectamine based complexes using 1 µg DNA, intracellular localisation is 
observed just 4 hours post treatment (Figure 4.6 b). On the other hand, cells treated 
with 5 µg of DNA appear to have a higher fluorescence associated with the cell 
membrane than inside the cell for lipofectamine based complexes (Figure 4.6 d). It is 
important to note here that a detector gain was higher to image cells incubated with 1 
µg DNA than with the cells incubated with 5 µg of DNA (640 and 550 respectively). 
The fluorescence intensity of the cells incubated with 5 µg of Cy5-DNA, as expected, 
are significantly higher even though a lower detector gain was used to image the 
cells treated with 5 µg of DNA than for 1 µg DNA for both Tat-LK15 and 
Lipofectamine based complexes, as shown in Table 4.2. Hence, the actual absolute 
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fluorescence intensity inside the cells is expected to be higher than the difference 
observed here. Additionally the key observation is that better internalisation was 
observed at a higher dose of DNA complexed to both Tat-LK15 and Lipofectamine. 
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Figure 4.6:  DNA uptake using confocal microscopy 4 hours after treatment. K562 
cells were transfected with Tat-LK15/Cy5-DNA (at a charge ratio of 2:1) and 
Lipofectamine/Cy5-DNA (at a weight ratio of 2:1) for 4 hours incubated in Opti-
MEM. Confocal microscopy was performed 4 hours post transfection (section 
3.18.3). Images showing the localisation of Tat-LK15/DNA complexes (a and b) 
formed at a charge ratio of 2:1 using 1 µg DNA (a) and 5 µg DNA (c). 
Lipofectamine/DNA complexes (b and d) at a weight ratio of 2:1 using 1 µg DNA (b) 
and 5 µg DNA (d) 4 hours post transfection. Cy5 labelled DNA was used to prepare 
the complexes. The images are an overlay of fluorescence confocal images and their 
corresponding DIC images. 
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Amount of labelled 
DNA 
Average Fluorescence Intensity of the cell 
Tat-LK15/DNA Lipofectamine/DNA 
1 µg 11.939 ± 5.05 11.619 ± 3.38 
5 µg 16.942 ± 5.24 16.195 ± 5.18 
Table 4.2: Intensity of Cy5 fluorescence observed for DNA uptake at 4 hours. The 
fluorescence intensity of the cells incubated with Tat-LK15 and Lipofectamine 
complexed to DNA (1 µg and 5 µg) evaluated using confocal microscopy 4 hours 
post treatment and was quantified using Image J (section 3.18.4). Detector gain of 
640 was used to image cells treated with 1 µg of DNA while a lower gain of 550 was 
used for cells treated with 5 µg DNA. Average fluorescence intensity of the cell was 
obtained from three representative images. The values represent mean ± SD, n=3. 
Statistical difference calculated using unpaired student t test and p value ≤0.05 was 
considered significant. A p value of <0.0001 was obtained when comparing 1µg and 
5µg for both vectors Tat-LK15 and Lipofectamine suggesting a very significant 
increase in intensity when 5µg DNA was used when compared to 1µg  
 
4.7.2 Impact on the cell morphology  
The effect of the complexes on the morphology of K562 cells were studied and 
presented in Figure 4.7. Incubation with Tat-LK15 based complexes did not seem to 
affect the cell morphology or to stress the cell in the presence of 1 g DNA (Figure 
4.7a) or 5 g DNA (Figure 4.7c). Conversely, incubation with Lipofectamine/DNA 
complexes results in change in the morphology of a fraction of cells which could 
eventually result in cell death. The cells which have undergone considerable change 
in morphology or appear distorted after treatment with Lipofectamine/DNA 
complexes when compared to K562 cells treated with the same amount of DNA 
complexed to Tat-LK15 (Figure 4.7 a and b), seen in Figure 4.7 c and d (as indicated 
by arrows). However,  the observation of stressed cells does not affect the viability of 
cells as evident from earlier cytotoxicity studies performed 24 hours post transfection 
(Figure 4.2 d): indeed complexes formed with Lipofectamine and DNA (1 µg and 5 
µg) at a weight ratio of 2:1 were found not to be cytotoxic. This variation is 
explained in detail in the discussion (section 4.9.4).  
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Figure 4.7:  Morphological changes observed during DNA uptake. K562 cells were 
transfected with Tat-LK15/Cy5-DNA (at a charge ratio of 2:1) and 
Lipofectamine/Cy5-DNA (at a weight ratio of 2:1) incubated in Opti-MEM. Confocal 
microscopy was performed 4 hours post transfection (section 3.18.3). a and b images 
showing the localisation of Tat-LK15/DNA complexes using 1 g of DNA (a) and 5 
g of DNA (b). c and d shows the morphological changes observed on treatment 
with Lipofectamine/DNA complexes using 1 g of DNA (c) and 5 g of DNA (d). Cy5 
labelled DNA was used to prepare the complexes. The images are an overlay of 
fluorescence confocal images and their corresponding DIC images. Arrows are used 
to indicate the cells whose morphology has changed. 
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4.7.3 Intracellular localisation of Cy5-labelled DNA at 24 hours  
For these experiments, K562 cells treated with 1 µg of Cy5-labelled DNA 
complexed to Tat-LK15 or Lipofectamine were studied using confocal microscopy 
24 hours post treatment. Syto 16 nuclear stain was used to label the nucleus. In cells 
treated with Tat-LK15 based DNA complex, Figure 4.8 (a and b) shows large 
presence of Cy5 labelled DNA (red stain) inside the cell. Both cytoplasmic and 
nuclear localisation is evident, indicating TatLK15 based complexes have crossed the 
cell membrane and has largely attained nuclear localisation. These results are 
consistent with the earlier studies showing transfection efficiency at 4 hours using 
luciferase assay (Figure 4.2a) and the cellular localisation at 4 hours (Figure 4.6 a 
and c). On the other hand, K562 cells treated using Lipofectamine based DNA 
complexes appear to have lower number of cells having Cy5 related fluorescence 
inside the cell as well as on the cell membrane 24 hours after incubation with the 
complexes (Figure 4.8 c and d).  
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Figure 4.8:  DNA uptake using confocal microscopy at 24 hours after treatment. 
K562 cells were transfected with Tat-LK15/Cy5-DNA (at a charge ratio of 2:1) and 
Lipofectamine/Cy5-DNA (at a weight ratio of 2:1) using 1 µg of Cy5 labelled DNA 
for 4 hours incubated in Opti-MEM. Confocal microscopy was performed 24 hours 
post transfection (section 3.18.3). Images showing the cellular localisation of Tat-
LK15/DNA complexes (a and b) and Lipofectamine/DNA complexes (c and d) 24 
hours post transfection. The presence of labelling using Lipofectamine/DNA is lesser 
than what is observed using Tat-LK15/DNA complexes. The images are an overlay of 
fluorescence confocal image observed at 488nm and 663nm (green and red 
fluorescence respectively) with their corresponding DIC images. The nucleus was 
labelled using Syto 16 (green fluorescence).  
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To substantiate the reduction in fluorescence intensity of DNA complexed with 
Lipofectamine, we further studied the DNA uptake using both 1 µg and 5 µg of 
labelled DNA and imaged after 24 hours. The reduction in Cy5 fluorescence 
intensity observed in Figure 4.8 was again evident in Figure 4.9. In the latter, the 
same confocal imaging settings (detector gain) were used to visualise the DNA 
complexed to Tat-LK15 (Figure 4.9a and d) and Lipofectamine based complexes 
(Figure 4.9 b and e) in K562 cells 24 hours after treatment. It is therefore possible to 
directly compare images (Figure 4.9 a,b,d and e) which are all at a same detector 
gain setting i.e. 620. Similarly, image Figure 4.9 c and f can be directly compared 
which were obtained with gain of 780. Comparison of cellular uptake of Cy5 
labelled DNA (1 µg) shows that the intensity of Cy5 in cells incubated with 
Lipofectamine/DNA was lower than that detected when cells were incubated with 
Tat-LK15/DNA (Figure 4.9 a and b) as shown in Table 4.3. However, when a higher 
gain was used in the case of lipofectamine based complexes (Figure 4.9 c and f), Cy5 
fluorescence could be easily detected. Similar observation was made with cells 
incubated with 5 µg DNA and imaged using the same settings (Figure 4.9 d and e). 
The intensity of Cy5 fluorescence becomes very low 24 hours after incubation with 
Lipofectamine based complexes, irrespective of the amounts of DNA, while the 
intensity remains high for Tat-LK15 based complexes.  
 
Considering Tat-LK15 results in isolation, the Cy5 fluorescence intensities between 
1 µg and 5 µg DNA complexed to Tat-LK15, higher Cy5 fluorescence intensity was 
observed when using 5 µg than 1 µg DNA clearly indicating a dose dependent 
uptake (Figure 4.9 a and d, Table 4.3).  
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Figure 4.9:  Comparison of DNA uptake at 24 hours between Tat-LK15 and 
Lipofectamine complexes. K562 cells were transfected with Tat-LK15/Cy5-DNA (at 
a charge ratio of 2:1) and Lipofectamine/Cy5-DNA (at a weight ratio of 2:1) for 4 
hours incubated in Opti-MEM. Confocal microscopy was performed 24 hours post 
transfection (section 3.18.3). Images (a and d) show the cellular localisation of Tat-
LK15/DNA using 1 µg DNA (a) and 5 µg DNA (d). Images (b,c,e and f) show the 
localisation of Lipofectamine/DNA complexes using 1 µg (b and e) and 5 µg DNA (c 
and f) at a weight ratio of 2:1, 24 hours post transfection. Cy5 labelled DNA was 
used to prepare the complexes. The images (a, b, d and e) were obtained using the 
detector setting of 620 while images (c and f) were obtained using detector gain of 
780. All the images are an overlay of fluorescence confocal image and DIC. 
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Amount of DNA Tat-LK15/DNA Lipofectamine/DNA 
Same setting as Tat-LK15 
1 µg 14.80 ± 5.02 4.90 ± 0.722 
5 µg 27.88 ± 11.49 3.78 ± 0.56 
 
Table 4.3: Intensity of Cy5 fluorescence associated with cells 24 hours after 
incubation. The fluorescence intensity of the cells treated with Tat-LK15 and 
Lipofectamine complexed to DNA (1 µg and 5 µg) 24 hours post transfection was 
quantified using Image J (section 3.18.4). Please note the cells treated with 1 µg and 
5 µg DNA were imaged using the same detector gain settings of 620. Average 
fluorescence intensity of the cell obtained from three representative images. The 
values represent mean ± SD, n=3. Statistical significance was calculated using 
unpaired student t test and p value ≤0.05 was considered significant. Comparison 
between 1µg and 5µg of DNA complexed to Tat-LK15 had a p value of <0.0001 
indicating a very significant increase in intensity using 5µg of DNA compared to 
1µg. 
 
4.7.4 EGFP expression after 24 hours 
The expression of EGFP 24 hours after incubation with Tat-LK15- and 
Lipofectamine- pEGFPLuc complexes were observed using CSLM. Tat-
LK15/pEGFPLuc transfection has led to expression of EGFP, as shown in Figure 
4.10 a and b. The results obtained here is an indirect proof that DNA transfected 
using Tat-LK15 has attained nuclear localisation. On the other hand, since intensity 
of Cy5-DNA transfected using Lipofectamine decreased, as shown in the Figure 4.9, 
the experiment was performed to ensure the expression of EGFP parallels the fall of 
Cy5 fluorescence intensity. As shown in Figure 4.10 c and d, there is expression of 
EGFP indicating effective translation of labelled DNA. Additionally considering the 
images were all obtained using the same detector gain setting (850), a comparison of 
the EGFP fluorescence intensity for the various treatments suggests: i) the difference 
in intensity of cells treated with Tat-LK15 based complexes (1 µg and 5 µg) is not 
significant, while the difference in Lipofectamine based complexes (1 µg and 5 µg) 
is significant when quantified (see Table 4.4). Moreover, when 1 µg DNA was used, 
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intensity of EGFP in cells treated with Tat-LK15/DNA complex is significantly 
higher than that of Lipofectamine, while the opposite is true for 5 µg of DNA based 
treatments (Table 4.4). The results obtained from EGFP measurements are in 
somewhat contrast to those observed using the luciferase assays (Figure 4.3) where 
transfection with 5 µg of DNA gives substantially higher luciferase than with 1 µg, 
whereas with EGFP expression there is no difference between 1 µg and 5 µg. With 
Lipofectamine higher EGFP expression is evident at higher dose of DNA which is in 
contradiction with luciferase expression where 5 µg DNA gives significantly lower 
expression than 1 µg (Figure 4.3). It is worth stressing that the methods used to 
quantify expression of luciferase and EGFP are based on different techniques and 
therefore may not be truly reflective of transfection efficiency. The following 
differences in quantification methods may explain some of the discrepancies 
observed between luciferase and EGFP: i) luciferase assay is a destructive, sensitive 
and quantitative assay while the confocal experiment to image EGFP expression is 
non-destructive semi quantitative and the intensity is measured using Image J (NIH 
Bethesda), ii) the luciferase protein requires no post translational modifications to 
become an active protein, hence more accurate indication of the transfection 
efficiency, while the EGFP protein requires post translational modifications which 
could affect the functionality of the protein, hence it does not provide a direct 
relationship with the transfection efficiency but rather also depends on other factors 
as well and iii) the quantification of EGFP intensity using Image J is not an ideal 
method to use when observing diffuse fluorescence intensity in the cell that makes 
quantification very difficult. Furthermore many fluorescent dyes are susceptible to 
self-quenching, photo bleaching, and degradation and hence this makes 
quantification unreliable. Hence, these factors need to be considered while 
comparing confocal method of determining the plasmid expression to a quantitative 
assay like luciferase. Nevertheless, the EGFP expression can provide qualitative and 
semi-quantitative data showing the expression of the plasmid after confirming the 
cellular uptake of Cy5 labelled DNA in the previous experiments.  
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Figure 4.10: Expression of EGFP using confocal microscopy. K562 cells were 
transfected with Tat-LK15/pEGFPLuc DNA (at a charge ratio of 2:1) and 
Lipofectamine/pEGFPLuc DNA (at a weight ratio of 2:1) using 1 µg and 5 µg of 
DNA for 4 hours incubated in Opti-MEM. Confocal microscopy was performed 24 
hours post transfection (section 3.18.3). Images showing the expression of EGFP of 
Tat-LK15/DNA complexes when transfected using 1 µg (a) and 5 µg (b). EGFP 
expression obtained with Lipofectamine/DNA complexes using 1 µg (c) and 5 µg (d) 
DNA. The images are an overlay of fluorescence confocal image observed at 488nm 
(green fluorescence) with the corresponding DIC images. 
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Amount of DNA Tat-LK15/DNA Lipofectamine/DNA 
1 µg 13.01 ± 3.85 10.90 ± 4.14 
5 µg 13.5 ± 3.9 16.2 ± 5.49 
 
Table 4.4: Intensity of EGFP expression at 24 hours. The fluorescence intensity of 
the cells treated with Tat-LK15 and Lipofectamine complexed to pEGFPLuc (1µg 
and 5µg) 24 hours post transfection was quantified using Image J (section 3.18.4). 
Please note the cells treated with 1 µg and 5 µg DNA were imaged using the same 
detector gain settings of 850. Average fluorescence intensity of the cell obtained 
from three representative images. The values represent mean ± SD, n=3. Statistical 
difference calculated using unpaired student t test and p value ≤0.05 was considered 
significant.Comparison between 1µg and 5µg DNA complexed to Lipofectamine 
showed a p value of 0.0007 indicating a very significant between the two values.  
 
4.8 Cellular localisation of Cy5 siRNA using confocal microscopy  
Similar to DNA uptake study, CLSM was also used to determine the intracellular 
localisation of Cy5 labelled siRNA based complexes at the charge and weight ratio 
of 3:1 for Tat-LK15 and Lipofectamine respectively. K562 cells were transfected as 
described in Materials and Methods (section 3.16) and incubated with the complexes 
for 4 hours. Figure 4.11 shows that using 1 µg or 5 µg of siRNA complexed with 
Tat-LK15 and Lipofectamine led to localisation primarily around the cell membrane 
and diffuse localisation inside the cell respectively. Direct comparisons between 1 µg 
and 5 µg cannot be made as the gain used to measure 5 µg (gain 830) was much 
lower than that of 1 µg (gain 940) siRNA. Hence, comparing the intensities obtained 
only at 1 µg siRNA complexed to Tat-LK15 and Lipofectamine, no significant 
difference between the two vectors was observed (Table 4.5). The uptake of 5 µg 
siRNA using Lipofectamine was significantly higher than that of the Tat-LK15 based 
complex. Crudely comparing the fluorescence intensities between 1 µg and 5 µg, no 
significantly different fluorescence intensities were detected even though lower gain 
was used with the latter. Hence, it could be concluded that the absolute uptake must 
be higher, indicating a dose dependent uptake for both Tat-LK15 and Lipofectamine.  
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Figure 4.11:  siRNA uptake using confocal microscopy at 4 hours. K562 cells were 
transfected with Tat-LK15/Cy5-siRNA (at a charge ratio of 3:1) and 
Lipofectamine/Cy5-DNA (at a weight ratio of 3:1) for 4 hours incubated in Opti-
MEM. Confocal microscopy was performed 4 hours post transfection (section 
3.18.3). Images (a and b) showing the localisation of Tat-LK15 (a) and 
Lipofectamine (b) based complexes using 1 µg of Cy5 labelled siRNA inside the cell. 
Images (c and d) showing the localisation of Tat-LK15 (c) and Lipofectamine (d) 
based complexes using 5 µg of Cy5 labelled siRNA 4 hours post transfection. 1 µg of 
siRNA images were measured at a detector gain of 940 and 5 µg of siRNA images 
were measured at a detector gain of 830.  
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Subsequently, the cellular localisation of Cy5 labelled siRNA was observed 24 hours 
post transfection. From Figure 4.12 (a and b), it can be seen that using 1 µg of 
labelled siRNA led to uniform intracellular distribution of the cells for both Tat-
LK15 and Lipofectamine. On the other hand at higher dose (5 µg of labelled siRNA), 
what seems to be an intracellular punctate distribution is observed for Tat-LK15 
based complexes, as evident from Figure 4.12c. Interestingly the punctate 
localisation increases in Cy5 fluorescence intensity and is more pronounced when 
cells were treated with Lipofectamine/siRNA complexes, as shown in Figure 4.12d. 
Quantitative analysis of these images (Table 4.5) shows that the fluorescence 
intensity of siRNA (1 µg) complexed to vectors, Tat-LK15 and Lipofectamine, is 
lower at 24 hours than that observed at 4 hours, for the same amount of siRNA. 
Comparing only the intensities measured at 24 hours (see Table 4.5), the intensity of 
cells treated with 1 µg siRNA is lower than those obtained using 5 µg siRNA even 
though a lower detector gain settings were used for the latter, indicating higher dose 
dependent cellular localisation of siRNA. 
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Figure 4.12: siRNA cell association using confocal microscopy at 24 hours. K562 
cells were transfected with Tat-LK15/Cy5-siRNA (at a charge ratio of 3:1) and 
Lipofectamine/Cy5-DNA (at a weight ratio of 3:1) for 4 hours incubated in OPTI-
Mem. Confocal microscopy was performed 24 hours post transfection (section 
3.18.3). Images (a and b) showing the localisation of Tat-LK15 (a) and 
Lipofectamine (b) based complexes using 1 µg of Cy5 labelled siRNA inside the cell. 
Images (c and d) showing the localisation of Tat-LK15 (c) and Lipofectamine (d) 
based complexes using 5 µg of Cy5 labelled siRNA 24hours post transfection. 1 µg of 
siRNA images were measured at a detector gain of 940 and 5 µg of siRNA images 
were measured at a detector gain of 830. 
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Amount 
of siRNA 
Vector/siRNA Duration after treatment (hours) 
4 hours 24 hours 
1 µg siRNA Tat-LK15/siRNA 22.25 ± 7.6 15.44 ± 4.05 
Lipofectamine/siRNA 23.15 ± 5.24 16.79 ± 7.08 
5 µg siRNA Tat-LK15/siRNA 22.07 ± 8.4 24.31 ± 12.21 
Lipofectamine/siRNA 27.12 ± 9.68 24.8 ± 13.1 
 
Table 4.5: Fluorescence intensity of Cy5 labelled siRNA observed at 4 hours and 
24 hours. Data showing the average fluorescence intensity of Cy5 labelled siRNA 
found associated with the K562 cells using various treatments (1 µg and 5 µg) and 
time points after transfection (4 hours and 24 hours) obtained using Image J (section 
3.18.4). Comparison can be made only for transfections using the same amounts of 
siRNA (for 1 µg of siRNA detector gain of 940 was used and for 5 µg of siRNA 
detector gain of 830 was used). Average fluorescence intensity of the cell obtained 
from three representative images. The values represent mean ± SD, n=3. Statistical 
difference calculated using unpaired student t test and p value ≤0.05 was considered 
significant. A p value of 0.0165 was obtained when comparing 5µg of siRNA for Tat-
LK15 and Lipofectamine at 4 hours, indicating a significant difference between the 
two groups. At 24 hours, comparing Tat-LK15 complexed to 1µg and 5µg siRNA 
gave a p value of 0.0001 and for Lipofectamine complexed to 1µg and 5µg siRNA 
gave a p value of 0.0061 indicating a significantly higher intensity with 5µg than 1µg 
siRNA. 
 
In summary, the cellular localisation studies have shown the intra cellular 
localisation of DNA and siRNA after delivery into the K562 cells using the vectors, 
Tat-LK15 and Lipofectamine. For DNA, this was evident from the nuclear 
localisation (Figure 4.9) and the expression of EGFP (Figure 4.10) that DNA has 
reached the nucleus and has also resulted in effective expression of the plasmid. The 
intra cellular localisation of siRNA possibly in the cell cytoplasm at 24 hours is 
evident from Figure 4.12.  
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4.9 Discussion   
Results published recently shows the increased transfection efficiency of Tat-LK15 
peptide when compared to Tat and LK15 peptides individually in HT29 and HT1080 
cells (Saleh et al., 2010). Preliminary work to determine the transfection efficiency of 
Tat-LK15 in K562 CML suspension cell lines has shown higher transfection 
efficiency of Tat-LK15 when compared to Tat (Appendix 1). Hence, the efficient 
transfection of Tat-LK15 observed in suspension cells has prompted the study of Tat-
LK15 for the delivery of shRNA plasmid and siRNA in comparison to the control 
vector Lipofectamine.  
 
4.9.1 Physicochemical characterisation of the complexes  
The physicochemical characteristics of the vector/DNA complex were investigated 
i.e. the complex formation, their sizes and charges. Figure 4.1a showed that Tat-
LK15 peptide and Lipofectamine were able to bind DNA and displace YO-PRO-1 
fluorescent dye thus confirming the ability of these vectors to form complexes. 
Indeed, at charge ratios as low as 1:1, less than 10% residual fluorescence intensity 
was observed, which is supported by Saleh et al. (2010). Cy5 molecules that come in 
close proximity as a result of DNA condensation or complexation also results in 
quenching of Cy5 fluorescence. However, when the complexation experiment was 
carried out using YO-PRO-1 labelled siRNA with increasing charge ratios of Tat-
LK15 and weight ratios of Lipofectamine, the complete displacement of YO-PRO-1 
from the siRNA was observed at higher ratios of 3:1 (Figure 4.1b). Three 
explanations can be put forward to account for these observations: i) the base:dye 
ratio was ten times higher for siRNA than for DNA (5:1 and 50:1 respectively), 
hence a likely higher amount of peptide molecules required to displace the YO-PRO-
1 from siRNA, ii) siRNA is a rod (25 bp) thus more rigid than the flexible DNA 
chain (6.4 kb) and iii) quantum yield of YO-PRO-1 with siRNA is likely to be 
different from that of DNA. A higher dye density means more polycations are 
required to displace or quench and possibly less quenching opportunities due to the 
presence of rods (different from flexible DNA chains). The likelihood of higher 
dye:base pair ratio affecting the displacement assay could be verified using DNA 
labelled with the same labelling ratio as the siRNA. Addressing the second point, 
siRNA are short and rigid rod like structures when compared to the DNA which are 
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flexible chains (Gary et al., 2007, Zhang et al., 2006a). Similar observation was also 
made by (Langlet-Bertin et al., 2010), who showed that complexation of siRNA 
required 2.5 to 5 times more peptide than complexation of DNA, due to the rod like 
nature of siRNA. This explanation is reasonable for Tat-LK15 peptide as complete 
displacement of siRNA took place at a charge ratio of 3:1 compared to 1:1 for DNA 
using Tat-LK15, and hence 3 times more amount of peptide (0.81 µg of Tat-LK15 
required for 1:1 ratio for 1 µg DNA compared to 2.43 µg for 3:1 for 1 µg siRNA) 
was required to complex siRNA. Kim et al. (2010) have also observed maximum 
retardation of siRNA on a gel electrophoresis using oligo arginine peptide (R15) at a 
charge ratio of 3:1. These results indicate maximum complexation of siRNA from a 
charge ratio of 3:1 (Kim et al., 2010), similar to that observed with Tat-LK15 based 
siRNA complexation. Hence, these studies indicate that a higher amount of peptide is 
required for complexation of siRNA than that required for DNA.     
 
The size and zeta potential measurements (Table 4.1) show that at charge ratio of 2:1 
Tat-LK15/DNA, there is a compact complex formed with a positive zeta potential. 
The size of Tat-LK15/DNA complex formed at charge ratio of 2:1 was a more 
homogeneous distribution with a mean of 850 ± 141 nm and a zeta potential of +4.09 
± 0.83. The low net positive charge is likely to influence aggregation of the 
complexes leading to higher complex size. Conversely, the size distribution of 
complexes formed with Tat-LK15/siRNA at a charge ratio of 3:1 was heterogeneous 
with a mean of 663.4 ± 256.1 nm and zeta potential of +10.55 ± 2.61. Results 
published by Saleh et al. (2010) shows that the size and zeta potential measurements 
of a 3:1 Tat-LK15/DNA complex has a size of 400 ± 186 nm (Saleh et al., 2010) 
while the complex of similar charge ratio of Tat-LK15/siRNA has a size of 663 ± 
256.1 nm. The reported zeta potential by Saleh et al. (2010) for the same complex 
was +25.3 ± 3.4 while the complex formed with Tat-LK15/siRNA results in 
complexes with net charge of +10.55 ± 2.61.  One of the main reasons for the 
difference in size and zeta potential is likely to be factors like the difference in 
structure of DNA chain and siRNA rods that are important in determining the size 
and charge of complex. The DNA chain offers flexibility to form smaller complexes 
while the rigidity of the siRNA rods renders it less likely to form small complexes 
(Spagnou et al., 2004). Another study using R15 peptide for the complexation of 
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siRNA observed a complex size of 224 nm (Kim et al., 2010). However, the amount 
of siRNA used for the size measurement was 0.5 µg of siRNA, whereas 10 µg of 
siRNA was used in this study. Hence, the size of the complexes observed in this 
study could likely be a result of aggregation of the siRNA complexes. In such cases, 
methods like sonication could be employed to form complexes of smaller size and 
further improve the physicochemical characterisation of the complexes.  
4.9.2 Determination of transfection efficiency using luciferase assay 
pEGFPLuc, that expresses both luciferase and enhanced GFP, was used to assess the 
transfection efficiency of DNA complexes. Tat-LK15/DNA complexes gave higher 
luciferase expression (Figure 4.2) at a ratio of 2:1 than 3:1 (468 ± 17 RLU/mg and 
295 ± 32 RLU/mg respectively). These results slightly contradict the results 
published with Tat-LK15 (Saleh et al., 2010) that shows an optimum charge ratio of 
3:1 in HT29 and HT1080 cell lines, where difference in cell lines and 
physicochemical characterization could play a role. Additionally, the transfection 
efficiency of Tat-LK15 has never been tested using varying amounts of plasmid 
DNA. Here, understanding the DNA dose dependent transfection efficiency of the 
vector was essential since in the gene silencing experiments varying amount of DNA 
was used. Consistent with the observed optimum charge ratio of 2:1 using 1 µg of 
pEGFPLuc in K562 cells, the same Tat-LK15/DNA ratio was also found efficient 
using a higher amount of DNA (5 µg of pEGFPLuc) giving approximate value of 
2400 ± 160 RLU/mg for 2:1 and 700 ± 30 RLU/mg for 3:1. It is important to note 
that the cytotoxicity studies revealed that increasing the charge ratio and amount of 
DNA does not affect the cell viability using Tat-LK15 based complexes in K562 
cells (see section 4.4.1).  
 
On the other hand, Lipofectamine/DNA complexes showed a higher luciferase 
expression at 3:1 than 2:1 (36000 ± 1200 RLU/mg and 9100 ± 420 RLU/mg 
respectively), however the cell viability decreased significantly at 3:1 weight ratio 
compared to cell viability at 2:1 using 1 µg and 5 µg pEGFPLuc (Figure 4.2c). 
Additionally, due to the decrease in luciferase expression when 5 µg of DNA is used 
with Lipofectamine at a weight ratio of 3:1, 2:1 ratio seems to be an attractive option. 
Hence, 2:1 weight ratio of Lipofectamine/DNA was chosen for further experiments.  
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4.9.3 Determination of DNA and siRNA uptake using flow cytometry  
The quantification of the uptake i.e. number of cells and amount was carried out by 
flow cytometry. Figure 4.4 shows that the amount of DNA complexed with Tat-
LK15 is directly proportional to the amount of DNA that penetrates the cells (MFI of 
452 ± 5 for 1 µg DNA and 1524 ± 41 for 5 µg DNA): this information is of interest 
in the event of studying whether higher amount of shRNA plasmid influences the 
efficiency of gene silencing. Indeed, increasing the amount of DNA incubated results 
in a higher population of cells that internalise DNA when Tat-LK15 is used as a 
vector (63 ± 1% of cells using 1 µg DNA and 79 ± 1% of cells using 5 µg DNA). 
The property of Tat-LK15 to transfect a higher population of cells could possibly be 
due to the membrane lytic activity of LK15 peptide. LK15 peptide when fused to Tat 
peptide does not lose its membrane lytic activity when complexed with DNA, thus 
enabling higher transfection efficiency (Saleh et al., 2010). The results of this are 
also in agreement showing that Tat-LK15 like LK15 peptide retains most (80%) of 
the membrane lytic activity on complexation with DNA (Saleh et al., 2010). In 
contrast, flow cytometry results obtained with Lipofectamine based DNA complexes, 
indicates that only few cells (28 ± 1% using 1 µg DNA and 20 ± 5% of cells using 5 
µg DNA) have DNA uptake but these cells have internalised high quantities of DNA. 
The uptake of Lipofectamine/DNA complex at a weight ratio of 2:1 using varying 
amounts of DNA correlates with the results obtained from the luciferase assay 
(Figure 4.2 c) showing that increasing amounts of DNA do not always increases the 
transfection efficiency. These results show that there is potentially a direct 
relationship between the number of cells taking up the DNA complexes and the 
number of transfected cells. 
 
The uptake of siRNA based complexes at charge and weight ratio of 3:1 shows a 
concentration dependent uptake for Tat-LK15 (MFI of 11 ± 0.5 for 1 µg DNA and 
1952 ± 47 for 5 µg DNA) and Lipofectamine based complexes (MFI of 255 ± 55 
using 1 µg DNA and 1348 ± 172 using 5 µg DNA). Interestingly, both Tat-LK15 and 
Lipofectamine based siRNA complexes show a similarly evolving profile as a 
function of siRNA dose. Lipofectamine/siRNA complexes show a similarity in 
uptake between 1 and 2 µg of siRNA which is also seen with DNA based complexes 
at 2:1 weight ratio (Figure 4.4 and Figure 4.5). 
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4.9.4 Determination of DNA and siRNA uptake using confocal 
microscopy  
Subsequently, the uptake of DNA and siRNA complexes was studied using confocal 
microscopy. It is important to note here that the experimental condition remains the 
same as that used for flow cytometry with the exception of the trypsinisation of cells 
which was carried out for flow cytometry to remove cell bound complexes, but 
avoided for confocal experiments due to the nature of subsequent transfection 
experiments performed. Hence, it was necessary to observe the cells under the same 
conditions as transfections.  
 
DNA uptake studies using confocal microscopy revealed interesting information on 
the differences in the uptake of Tat-LK15 and Lipofectamine at different time points 
(4 hours and 24 hours after treatment). Initial cellular uptake with Tat-LK15 and 1 
µg of DNA show localisation primarily on the surface of cell membrane indicating 
slower rate of cell entry whereas intracellular localisation was observed with 5 µg of 
DNA (Figure 4.6 a and c). Even though a lower gain (550 for 5 µg compared to 640 
for 1 µg DNA) was used, the intensity observed is higher when using 5 µg DNA. 
This indicates a dose dependent uptake of DNA for Tat-LK15 based complexes 
where the amount also affects the cellular localisation of the complex. On the other 
hand, Lipofectamine/DNA complexes showed rapid cellular entry just 4 hours after 
treatment with 1 µg DNA, but with 5 µg DNA higher localisations on the cell 
membrane was observed rather than inside the cells. Nevertheless, there have been 
cases of cell trauma leading to change in cell morphology when treated with 
Lipofectamine based DNA complexes, as shown in Figure 4.7 c and d. The stress 
caused by Lipofectamine on cells did not however relate to the cell cytotoxicty due 
to various reasons. Three explanations can be put forward for these observations: i) 
the confocal experiment was performed at 4 hours while the MTT assay was 
performed at 24 hours post treatment, ii) taking into account the MTT assay is 
performed 24 hours post treatment, the cells could recover from the initial stress 
caused by treatment with Lipofectamine based complexes and iii) MTT assay 
requires the mytochondria of a cell to reduce the MTT, which could also be 
performed by cells under stress that is likely not to be reported as cell death. Hence, a 
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more sensitive cytotoxic assay could provide better indications of the toxicities of the 
complexes.  
 
To better understand the localisation of the DNA after uptake, the confocal 
experiment was performed 24 hours post incubation. For cells treated with Tat-
LK15/DNA complexes, confocal results 24 hours post incubation indicates presence 
of cytoplasmic and nuclear localisation of Cy5 labelled DNA (Figure 4.8 a and b). 
However, cells treated with Lipofectamine based complexes showed very little 
labelling on the cell membrane and no labelling in the cytoplasm 24 hours after 
treatment with the complexes (Figure 4.8 c and d). Further investigation into the 
reduction in Cy5 intensity of Lipofectamine based complexes after 24 hours, 
confirmed the same where the same settings were used to observe the cells which 
were treated with 1 µg and 5 µg of DNA complexed to Tat-LK15 and Lipofectamine 
(Figure 4.9 a,b,d and e). Here, comparing Tat-LK15 and Lipofectamine treated cells, 
labelled DNA was found in significantly higher intensity in cells treated with Tat-
LK15/DNA complex than cells treated with Lipofectamine based complexes (Figure 
4.9 a and b). It is however not sure whether the Cy5 dye (for Lipofectamine based 
complexes) has been quenched or Cy5 label been displaced inside the cell during 
transcription. Another likely explanation is the release of DNA into the cytoplasm 
after membrane fusion with the cell membrane or the endosomal membrane. 
Membrane fusion is a mechanism used by lipid based transfection reagents to 
penetrate the cells and escape the endosome respectively (El-Sayed et al., 2009, 
Schroeder et al., 2009). Hence, the release into the cytoplasm could lead to early 
degradation of DNA in the cell, one of the main barriers (Lechardeur et al., 1999) as 
discussed in Introduction (section 1.2.2.2.3). Ohba et al. (2004) observed that the 
Lipofectamine based complexes have a half life of 9 hours in K562 cells (Ohba et al., 
2004). This study helps ascertain the loss of Cy5 fluorescence intensity in 
Lipofectamine based DNA complexes. The early degradation of DNA could lead to 
effective short term gene expression resulting in protein synthesis in the short term, 
for example in luciferase assay and EGFP expression (Figure 4.10), but might not 
lead to satisfactory performance when long term expression is desired (in the case of 
long term gene silencing). On the other hand, from Figure 4.9 (a and d), it can be 
seen that there is a significant increase in intensity between 1 µg and 5 µg of labelled 
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DNA (14.80 ± 5.02 and 27.88 ± 11.49 respectively) complexed with Tat-LK15 
(Table 4.3), confirming a dose dependent uptake of DNA complexed to Tat-LK15.  
 
Subsequent siRNA uptake studies using confocal microscopy have shown similar 
cellular localisation for both Tat-LK15 and Lipofectamine. Taking into account the 
same settings used to image cells treated with 1 µg DNA (with Tat-LK15 and 
Lipofectamine), there is no significant difference in siRNA uptake between the 
vectors. However, Lipofectamine based complexes (using 5 µg siRNA) have a 
significantly higher intensity at 4 hours when compared to Tat-LK15 based siRNA 
complexes (Table 4.4). The study by Spagnou et al. (2004) also indicates rapid 
cellular entry by Lipofectamine based siRNA complexes evident even 1 hour after 
addition of the complexes to the cells (Spagnou et al., 2004). Interestingly, as Figure 
4.11 indicates, using a higher amount of siRNA has led to more increased 
localisation concentrated in a small region of the cell. This observation is more 
obvious 24 hours post transfection (Figure 4.12) and in presence of 5 µg of siRNA: 
there is more concentrated localisation within the cells whereas using 1 µg of siRNA 
has led to uniform distribution inside the cell. It is unsure whether this punctate 
localisation is in the endosome or other vesicular structures within the cell. There are 
reports of punctate localisation heterogeneously distributed within the cells for 
siRNA complexed to peptides (Kim et al., 2010) which has also been observed with 
Lipofectamine based siRNA complexes (Spagnou et al., 2004) leading them to 
postulate a endocytic mechanism of uptake for these complexes. One study showed 
the uptake of siRNA using Lipofectamine in K562 cells having a diffuse localisation 
at 4 hours and some punctate localisation at 6 hours with higher intensity (Ohba et al., 
2004). Hence, these studies confirm the observation of both diffuse and punctate 
localisation within the cells following treatment with siRNA based complexes using 
both peptides and Lipofectamine. On the other hand, some reports show perinuclear 
localisation of the labelled siRNA using Tat peptide and Lipofectamine complexed to 
siRNA (Chiu et al., 2004). This has also been widely observed by others (Wang et al., 
2007, Kim et al., 2010). These studies clearly indicate the presence of siRNA in the 
cytoplasmic region of the cells.  
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One of the main factors to be considered while analysing the images obtained using 
CSLM is the accuracy of the intensity measurement by the software, Image J. In the 
case of siRNA (1 µg complexed to Tat-LK15 and Lipofectamine) 24 hours post 
treatment the mean of the intensity of Cy5 labelled siRNA is less than those observed 
at 4 hours (15.44 ± 4.05 at 24 hours against 22.25 ± 7.6 at 4 hours for Tat-LK15, 
17.79 ± 7.08 at 24 hours against 23.15 ± 5.24 at 4 hours for Lipofectamine) (Table 
4.3), although the same detector gain settings were used. A plausible explanation of 
this result could be the diffuse localisation of the siRNA within the cell at 24 hours 
post treatment (Figure 4.12 a and b) making it a challenging task to quantify the 
intensity using Image J. As a result, images that have punctate localisations are likely 
to give better results and this should be considered while analysing the data obtained.  
 
In this chapter, experiments like the physicochemical characterization, transfection 
efficiency and DNA/siRNA uptake were studied in detail, which are vital steps to be 
considered in designing a good gene delivery vector. Here, Tat-LK15 has shown 
efficient DNA/siRNA complexation ability and transfection. The peptide was also 
able to successfully deliver DNA and siRNA into K562 suspension cell lines and in 
some instances surpass the efficiency of Lipofectamine. Having established the key 
profiles for Tat-LK15 based complexes, it is now important to study the gene 
silencing efficiency mediated by these complexes in targeting bcr-abl in K562 CML 
cells.   
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Chapter 5 
siRNA and shRNA plasmid mediated gene silencing 
of bcr-abl in chronic myeloid leukemia cells 
5.1 Introduction   
In the previous chapter, the uptake of DNA and siRNA by the vectors, namely Tat-
LK15 and Lipofectamine, was studied. The results show different cellular uptake 
profile using flow cytometry (section 4.5 and 4.6) and localisation patterns using 
confocal microscopy (section 4.7 and 4.8) for Tat-LK15 and Lipofectamine. Tat-
LK15 exhibited comparable to or better DNA uptake efficiency than Lipofectamine 
when high quantities of DNA were used. However, Lipofectamine was more 
effective compared to Tat-LK15 in regards with the effectiveness of transfection as 
shown by luciferase assays (Figure 4.3). Although Tat-LK15 exhibited lower 
transfection efficiency compared to Lipofectamine, it displayed lower cytotoxicity. 
As a compromise between cytotoxicity and transfection efficiency, Tat-LK15 vector 
was further investigated by monitoring gene silencing. Given that Tat-LK15 was able 
to complex DNA and siRNA (section 4.3.1), it is reasonable to hypothesise that the 
vector may have the ability to mediate gene silencing by both shRNA plasmid and 
siRNA in chronic myeloid leukemia (CML) cells. Figure 5.1 presents a chronic 
myeloid leukemic cell, on the left side, depicts the fusion gene forming the BCR-
ABL fusion protein resulting in the leukemic condition. On the right half of the 
figure, two different ways of introducing siRNA into the cell is depicted, i) using 
shRNA expression plasmid denoted as „1‟and ii) using direct introduction of siRNA 
denoted as „2‟. In both cases, shRNA plasmid and siRNA are complexed to the 
vectors, Tat-LK15 and Lipofectamine for delivery into the cell. 
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Figure 5.1: Schematic representation of a chronic myeloid leukemic cell. Image 
showing synthesis of BCR-ABL (left side) and the chain of events that likely takes 
place on the introduction of shRNA plasmid using a gene delivery vector(eg: Tat-
LK15) and the induction of gene silencing (right side).  
 
5.2 Aim of the chapter  
The aim of this chapter was to evaluate the peptide based gene delivery vector Tat-
LK15, relative to Lipofectamine, to deliver functional shRNA plasmid and siRNA 
that target and reduce the expression of BCR-ABL oncoprotein in K562 cells. 
Although peptide based delivery vectors have been used to deliver siRNA into a 
range of cell lines, its use has not been reported yet for the study of gene silencing 
using siRNA and shRNA plasmid in chronic myeloid leukemia.  
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5.3 Results  
5.3.1 Cloning of the pSilencer 2.0 H1 vector  
In order to construct a plasmid DNA that can transcribe and synthesise a shRNA to 
reduce the expression of target protein, the oligonucleotide insert necessary to silence 
the gene expression has to be inserted into the plasmid DNA. Here, the plasmid 
pSilencer 2.0 U6 hygro (Applied Biosystems, UK) was specifically chosen due to the 
presence of U6 promoter and the presence of the restriction enzyme sites (Bam HI 
and Hind III) required to ligate the insert of choice within its multicloning site. The 
cloning consists of two main steps, annealing of the oligonucleotides and ligation of 
the annealed oligonucleotides into the linear plasmid. Tests to confirm the presence 
of the insert and verification of the sequence were also performed.  
Annealing of the oligonucleotides  Based on the sequence of the mRNA to be 
targeted, the insert (made of sense and antisense strands) was chosen and synthesized 
in a way that sense strand has the same sequence as the target mRNA, followed by a 
loop region and the sequence complementary to the target mRNA. The antisense 
strand of the insert is complimentary to the sense strand. In this case the target 
mRNA is that of bcr-abl and hence the sense and antisense strands were designed 
based on the sequence of the bcr-abl mRNA (obtained from NCBI Gene database). 
The sense strand was designed in a way that it overlaps the fusion region between bcr 
and abl (fusion sequence: GTTCAA/AAGCCCTT) thus improving the specificity of 
the gene silencing.  
In order to ligate the insert into the plasmid DNA, it is essential to include the partial 
sequence of the restriction enzyme sites onto the ends of the insert. Therefore, the 
sense strand was synthesized having the sequence of the Bam H1 restriction enzyme 
followed by the sequence of the sense strand then the loop sequence followed by the 
antisense strand ending with the Hind III restriction enzyme site. The antisense 
strand having the sequence complementary to the sense strand was also synthesized. 
The sequence of the sense and antisense strands is provided in Materials and 
Methods (section 3.11.2, Table 3.1). These single stranded oligonucleotides were 
then annealed as described in the Materials and Methods (section 3.11.3).  
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The annealed oligonucleotides were then verified by resolving them on a 12% w/v 
non-denaturing polyacrylamide gel electrophoresis (section 3.11.10). The principle 
that double stranded DNA (dsDNA) runs slower than a single stranded DNA 
(ssDNA) on a gel was used to interpret this result. The polyacrylamide gel (Figure 
5.2), as indicated by arrows, shows that the annealed dsDNA (lane 4) runs slower 
than the ssDNA (lanes 2 and 3), confirming successful annealing of the 
complementary sequences. It is also evident from Figure 5.2 that the annealing 
reaction was complete due to the absence of bands in lanes 4 and 5 corresponding to 
individual ssDNA. 
 
Figure 5.2: Polyacrylamide gel to confirm annealing reaction. 12% w/v non-
denaturing polyacrylamide gel electrophoresis image showing the single stranded 
and annealed oligonucleotides. Sample lanes 1-1Kbp DNA ladder, 2- single stranded 
sense oligo, 3-single stranded antisense oligo, 4-annealed oligonucleotide sample of 
the B3A2 insert and 5- the diluted annealed sample.  
Ligation of the insert and vector and propagation of the plasmid DNA  
The annealed oligonucleotides were then ligated into the linearised pSilencer 2.0 U6 
hygro vector at 16C overnight (section 3.11.4) and then was immediately 
transformed into competent DH5 cells (section 3.11.6) and plated onto Ampicillin 
containing Luria Bertani (LB)-agar plates. Colonies in both the plus-insert and 
Annealed sample 
Single stranded DNA 
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minus-insert ligation reactions were counted. Typically, the number of colonies in 
the plus-insert ligation should be 10 fold higher than the minus-insert ligation 
control. But the minus-insert ligation did not have any colonies showing efficient 
cloning. The colonies from the plus-insert were then inoculated in LB broth 
containing the same amount (50 µg/mL) of antibiotic. Cells were pelleted and DNA 
extraction (Plasmid Mini Prep Kit, Qiagen) was performed (section 3.11.7). The 
Figure 5.3 indicates that the plasmid DNA (indicated by an arrow) appears as a band 
between 4kb and 5kb indicating the preparation of the correct plasmid DNA.  
 
Figure 5.3: Agarose gel of cloned plasmid DNA. 1% w/v Agarose gel (section 
3.11.8) of the plasmid DNA sample preparations (indicated by arrow) for the 
colonies selected and cultured after transformation. Sample Lane: 1-1Kbp DNA 
ladder and the lanes 2-5 are the DNA samples from different B3A2 clones obtained. 
The agarose gel was run for 45 minutes at an electric field of 6.15 V/cm on a Mupid 
exU gel electrophoresis system. 
Cloned plasmid DNA 
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Confirmatory tests to determine effective cloning  To further confirm effective 
ligation of the insert and the plasmid, the ligated circular plasmid DNA was digested 
with BamHI and HindIII enzymes to verify the release of an excised fragment 
(section 3.11.9). As shown in Figure 5.4, the samples digested with the two enzymes 
did not migrate far on the gel when compared to the uncut circular plasmid, 
providing evidence that they have been linearised, as indicated by arrows on Figure 
5.4. It is important to note that the 60 bp excised fragment (i.e. annealed insert) 
cannot be detected on the agarose gel and hence improved resolution was required. 
 
 Figure 5.4: Agarose gel of restriction enzyme digested DNA. 1% w/v Agarose gel 
image (section 3.11.8) of the DNA samples which were digested with BamHI and 
HindIII. The first well is a 1 Kb DNA ladder. Every odd numbered lane is the uncut 
control DNA and the even numbered lanes are the samples cut with restriction 
enzymes BamHI and HindIII. The size of the uncut circular plasmid is 4885 bp and 
the size of the excised fragment is 60bp.  
 
To confirm the presence of a 60 bp excised fragment, a non-denaturing 
polyacrylamide gel electrophoresis (3.11.10) was used. As shown in Figure 5.5, the 
band (indicated by arrows) could now be seen in all the samples. This confirms the 
presence of an excised out fragment when digested with BamHI and HindIII 
Uncut plasmid DNA 
Digested plasmid DNA 
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enzymes indicating the likely presence of a positive clone. Here, Figure 5.5 indicates 
DNA samples obtained from the B3A2 construct. 
The integrity of the insert was verified by gene sequencing using the primers as 
mentioned in the Materials and Methods (section 3.11.11). The gene sequencing 
experiment ensures the correctness of the insert cloned. The results of the gene 
sequencing, provided in the Appendix 2, were as expected.  
 
 
Figure 5.5: Polyacrylamide gel of restriction enzyme digested DNA. 12% w/v Non-
denaturing polyacrylamide gel (section 3.11.10) with the same DNA samples 
digested with BamHI and HindIII to confirm the presence of an excised fragment of 
around 60 base pairs. a) Sample lanes: 1- 1 Kbp DNA ladder, 2-B3A2 clone 1 DNA 
uncut, 3-B3A2 clone 1 DNA cut, 4-B3A2 clone 2 DNA uncut, 5-B3A2 clone 2 DNA 
cut. 
 
To summarize the cloning experiments, the insert was successfully annealed (Figure 
5.2) and ligated into the linear plasmid DNA (Figure 5.3). The ligation of the correct 
insert was confirmed through gene sequencing studies (as showed in Appendix 2). 
With the successful cloning of the insert into the plasmid DNA, pSilencer 2.1 U6 
hygro, the shRNA plasmid can now be used to transfect K562 cells to determine the 
efficiency of gene silencing mediated by the shRNA plasmid based complexes.  
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5.3.2 siRNA  
The siRNA was also synthesized (Dharmacon, UK) matching the B3A2 isoform of 
the bcr-abl fusion gene. The siRNA sequence used was: 5′ 
GCAGAGUUCAAAAGCCCUU 3′ and was obtained lyophilised. The sample was 
dissolved to a concentration of 10 µg/µL and further dilutions were made as 
required. The negative control siRNA that does not target any mRNA in the 
eukaryotic cell was purchased from Sigma (All stars negative control, Sigma, UK). 
The sequence of the negative control siRNA was not revealed by the manufacturer.  
 
5.3.3 Studying gene silencing using vector/shRNA plasmid complex  
Subsequent to obtaining the desired cloned plasmid DNA, it was then necessary to 
determine the gene silencing mediated by the shRNA plasmid DNA complexed to 
the vectors, Tat-LK15 and Lipofectamine. Hence, the ability of Tat-LK15 and 
Lipofectamine based shRNA plasmid complexes to mediate gene silencing of bcr-
abl in K562 was evaluated. RNAi mediated effect can be evaluated at two stages: 
reduction in protein expression levels and decrease in the target mRNA levels. 
Reduction in protein expression in the cells can be detected using western blot 
analysis, while the changes in mRNA expression can be detected using quantitative 
real time Reverse Transcriptase PCR (qRT-PCR) utilizing SYBR green chemistry.  
 
5.3.3.1 Amount and time dependent screening of shRNA plasmid  
To determine the efficiency of vector/shRNA plasmid complexes to silence a target 
gene, the amount of shRNA plasmid required to cause reduction in protein levels 
must be optimised. Additionally, it is necessary to determine the time taken to cause 
reduction in protein expression since proteins have varying half lives that could 
affect reduction in the total protein when quantified. Hence, preliminary studies to 
reduce the expression of BCR-ABL were focussed on determining the dose and time 
required to induce gene silencing. Therefore, Tat-LK15/shRNA plasmid complexes 
were used at a charge ratio of 2:1, as found to be the optimum charge ratio (Figure 
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4.1 and Figure 4.2) for DNA complexation and luciferase expression. The 
experiment was performed with varying amounts of BCR-ABL shRNA plasmid and 
negative control shRNA plasmid, which does not target any specific protein, were 
complexed to Tat-LK15. The complexes were incubated in K562 cells for 4 hours as 
described in Materials and Method (section 3.16). The cells were then incubated in 
RPMI medium for varying time periods. In this case, cells were lysed at 24 hours or 
48 hours and their total protein was extracted using the cell lysis method described in 
Materials and Methods (section 3.19.1). The protein samples were then resolved 
using western blot and incubated with antibodies specific for BCR-ABL and α-
Tubulin to determine their respective protein expression levels. The expression of α-
Tubulin, a housekeeping gene, was monitored to ensure lack of non-specific increase 
or decrease of proteins in the cells caused by external factors. Figure 5.6 shows the 
expression of BCR-ABL and α-Tubulin in cells treated with Tat-LK15/shRNA 
plasmid (bcr-abl specific and negative control) at 24 hours (Figure 5.6 a) and 48 
hours (Figure 5.6 b). In these Figures (5.6a and 5.6b), no reduction in levels of BCR-
ABL protein in cells treated with the bcr-abl specific shRNA plasmid was observed 
when compared to the negative control shRNA plasmid treatment suggesting that 
longer incubation time may be required to silence the expression of BCR-ABL and 
likely a higher dose of shRNA plasmid transfected. The long half-life of BCR-ABL 
oncoprotein (Wilda et al., 2002), could play an important role in the time taken to 
reduce the expression of BCR-ABL and hence the time required to silence this 
protein had to be determined. 
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Figure 5.6: Tat-LK15/shRNA plasmid mediated gene silencing at 24 and 48 hours. 
Western blot images showing the different doses of bcr-abl shRNA plasmid used to 
test the efficiency of Tat-LK15 in silencing the BCR-ABL protein. a) Western blot 
image showing the expression of BCR-ABL (210 kDa) and α-Tubulin (55kDa) 
Protein samples from cells transfected using Tat-LK15/shRNA plasmid (bcr-abl 
specific and negative control shRNA plasmid) complex at a charge ratio of 2:1 and 
cells were lysed at 24 hours. The western blot image shows little or no reduction in 
expression of BCR-ABL protein bands with respect to the control treatment. b) Cells 
were transfected using bcr-abl shRNA plasmid (left) and negative control shRNA 
plasmid (right) complexed to Tat-LK15 and the protein expression was determined at 
48 hours. The western blot images show that there is no reduction in the expression 
of BCR-ABL protein bands with respect to the control treatment. Non-transfected 
cells were considered as control. 
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5.3.3.2 Short term gene silencing mediated by shRNA plasmid based 
complexes  
Further experiments were performed using higher amount of shRNA plasmid (10 µg, 
20 µg and 30 µg) and prolonging the time taken by Tat-LK15 and Lipofectamine 
based complexes to inhibit the expression of BCR-ABL. In order to improve the 
reliability of the experiments, these experiments were performed using uniformly 
transfected cells to demonstrate that the silencing observed in the transfected samples 
was dependent on the amount of shRNA plasmid and not a result of the stress caused 
by transfection itself. Therefore, various controls were used. One of them involved 
controls like „mock‟ as shown in Figure 5.7, in which cells were transfected with 30 
µg of a control plasmid DNA pcDNA3 that does not express any gene. Additionally 
the total quantity of DNA (pcDNA3 and shRNA plasmid) used for transfection was 
kept constant. To ensure uniform transfections for all samples, for instance when the 
mock sample is treated with 30 µg of pcDNA3, a sample treated with 10 µg of B3A2 
shRNA plasmid is also co-incubated with 20 µg of pcDNA3. To complete the set of 
controls, a negative control shRNA plasmid was used as it results in synthesis of 
shRNA plasmid without reducing the expression of any protein in mammalian cells. 
The negative control shRNA plasmid ensures there is no non-specific reduction in 
the target protein‟s levels. Additionally, the expression of α-Tubulin was determined 
to eliminate the possibility of non-specific changes in the expression of other cellular 
proteins. Slight variations are however frequently expected. Hence, to exclude the 
effect the aberrant expression of proteins, the levels of BCR-ABL are normalised 
with the expression levels of α-Tubulin. Thus, placing important controls help 
determine the gene silencing effect that is caused only by the shRNA plasmid.  
 
Figure 5.6 indicates that Tat-LK15 based shRNA plasmid complexes did not induce 
reduction in levels of BCR-ABL using low amounts of bcr-abl shRNA plasmid (1 µg 
to 5 µg) at 24 hours and 48 hours in K562 cells. Hence, higher amounts of bcr-abl 
shRNA plasmid (10 µg, 20 µg and 30 µg) were used and the expression of BCR-
ABL was determined at 96 hours post transfection. Cells were transfected as 
described in Materials and Methods (section 3.16) using Tat-LK15/DNA complex at 
Chapter 5 
143 
 
a charge ratio of 2:1. Gene silencing studies with Tat-LK15 based complexes show 
that 96 hours post transfection reduction in BCR-ABL protein levels could be 
observed (Figure 5.7 a and b). Here, reduction in protein levels using the Tat-
LK15/shRNA plasmid complex, relative to the mock, with 60% reduction in BCR-
ABL protein expression using 10 µg and reaching a maximum of 80% using 30 µg of 
shRNA plasmid as shown in Figure 5.7 a and b. It is noteworthy that the levels of -
Tubulin, which is used as a housekeeping gene, remains stable indicating lack of 
non-specific reduction in protein levels induced by the shRNA plasmid.  
After establishing the ability of Tat-LK15 vector to mediate gene silencing, it was 
important to determine and compare the efficiency of Lipofectamine/shRNA plasmid 
complexes to reduce the expression of the BCR-ABL protein. K562 cells were 
treated with Lipofectamine/shRNA plasmid at a weight ratio of 2:1, as concluded 
from the YO-PRO-1 displacement assay (section 4.3.1) and the luciferase assay 
(section 4.4.1). Treatment of cells with Lipofectamine based shRNA plasmid 
complexes shows that reduction in protein levels could also be observed at 96 hours 
post transfection, as evident from Figure 5.7 c and d. When transfected with 10 µg of 
Lipofectamine/shRNA plasmid along with 10 µg of pcDNA3 gave a gene silencing 
to about 40% of the initial protein expression levels compared to 80% when 
transfected with 20 µg of shRNA plasmid. These results suggest a dose dependent 
increase in gene silencing when complexed with Lipofectamine at 96 hours post 
transfection. These experiments show that both Tat-LK15 and Lipofectamine based 
shRNA plasmid complexes are able to induce reduction in protein levels of BCR-
ABL in K562 cells at 96 hours post treatment. It is then important to establish the 
duration of the gene silencing mediated by the vectors namely Tat-LK15 and 
Lipofectamine beyond 96 hours. 
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Figure 5.7: shRNA plasmid mediated gene silencing at 96 hours. a) Western blot 
image showing the expression of BCR-ABL (210 kDa) and -Tubulin (55 kDa). K562 
cells were transfected using Tat-LK15/shRNA plasmid (a) and Lipofectamine/shRNA 
plasmid complex (c) at a charge and weight ratio of 2:1 respectively and were lysed 
96 hours post transfection. Cells transfected using 30 µg of pcDNA3 and 30 µg of 
negative control shRNA plasmids were considered as controls for cells treated with 
Tat-LK15 based complexes. Cells transfected using 20 µg of pcDNA3 and 20 µg of 
negative control shRNA plasmids are considered as controls for cells treated with 
Lipofectamine based complexes. b) and d) Graphs showing the relative protein 
expression obtained by normalising the intensity of the BCR-ABL band with the 
intensity of the -Tubulin. The relative intensities obtained by analysis of the western 
blots by Image J showed a reduction in the relative expression of BCR-ABL (b and d) 
when treated with 10 µg, 20 µg and 30 µg of shRNA plasmid when compared to 
negative control shRNA plasmid.  Bars represent mean ± SD, n=3. Figure 5.7 is 
published in (Arthanari et al., 2010).  
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5.3.3.3 Long term gene silencing mediated by shRNA plasmid based 
complexes  
Induction of stable reduction in protein levels is a key aspect of shRNA plasmid 
induced gene silencing. After studying the effect of Tat-LK15 and Lipofectamine 
based shRNA plasmid complex producing short term gene silencing, it appeared 
interesting to determine the longevity of the gene silencing effect produced by the 
complexes. Therefore the expression of the BCR-ABL protein was checked at 192 
hours post transfection. K562 cells were transfected with 2:1 charge ratio of Tat-
LK15/shRNA plasmid complexes and the protein expression levels were determined 
which are presented Figure 5.8 a.  The Figure 5.8b indicates that a reduction in BCR-
ABL expression of up to a maximum of approximately 85% was observed, while no 
reduction in the expression of -Tubulin was evident (Figure 5.8 a). The expression 
of BCR-ABL seems to decrease in a dose dependent manner. 
 
Figure 5.8: shRNA plasmid mediated gene silencing at 192 hours. a) Western blot 
image showing the expression of BCR-ABL (210 kDa) and -Tubulin (55 kDa). K562 
cells were transfected using Tat-LK15/shRNA plasmid at a charge ratio of 2:1 and 
cells were lysed at 192 hours post transfection. c) Cells were transfected using 
Lipofectamine/DNA complex at a weight ratio of 2:1 and were lysed 192 hours post 
transfection. Cells transfected using 30 µg of negative control shRNA plasmid and 
30 g of pcDNA3 was considered as controls. b) and d) Graphs showing the relative 
protein expression obtained by normalising the intensity of the BCR-ABL band with 
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the intensity of the -Tubulin. The relative intensities obtained by analysis of the 
western blots by Image J showed a reduction in the relative expression of BCR-ABL 
when treated with 30 µg of shRNA plasmid complexed with Tat-LK15 (a and b). 
Similarly, reduction in protein expression was found with 10 µg and 20 µg of shRNA 
plasmid for Lipofectamine based complexes (c and d) when compared to negative 
control shRNA plasmid. Bars represent mean ± SD, n=3. Figure 5.8 is published in 
(Arthanari et al., 2010). 
 
For cells transfected with Lipofectamine/shRNA plasmid at a weight ratio of 2:1, the 
protein levels were determined at 192 hours as presented in Figure 5.8 c. As shown 
in Figure 5.8 c and d, it can seen that Lipofectamine/shRNA plasmid complexes 
caused reduction in the expression of the BCR-ABL protein at 192 hours (8 days) 
post transfection up to a maximum of 40% using 10 µg of shRNA plasmid (treatment 
of 10 µg of shRNA plasmid plus 20 µg of pcDNA3). However, transfection using 
higher amounts of shRNA plasmid (20 µg) resulted in increase in BCR-ABL protein 
levels. The increase in BCR-ABL levels could be due to the saturation of proteins 
involved in the RNAi pathway. Such an event could lead to shutting down of the 
proteins involved in the RNAi machinery (Grimm et al., 2006). Hence, an increase in 
the amount of shRNA plasmid transfected, due to saturation, does not result in 
increase in the gene silencing efficiency mediated by the Lipofectamine based 
complexes.  
In summary, it was evident that there was stable gene silencing mediated by both the 
vectors, Tat-LK15 and Lipofectamine. Tat-LK15 based complexes mediated higher 
gene silencing efficiency than Lipofectamine based complexes at 192 hours in K562 
cells. 
5.3.3.4 Quantification of mRNA   
Gene silencing can also be determined using mRNA expression levels. To determine 
the mRNA expression, quantitative real time RT-PCR was used (section 3.20.2). 
Here, the expression of mRNA was determined at 48 hours since gene silencing was 
observed at 96 hours (Figure 5.7). To determine reduction in expression of bcr-abl 
mRNA, quantitative RT-PCR was performed on RNA extracted from cells 
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transfected with controls (30 µg of negative control shRNA plasmid and 30 µg of 
pcDNA3) and increasing amounts of shRNA plasmid, 48 hours post transfection 
(Figure 5.9). Figure 5.9 shows that for Lipofectamine based shRNA plasmid 
complexes, a dose dependent decrease in levels of bcr-abl mRNA was observed that 
reached 90% reduction when treated with 30 µg of bcr-abl shRNA plasmid. In the 
case of controls (mock and negative control shRNA plasmid), there was a decrease in 
mRNA levels (20%) in cells transfected with negative control shRNA plasmid, 
indicating possibility of the RNAi mechanism itself affecting the expression of 
protein.  
Subsequently, the reduction of bcr-abl mRNA expression in cells treated with Tat-
LK15/shRNA plasmid was determined in a similar way as that described for 
Lipofectamine/shRNA plasmid treated cells (Figure 5.9). The results (Figure 5.9) 
show that for Tat-LK15 based shRNA plasmid complexes there was a dose 
dependent decrease in levels of bcr-abl mRNA (statistically significant decrease 
between 10 and 20 µg shRNA plasmid, p=0.0033), reaching 85% reduction when 
treated with 20 µg of bcr-abl shRNA plasmid, but at 30 µg shRNA plasmid only 
70% reduction was observed. However, similar to results obtained using 
Lipofectamine based shRNA plasmid controls, transfection with control (30 µg of 
negative control shRNA plasmid) has also resulted in 30% reduction in mRNA 
levels, relative to the „mock‟ transfection (30 µg of pcDNA3). Hence, the observed 
reduction with negative control shRNA plasmid is likely to be due to the cell 
undergoing RNAi pathway. 
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Figure 5.9: shRNA plasmid mediated reduction in bcr-abl mRNA. Results obtained 
using quantitative RT-PCR experiments on mRNA extracted from cells transfected 
with the following complexes: 30 µg of negative control shRNA plasmid and 30 µg of 
pcDNA3 were controls; increasing amounts of shRNA plasmid complexed to Tat-
LK15 (dark grey bars) and Lipofectamine (light grey bars) were used. The values 
obtained for bcr-abl mRNA (corresponding to B3A2 primer) was normalized to 
expression of Rpl19 housekeeping gene (corresponding to Rpl19 primer). mRNA was 
extracted from cells 48 hours post transfection. The graph indicates a 70% to 80% 
reduction in expression for Tat-LK15 based shRNA complexes and 50% to 80% 
reduction in expression for Lipofectamine based shRNA complexes, when compared 
to the Mock treated cells. Bars represent mean ± SD, n=3. Figure 5.9 is published in 
(Arthanari et al., 2010). 
 
5.3.4 siRNA mediated gene silencing  
In addition to shRNA plasmid mediated gene silencing, RNAi can also be achieved 
using siRNA. In contrast to shRNA plasmid, this approach employs the direct 
introduction of siRNA into the cells which then induces RNAi. This method was 
used to evaluate the efficiency of siRNA mediated gene silencing compared to 
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shRNA plasmid mediated gene silencing of bcr-abl in K562 cells using Tat-LK15 
and Lipofectamine. Due to the lack of evidence for the ability of Tat-LK15 to 
mediate gene silencing using siRNA, it was worth testing its efficiency and compare 
it to shRNA plasmid mediated silencing. This objective was achieved by assessing 
the efficiency and duration of the gene silencing mediated by siRNA on different 
time scales and amounts of siRNA.  
 
Figure 5.10: Tat-LK15/siRNA mediated gene silencing at charge ratio of 2:1. a) 
Western blot image showing the expression of BCR-ABL (210 kDa) and -Tubulin 
(55kDa). K562 cells were transfected using Tat-LK15/siRNA complex at a charge 
ratio of 2:1 and cells were lysed 48 hours post transfection. The amount of protein in 
each sample was normalised by determining the protein concentration using 
Bradford’s reagent. b) Graph showing the relative protein expression obtained using 
Image J by normalising the intensity obtained from the BCR-ABL band to the 
intensity of the -Tubulin. From (b) it is evident that the treatment with Tat-
LK15/siRNA complexes resulted in 40% to 50% reduction in relative expression of 
BCR-ABL. Bars represent the mean. 
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Preliminary studies on the ability of TatLK15/siRNA to mediate reduction in levels 
of BCR-ABL after 48 hours were carried out and the results are presented in Figure 
5.10. Cells were transfected similar to DNA complexes using charge ratio of 2:1 for 
Tat-LK15/siRNA complexes. The results indicate a dose dependent decrease in 
BCR-ABL protein levels (40% and 50% using 20 g and 30 g of siRNA 
respectively) compared to untreated cells as control. These results show that gene 
silencing can be achieved at 48 hours a major difference with shRNA plasmid based 
complexes as no reduction had been observed at 48 hours (Figure 5.6b). Due to the 
relatively low gene silencing (maximum of 50%) observed here it seemed 
worthwhile to increase the charge ratio of the complexes to 3:1 as Figure 4.1b 
indicated maximum YO-PRO-1 displacement (Figure 4.1b) at this ratio.  
At 3:1 charge ratio, K562 cells were transfected with increasing amounts of siRNA 
(1 g, 5 g, 10 g, 20 g and 30 g) complexed to Tat-LK15 and BCR-ABL protein 
expression was determined 48 hours post transfection and the results are presented in 
Figure 5.11a. BCR-ABL protein expression was compared to negative control 
siRNA, (10 g , 20 g  and 30 g) complexed to Tat-LK15 at the same charge ratio. 
Figure 5.11a and b shows that the transfection of bcr-abl specific siRNA resulted in 
reduction in BCR-ABL expression between 60% and 80% (from 1 µg to 30 µg)  in a 
non-dose dependent manner compared to the negative controls. It is also worth 
noting that there is no reduction or change in expression of α-Tubulin indicating lack 
of non-specific gene silencing. Hence, it can be assumed that siRNA mediated 
transfection occurs earlier than shRNA plasmid mediated transfection which also led 
to very effective decrease in the expression of BCR-ABL. 
To determine the efficiency of Lipofectamine based siRNA complexes, a positive 
control, cells were transfected with these complexes at a 3:1 weight ratio in presence 
of different siRNA doses (5 g, 10 g, 20 g). The expression of BCR-ABL was 
determined at 48 hours as presented in Figure 5.11 c and d. As indicated in these 
Figures, BCR-ABL levels were reduced by approximately 60% to 70% using 5 g, 
10 g and 20 g of siRNA. These results show that Tat-LK15/siRNA complexes are 
as efficient as Lipofectamine based complexes in mediating gene silencing. 
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Figure 5.11: siRNA mediated gene silencing at Tat-LK15/siRNA charge ratio of 
3:1 and Lipofectamine/siRNA weight ratio of 3:1. Western blot image showing the 
expression of BCR-ABL and -Tubulin in K562 cells transfected using Tat-
LK15/siRNA complex (a) or Lipofectamine/siRNA (c) and cells were lysed 48 hours 
post transfection. b and d) Graphs showing the relative protein expression obtained 
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using Image J by normalising the intensity obtained from the BCR-ABL band to the 
intensity of the -Tubulin.  a) and b) show that Tat-LK15 based siRNA complexes 
induce reduction in relative levels of BCR-ABL from 70% to 80% from 1 µg to 30 µg 
siRNA. c) and d) show that Lipofectamine based siRNA complexes induce reduction 
in relative levels of BCR-ABL from 50% to 70% compared to the negative control 
siRNA. Bars represent mean ± SD, n=3. Figure is published in (Arthanari et al., 
2010). 
 
In order to determine if further increasing charge ratio lead to higher gene silencing 
efficiency, Tat-LK15/siRNA complexes were prepared at a charge ratio of 4:1. Cells 
were transfected with these complexes and the expression of BCR-ABL presented in 
Figure 5.12. This Figure clearly shows that increasing amount of siRNA did result in 
reduction in expression of the BCR-ABL protein and in very low or no protein yield 
in cells treated with higher amount of siRNA (20 µg and 30 µg). It is presumably due 
to low cell viability, particularly due to the absence of -Tubulin expression at 20 
and 30 µg siRNA.    
 
Figure 5.12: Tat-LK15/siRNA mediated gene silencing at charge ratio of 4:1. 
Western blot image showing the expression of BCR-ABL (210 kDa) and -Tubulin 
(55 kDa) in K562 cells transfected using Tat-LK15/siRNA complex and lysed 48 
hours post transfection. The figure shows reduction in expression of BCR-ABL for 1 
µg, 5µg and 10 µg of siRNA and no protein expression (both BCR-ABL and α 
Tubulin) when treated with 20 µg and 30 µg of siRNA complexed to Tat-LK15. 
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5.3.4.1 Transient siRNA mediated gene silencing  
From the gene silencing data obtained, 3:1 was found to be the optimum charge ratio 
and was used for further experiments. In order to determine the long term gene 
silencing efficiency by the siRNA based complexes, cells were transfected with Tat-
LK15/siRNA (charge ratio of 3:1) and Lipofectamine/siRNA (weight ratio of 3:1) 
and the protein was extracted at 96 hours. The results presented in Figure 5.13 a and 
b shows that there is no reduction in levels of BCR-ABL in case of both Tat-LK15 
(Figure 5.13 a) and Lipofectamine (Figure 5.13 b) based complexes. These results 
suggest that siRNA mediated RNAi is transient for both Tat-LK15 and 
Lipofectamine based complexes.  
 
Figure 5.13: siRNA mediated gene silencing at 96 hours. a) Western blot image 
showing the expression of BCR-ABL (210 kDa) and -Tubulin (55 kDa) in K562 
cells transfected using Tat-LK15/siRNA complex at a charge ratio of 3:1 and lysed 
96 hours post transfection. b) K562 cells were transfected using 
Lipofectamine/siRNA complex at a weight ratio of 3:1 and cells were lysed 96 hours 
post transfection. The images show little or no reduction in the expression of BCR-
ABL when treated with both Tat-LK15 and Lipofectamine based siRNA complexes.  
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5.3.5 Vector/oligonucleotide cytotoxicity  
To study the cytotoxicity of the vector/DNA or vector/siRNA complexes, a MTT 
cytotoxicity assay was performed. K562 cells were transfected with varying amounts 
of DNA and siRNA complexed to the vectors. The cells were incubated with the 
DNA complexes for 24 hours before measuring the cytotoxicity of the complexes as 
described in the Materials and Methods (section 3.21). Figure 5.15 (a) shows that the 
cytotoxicity of 2:1 charge ratio Tat-LK15/shRNA plasmid complexes containing 10 
µg, 20 µg and 30 µg of shRNA plasmid did not have a significant difference when 
compared to Tat-LK15/control DNA complexes (p>0.05). These results indicate that 
there is no non-specific toxicity induced as a result of the shRNA plasmid when 
compared to untreated cells as control. Similarly, the cell viability of Lipofectamine 
based shRNA plasmid complexes do not vary significantly when compared to the 
control DNA as observed in Figure 5.14 b. On the whole for shRNA plasmid, the 
relative cell viability approached 100% indicating no toxicity. The average values of 
the cell viability were uniform for the different amounts except for 
Lipofectamine/shRNA plasmid complex at 20 g, although the decrease is 
insignificant (p≥0.05). Hence, it can be assumed that the toxicity of the complexes 
did not have any effect on the gene silencing of bcr-abl observed.  
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Figure 5.14: Cytotoxicity of vector/DNA complexes and vector/siRNA complexes. 
The viability of K562 cells transfected using the Tat-LK15/DNA complexes (a), 
Lipofectamine/`DNA complexes (b), Tat-LK15/siRNA complexes (c) and 
Lipofectamine/siRNA complexes (d) was evaluated using MTT assay 24 hours post 
transfection (section 3.21). The absorbance produced by dissolving the blue 
precipitate using DMSO was measured at 550nm. Absorbance of the non-transfected 
cells was assumed to be 100% viable and the readings of the transfected cells were 
calculated relative to the non-transfected cells. Bars represent mean ± SD, n=3. 
Figure 5.14 is published in (Arthanari et al., 2010). 
 
A MTT assay was also performed on cells transfected with vector/siRNA complexes 
(3:1 charge ratio for Tat-LK15 and 3:1 weight ratio for Lipofectamine) 24 hours after 
incubation and results presented in Figure 5.14 c and d. In contrast to the results 
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observed using vector/DNA complexes (Figure 5.14 a and b), the cytotoxicity studies 
of the vector/siRNA complexes (Figure 5.14 c and d) showed that the relative 
viability of cells appears to be reduced. For Tat-LK15/siRNA complexes, there is a 
significant decrease in viability between 10 µg and 20 µg siRNA (p<0.05), but no 
difference between 20 µg and 30 µg siRNA (p>0.05). On the other hand, 
Lipofectamine based B3A2 siRNA complexes display toxicity in a dose dependent 
manner. Interestingly, when comparing the viability of cells treated with 
vector/negative control siRNA and vector/B3A2 siRNA, no significant difference 
(p>0.05) in reduction was observed. Effective gene silencing approaching 80% was 
therefore achieved using amounts 10 µg or less siRNA (Figure 5.11) without 
affecting the cell viability (Figure 5.14 c and d). Even though at higher amounts of 
siRNA, 20 µg and 30 µg, there is efficient gene silencing of up to 70% (Figure 5.11) 
a significant cellular toxicity of vector/siRNA complexes was observed in Figure 
5.14 c and d. 
 
5.4 Discussion  
In the chapter 4, it was shown that Tat-LK15 functions effectively in cellular 
delivery comparable to Lipofectamine (Figure 4.4 and 4.5). However, transfection 
studies using luciferase assay revealed that the transfection efficiency of 
Lipofectamine was much higher compared to Tat-LK15 (Figure 4.3). The reduction 
in transfection efficiency could be due to the poor endosomal escape or nuclear 
delivery mediated by the peptide. Consequently, it was essential to determine if this 
reduction in transfection efficiency relates to reduced gene silencing efficiency of 
Tat-LK15 based complexes. In this chapter we have used Tat fusion peptide, Tat-
LK15, to study the silencing of bcr-abl fusion gene present in chronic myeloid 
leukaemic K562 cells and compared it to Lipofectamine. Additionally, studies 
focussed on gene silencing of bcr-abl mediated using shRNA plasmid and siRNA 
based complexes.  
5.4.1 shRNA plasmid mediated gene silencing  
Tat-LK15/shRNA plasmid transfection in K562 cells resulted in decrease in the 
mRNA levels up to 80% (Figure 5.9) compared to the control cells as determined by 
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qRT-PCR studies 48 hours post transfection. Western blotting 96 hours post 
transfection (Figure 5.7 a and b) showed gene silencing of bcr-abl from 60% (using 
10µg shRNA plasmid) to 80% (using 30 µg of shRNA plasmid). Similarly, qRT-
PCR performed on cells transfected using Lipofectamine/shRNA plasmid complexes 
at a weight ratio of 2:1 (Figure 5.9), indicated a decrease in bcr-abl mRNA levels 
between 40% and 90% at 48 hours and 80% reduction in protein levels using 20 µg 
of shRNA plasmid (Figure 5.7 c and d) at 96 hours. This data shows that Tat-
LK15/shRNA plasmid is as effective as control vector Lipofectamine based shRNA 
plasmid complex in mediating gene silencing. Others have also followed a transient 
reduction in levels of BCR-ABL by electroporating the K562 cells with the plasmid 
harbouring the insert required to synthesise a shRNA plasmid (Scherr et al., 2005) in 
which shRNA plasmid led to 90% gene silencing which lasted up to 72 hours (Scherr 
et al., 2005, Myssina et al., 2009). This method offers slightly higher gene silencing 
but the inapplicability in vivo conditions and higher toxicity associated with the 
process limits its use (Nishikawa and Huang, 2001).    
One of the advantages of using shRNA plasmid to mediate gene silencing is the 
ability to sustain reduction in expression of the target protein. Continuous 
transcription of the plasmid leads to continuous synthesis of short hairpin RNA 
targeting the B3A2 fusion site resulting in a more stable reduction of the target 
protein. In this respect, there was a reduction in the expression levels of BCR-ABL 
even at 192 hours post transfection reaching up to a maximum of 80% using 30 g of 
shRNA plasmid (Figure 5.8 a and b) when complexed to Tat-LK15. It is also worth 
noting that the varying amounts of shRNA plasmid (10 g, 20 g and 30 g) 
complexed to Tat-LK15 did not result in cellular toxicity (Figure 5. 14) when 
compared to the controls. Long term gene silencing has been reported using lentiviral 
transductions to target the expression of BCR-ABL: although more than 90% 
reduction in levels of BCR-ABL in K562 cells was observed for 5 days (120 hours) 
(Scherr et al., 2005, Futami et al., 2008, Myssina et al., 2009), shorter duration than 
that observed with Tat-LK15 based complexes. Tat-LK15 peptide performed similar 
to both viral vectors and electroporation, while these methods (electroporation and 
viral vectors) are limited by their toxicity (Nishikawa and Huang, 2001, Thomas et 
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al., 2003). Additionally, electroporation based shRNA plasmid treatments does not 
sustain long term gene silencing (Scherr et al., 2005, Myssina et al., 2009).  
In contrast to the efficient gene silencing observed with Tat-LK15 based complexes 
(Figure 5.8 a), Lipofectamine based shRNA plasmid complexes yielded a reduction 
in BCR-ABL protein expression of up to only 40% using 10 µg shRNA plasmid, as 
seen in Figure 5.8 c and d. Increasing the amount of shRNA plasmid increases the 
gene expression to almost 120% using 30 µg shRNA plasmid. A plausible 
explanation for the observed increase in the protein level, therefore lack of gene 
silencing, maybe the saturation of the nuclear transport proteins. This occurs due to 
continuous export of mRNA from the nucleus to the cytoplasm when there is more 
mRNA than the cell can handle (Grimm et al., 2006). Such an event would lead to 
reduction in levels of gene silencing that could be induced by shRNA plasmid. 
Hence, in such cases a strict correlation between amount of shRNA plasmid 
transfected and the efficiency of gene silencing observed may not be followed.  
5.4.2 siRNA mediated gene silencing  
As mentioned in the previous chapter, different cellular localisation is required for 
efficient transfection. shRNA plasmid requires the plasmid to be delivered into the 
nucleus while siRNA requires delivery into the cytoplasm for it to be functional. 
There is no reported work of peptide based delivery systems for silencing bcr-abl. 
Therefore, the efficiency of silencing bcr-abl is discussed separate from the 
efficiency of the peptide/siRNA complex. This part of the discussion has been 
conveniently divided into the following two sections.  
To aid in the comparison between various research articles that have published data 
using siRNA concentration rather than amounts, it was necessary to construct Table 
5.1 which reports not only the amount of siRNA used but also molarity, charge ratio 
and molar ratio of peptide/siRNA.  
Chapter 5 
159 
 
 
Table 5.1: Conversion of charge ratio and amount of siRNA. a) The amount of 
siRNA used has been converted to concentration of siRNA when added to the cells. 
b) The charge ratio has been converted to molar ratio of Tat-LK15/siRNA used for 
various transfection experiments. 
 
Bcr-abl gene silencing using siRNA: Treatment of K562 cells with Tat-LK15 based 
siRNA complexes showed that at 48 hours post transfection, there was about 70% 
reduction in levels of BCR-ABL using 75 nM (1 µg, Table 5.1) siRNA. It has been 
reported that siRNA can be introduced into the cell cytoplasm using electroporation. 
In one such study, 75 nM siRNA was electroporated into cells twice with a 24 hour 
interval (Rangatia and Bonnet, 2006). Such a treatment led to 90% gene silencing at 
12 hours after the second electroporation. There was also an increase in protein 
levels after 24 hours leading to 50% of protein expression at 72 hours (Rangatia and 
Bonnet, 2006). Another study showed similar increase in protein levels (Wohlbold et 
al., 2003) where treatment with 800 nM siRNA (electroporated twice) resulted in 
knockdown of BCR-ABL protein at 24 hours but increased at a later time. Yet 
another study using 37 nM siRNA combined with electroporation resulted in 70 to 
80% gene silencing at 24 hours (Scherr et al., 2003b). 
Other non-viral methods of siRNA delivery to target BCR-ABL were carried out 
using commercially available lipid based reagents like Lipofectamine, 
Oligofectamine and siPORT Amine. Transfection of K562 cells using lipid based 
reagents with siRNA twice at a 24 hour interval led to gene silencing of 84% that 
lasts up to 72 hours (Withey et al., 2005) while another study reported complete 
Chapter 5 
160 
 
knockdown at 48 hours with a single transfection (Wilda et al., 2002). However, in 
both cases, the concentration of siRNA was not mentioned. Transfection of primary 
CML cells with lipid based reagents led to reduction of up to 67% at the protein 
levels (Withey et al., 2005). Finally a study by (Merkerova et al., 2007) showed a 
reduction in mRNA levels up to 23% using lipid reagents compared to 50% using 
electroporation.  
Efficiency of peptide mediated gene silencing   
Transfection with 2:1 charge ratio Tat-LK15/siRNA at (molar ratio of 6.5/1) led to a 
BCR-ABL reduction up to 50% (Figure 5.10) just 48 hours after transfection. 
Increasing the charge ratio to 3:1 (molar ratio of 10/1) resulted in increased 
reductions i.e. 70% to 80% (between 1 µg and 30 µg) when compared to the negative 
controls (Figure 5.11 a). One of the possible explanations for the low gene silencing 
efficiency at 2:1 compared to 3:1 could be gathered from the YO-PRO-1 
displacement assay (Figure 4.1b) as, at a 2:1 charge ratio, the complex formation 
may be incomplete. In contrast, effective complex formation of Tat-LK15 and 
siRNA appeared to be complete at 3:1 charge ratio based on the complete 
displacement of YO-PRO-1 (only residual fluorescence intensity is observed at a 3:1 
charge ratio). Further experiments performed at a 4:1 charge ratio (molar ratio of 
13.2/1) showed little or no reduction in BCR-ABL protein levels, as observed in 
Figure 5.12. Others have also observed similar decrease in efficiency of gene 
silencing by Crombrez et al. (2009). Using MPG-8 peptide, it was observed that 
lower molar ratios did not perform efficiently due to poor uptake and stability while 
the complexes prepared at higher molar ratios suffered from increase in size 
(Crombez et al., 2009b). Hence, gene silencing is known to peak at an optimum 
charge or molar ratio. Therefore, for siRNA based gene silencing it can be assumed 
that 3:1 charge ratio (molar ratio of 10/1) of Tat-LK15/siRNA is optimum for gene 
silencing studies in K562 cells.  
Consequently, 75 nM (1 µg) siRNA complexed to Tat-LK15 at a 3:1 charge ratio 
peptide/siRNA (molar ratio of 10/1) resulted in an average reduction in BCR-ABL 
protein levels up to 70% and increasing siRNA concentration to 700 nM (10 µg 
siRNA) led to a maximum of 80% gene silencing. Gene silencing by siRNA using 
peptide based delivery systems has already been reported however comparing studies 
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is difficult due to variations in conditions, concentration of siRNA and nature of 
target. Based on this, comparisons have been made only on the basis of concentration 
of siRNA, in general terms. Simeoni et al. (2003) showed that using MPG peptide in 
Cos-7 and Hela cells with a molar ratio of 10/1 and at a siRNA concentration of 50 
nM resulted in 75% to 85% reduction in luciferase expresssion, when compared to 
90-95% gene silencing using NLS mutant peptide namely the MPG
∆NLS
. Targeting 
GAPDH expression using siRNA of 100 nM with MPG peptide, at a molar ratio of 
10/1, led to 60% in gene silencing while 25 nM of siRNA along with MPG
∆NLS
 was 
sufficient to cause 80% gene silencing (Simeoni et al., 2003). Hence, the efficiency 
of the MPG
∆NLS
 /siRNA is significantly better when compared to the MPG peptide 
harbouring the intact NLS sequence from SV-40 T antigen. Although, Tat-LK15 has 
performed similar to Lipofectamine, it still harbours the NLS sequence and hence 
mutation of NLS sequence could provide further potential for increasing the gene 
silencing. Another study using the MPG-8 peptide that contains various alterations 
from the MPG peptide (Table 5.2) has shown further increase in efficiency when 
compared to MPG
∆NLS
 itself (Crombez et al., 2009b).  Here, MPG
∆NLS
 /siRNA at a 
20/1 molar ratio resulted in only 50% gene silencing while MPG-8/siRNA resulted in 
>85% gene silencing using 20 nM siRNA in Hela cells (Crombez et al., 2009b). 
Another siRNA delivery peptide, unrelated to MPG is the peptide CADY which 
achieved remarkable gene silencing as it was able to completely knockdown the 
expression of GAPDH at a concentration of 10nM using a molar ratio of 40/1 and 
80/1 (Crombez et al., 2009a).  
One plausible explanation for the difference in gene silencing observed using Tat-
LK15 and MPG based peptides is the duration for which the complexes are allowed 
to interact with the cells. In case of Tat-LK15, the cells were incubated with the 
siRNA complexes for 4 hours after which the cells were washed and incubated with 
medium containing serum, as discussed in the Materials and Methods section 
(section 3.16). Whereas in the case of MPG based peptides, the complexes were 
incubated with the cells initially for 30 minutes after which medium containing 
serum was added to the cells without washing step to remove any extracellular 
complexes. The cells were then allowed to incubate along with the complexes until 
they are lysed.   
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Peptides Amino Acid sequence 
MPG GALFLGFLGAAGSTMGAWSQPKKKRKV 
MPG 
∆NLS
 Ac-GALFLGFLGAAGSTMGAWSQPKSKRKV-cysteamide 
MPG-8 β AFLGWLGAWGTMGWSPKKKRK -Cysteamide 
CADY Ac-GLWRALWRLLRSLWRLLWRA-cysteamide 
EB1 LIRLWSHLIHIWFQNRRLKWKKK-amide 
Transportan-K6 RQIKIWFQNRRMKWKKXC- CKKKKKK 
Transportan-H6K6 RQIKIWFQNRRMKWKKXC- CHHHHHHKKKKKK 
Tat-K10 GRKKRRQRRRPPQXC-CKKKKKKKKKK 
Tat-LK15 RKKRRQRRRGGGKLLKLLLKLLLKLLK-COOH 
 
Table 5.2: The amino acid sequences of the peptides used for comparison in this 
chapter are listed here.  
 
Studies by Lundberg et al. (2007), targeting Luciferase expression in Hela cells, 
compared MPG
∆NLS
 and EB1 peptide and showed that both peptides complexed to 
siRNA at a molar ratio of 25/1 and at a siRNA concentration of 100 nM resulted in 
only 50 to 55% gene silencing. Hence considering this study, Tat-LK15 performed 
better than both EB1 and MPG
∆NLS 
with greater than 70% gene silencing using 75 
nM siRNA (Lundberg et al., 2007).  
siRNA study using TAT PTD-DRBD showed that at a siRNA concentration of 400 
nM 90% of gene silencing could be observed when targeting both GAPDH and GFP 
(Eguchi et al., 2009). This data is comparable to the gene silencing efficiency 
obtained using 375 nM siRNA complexed to Tat-LK15 peptide targeting BCR-ABL. 
The results from Eguchi et al. (2009) and Michiue et al. (2009) have showed that 
treatment with negative control siRNA resulted in 20% reduction in levels of protein 
similar to that observed in case of Tat-LK15 based shRNA plasmid complexes and 
also siRNA complexes. 
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A study of much relevance to Tat-LK15 is the use of Tat peptide covalently 
conjugated to the siRNA targeting EGFP (Chiu et al., 2004), showed that 70% of 
gene silencing was observed using 300 nM siRNA. Same vector targeting Cdk9 
using siRNA resulted in only 54% and 82% reduction in Cdk9 levels using 200 nM 
and 400nM siRNA respectively (Chiu et al., 2004). It can be inferred from these 
results that Tat-LK15 performs better than Tat peptide using a similar concentration 
of siRNA. By comparing Tat-LK15 results with another study where they have used 
oligo arginine peptide conjugated to cholestryl group (R9-chol), it is clear that the 
efficiency of Tat-LK15 exceeds that of oligo arginine. In the latter study, they 
showed that using 0.7µg of siRNA led to only 55% reduction in levels of VEGF 
protein compared to untreated control (Kim et al., 2006).  
Ishihara et al. (2009) have used three different CPPs namely Tat, Penetratin and 
Transportan (TP) conjugated to stretches of cationic peptides like K6, K10 and 
H6K6. The maximum gene silencing mediated by the complexes at a 60 nM 
concentration of siRNA was 30 to 40% using TP-H6K6 and TP-K6, while Tat based 
complexes did not achieve sufficient cellular uptake (Ishihara et al., 2009). 
Comparing this study to Tat-LK15 based complexes shows that Tat-LK15 achieved 
good cellular uptake and also efficient gene silencing of up to 70% using 75 nM 
siRNA. The relatively reduced efficiency of TP-K6 and TP-H6K6 could be due to 
the poor lytic ability of these peptides (Ishihara et al., 2009). This could lead to poor 
membrane permeability and endosomal escape. In fact, TP-K6 and TP-H6K6 showed 
same level of gene silencing indicating that the addition of six histidine residues did 
not positively influence the efficiency of gene silencing. Moreover, Tat-K6 and Tat-
K12 did not show significant cellular uptake when compared to Tat peptide. Hence, 
the membrane lytic activity of the LK15 peptide has played an important role in 
increasing the cellular uptake of Tat-Lk15 complexes resulting in effective gene 
silencing.  
Effect of concentration: Tat-LK15/siRNA complexes formed at a charge ratio of 
3:1 showed that increasing the concentration of siRNA (75 nM to 2250 nM) did not 
result in higher gene silencing (Figure 5.11a). The results indicate that the proteins 
involved in the degradation of mRNA might have reached saturation. Similar 
observation was also made by (Davidson et al., 2004) where same level of gene 
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silencing was observed from 8 nM to 320 nM siRNA using Penetratin peptide 
covalently conjugated to the siRNA.  
Duration of gene silencing: Determination of the duration for which the reduction 
in BCR-ABL protein levels persisted showed that at the optimum charge ratio of 3:1 
(molar ratio of 10/1), there was very little or no gene silencing observed at 96 hours 
(Figure 5.13a). Similar observation was also made for Lipofectamine based 
complexes (Figure 5.13b). Comparable results on the loss of gene silencing 
efficiency had already been observed by (Eguchi et al., 2009) and (Lundberg et al., 
2007) after 48 hours post transfection. Some siRNA based studies determined the 
expression of the protein at 48 hours or sooner (Davidson et al., 2004, Kim et al., 
2006), while some studies observed a time course dependent gene silencing for 
siRNA (Crombez et al., 2009a, Michiue et al., 2009).  
Cytotoxicity: The toxicity studies of Tat-LK15/siRNA based complexes showed that 
at a concentration of 750 nM siRNA (10µg) there was no toxicity associated with the 
complex. The data indicates that the gene silencing observed with siRNA 
concentrations of 75 nM to 750 nM is not likely to be a consequence of toxicity 
associated with the complexes. The cytotoxicity studies on MPG-8 peptide showed 
that MPG-8/siRNA complexes were not toxic till 20 µM concentration (Crombez et 
al., 2009b). However, Tat-LK15/siRNA complexes were toxic at 4 µM 
concentration. One of the main reasons for the relatively high toxicity associated 
with the Tat-LK15 complexes is the membrane lytic activity of the Tat-LK15 
peptide. The Tat-LK15 peptide retains most of the lytic activity (80%) even after 
complexation to oligonucleotides, as observed by Saleh et al. (2010). Another likely 
reason could be due to the number of positive charges (13) in the peptide, while 
MPG-8 peptide has only 5 positive charges. The high number of positive charges 
may encourage interaction with membrane phospholipid head group which could 
cause cytotoxicity or damage to the cells. Another possible explanation could also be 
the size of the complex that is likely to play a role in the toxicity.  
In summary, Tat-LK15 has showed efficient delivery of DNA and siRNA. And 
furthermore the shRNA plasmid and siRNA delivered this way have resulted in 
higher gene silencing than Lipofectamine and in some cases comparable to 
Lipofectamine. The study has also provided evidence for sustained shRNA plasmid 
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mediated gene silencing over longer course when compared to the transient nature of 
siRNA. 
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Chapter 6 
Conclusions and future work 
6.1 Conclusions  
Recently, our group showed that the synthesis of a multifunctional peptide (Tat-
LK15) based on Tat peptide fused to the membrane lytic peptide LK15 contributed to 
increase in transfection efficiency in adherent HT29 and HT1080 cells when 
compared to Tat and LK15 peptides alone. Based on these encouraging results, the 
present study aimed at evaluating the ability of Tat-LK15 to transfect K562 
suspension cells. Of particular interest in K562 chronic myeloid leukemic cells is the 
presence of bcr-abl fusion gene which translates into BCR-ABL protein that is 
directly involved in the pathogenesis of the disease. Hence, this study aimed to 
inhibit or decrease the expression of BCR-ABL using RNA interference. For this 
purpose, two different strategies were used: plasmid based shRNA expression and 
siRNA. The first part of the study presents the physico-chemical characterisation, 
cellular uptake and cellular localisation of the peptide/DNA and peptide/siRNA 
complexes. The second part of the study covers the shRNA plasmid and siRNA 
mediated reduction in expression of BCR-ABL.  
 
In the present study, non-covalent complexation of peptide/DNA was used a strategy 
adopted for the following reasons over covalent complexation. Firstly, the simplicity 
involved in preparation of the complexes; Secondly, non-reducible covalent 
complexation of the peptide and DNA or siRNA could interfere with the function of 
the DNA or siRNA inside the cell; Thirdly, reducible covalent complexation between 
the peptide and DNA could result in reduction of the bond before the target cell 
could be reached, resulting in release of free DNA or siRNA outside the cells.  
 
Complex formation: The ability of Tat-LK15 to complex DNA and siRNA was 
evaluated using YO-PRO-1 displacement assay. Tat-LK15 was able to complex 
DNA, as already shown by Saleh et al. (2010), by competitively displacing YO-
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PRO-1 from the DNA. The peptide demonstrated the ability to complex DNA even 
at a charge ratio of 1:1. Similarly, Lipofectamine exhibited maximum displacement 
of YO-PRO-1 from DNA from a weight ratio of 1:1. Tat-LK15 displaced YO-PRO-1 
efficiently from siRNA, however, maximum displacement was achieved only from a 
charge ratio of 3:1 indicating more peptide was required to displace YO-PRO-1 from 
siRNA or quench its fluorescence. The difference in structure between DNA and 
siRNA could play a role in the difference observed in the YO-PRO-1 displacement 
assay. In particular, upon addition of a vector, DNA can condense to form smaller 
particles due to its flexible nature, whereas, siRNA behave as rigid rods that are 
relatively less flexible to form small particles. The difference in structure of DNA 
and siRNA was found to also affect the size and zeta potential (Spagnou et al., 2004). 
Saleh et al. (2010) showed that Tat-LK15/DNA complexes at a charge ratio of 3:1 
produced complexes of approximately 400nm with a zeta potential of +25. However, 
the size of Tat-LK15/siRNA complexes, formed at a similar charge ratio of 3:1, was 
660nm with a net charge of +10. The difference in the observed size between the 
Tat-LK15/DNA (Saleh et al., 2010) and Tat-LK15/siRNA at a charge ratio of 3:1 is 
likely due to the difference in structure between the DNA and siRNA. Since siRNA 
act as rigid rods they are less likely to form smaller complexes (Spagnou et al., 
2004). On the other hand, determination of size and zeta potential of the Tat-
LK15/DNA complexes (at a charge ratio of 2:1) showed that the average size of the 
complexes was found to be approximately 850nm with a net charge of +4.  
 
Effect of complexation on transfection efficiency: A maximum displacement of 
YO-PRO-1 observed from a (+/-) charge ratio of 3:1, suggesting maximum 
complexation of siRNA by the peptide at this particular charge ratio. The degree of 
complexation of siRNA by the vector has a direct effect on the transfection 
efficiency of the complex (Volcke et al., 2006). In case of siRNA, optimum charge 
ratio can be determined only by the observation of gene silencing.  Gene silencing 
experiments indicate that at a charge ratio of 2:1, where 80% of YO-PRO-1 was 
displaced by Tat-LK15, only 50% reduction in expression of BCR-ABL was 
observed using 30µg of siRNA. Interestingly, at a charge ratio of 3:1, when YO-
PRO-1 appears to be completely displaced, an 80% gene silencing using siRNA as 
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low as 1µg was observed. Although, charge ratio of 4:1 showed similar level of YO-
PRO-1 displacement and higher gene silencing efficiency, these results are 
undermined by the toxicity to the cells. Hence from this part of the study, it can be 
concluded that condensation or complexation of siRNA has a direct effect on the 
gene silencing efficiency.    
 
Effect of size of the complex on uptake, cellular association and transfection 
efficiency: The size of the complexes could also have an effect on the transfection 
efficiency of the complexes. Different factors play a key role in the formation of 
complexes of varying sizes. One of the most important factors is the constituents of 
the buffer used and in particular the amount of ions i.e. the salt concentration. Ogris 
et al. (1998) showed that PEI/DNA complexes varied significantly based on the salt 
concentration: complexes prepared in physiological salt concentrations exhibited 
higher complex size compared to complexes prepared in salt free or low salt 
conditions. Aggregation of the complexes was postulated to be the reason for 
increased size. Interestingly, they also observed that the larger complexes, prepared 
in high salt concentrations, exhibited about 100 fold higher transfection efficiency in 
K562 cells compared to the smaller complexes, prepared in low salt concentrations 
(Ogris et al., 1998). This could be one of the likely reasons for the observed increase 
in transfection efficiency of complexes formed at 2:1, having an approximate size of 
850nm (Arthanari et al., 2010) than at 3:1, having an approximate size of 400nm 
(Saleh et al., 2010). Cell type dependence could also be one of the other reasons for 
increased transfection efficiency at 2:1 than at 3:1.  
 
The larger complexes have a higher probability of cell interaction by sedimentation 
or depositing on the cell. Confocal microscopy observation of Tat-LK15/DNA and 
siRNA also showed huge increase in intensity on the surface of K562 cells 
resembling aggregates. Using 1µg of DNA, led to Cy5 intensity primarily on the 
surface of the cell membrane mainly due to attachment of the complexes on the cell 
surface, as also observed by (Ogris et al., 2001b).  
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Aggregation of the complexes could also lead to lower percentage of transfected 
cells. Studies using smaller complexes in the range of 50 to 120nm (Crombez et al., 
2009a), have led to almost 100% of the cells being transfected. Flow cytometry 
analysis has showed only 60% of cells that internalise DNA complexes, using 1µg 
DNA, which increases to 80% when transfected with 5µg DNA. Even though a 
DNA-dose dependent increase in cells that internalise DNA is observed, 100% 
transfected cells were not achieved in this case. However, there is a possibility of 
achieving higher percentage of cells using 30µg of DNA, where maximum shRNA 
plasmid mediated gene silencing is observed. Additionally, decreasing the size of the 
complexes is likely to increase the number of particles and hence could potentially 
increase the number of cells that internalise DNA. 
 
Size of the siRNA complexes also has an effect on the gene silencing mediated by 
the siRNA complexes. Crombrez et al. (2009b) have observed a correlation between 
size of the complexes, where MPG-8/siRNA complexes in the size range of 120nm 
resulted in 90% reduction in levels of cyclin B1 (Crombez et al., 2009b). Complexes 
in the size range of 700nm resulted in only 20% gene silencing. In contrast, 
complexes of similar size obtained with Tat-LK15/siRNA resulted in greater than 
80% reduction in BCR-ABL protein levels. However, the large size of these 
complexes caused likely due to aggregation should be broken down to smaller 
complexes of homogenous size to enhance further the siRNA mediated gene 
silencing. 
 
Relationship between amount of DNA or siRNA with cellular association and 
uptake: The cellular uptake of the DNA and siRNA complexes mostly follows a 
dose dependent increase in uptake. The cellular association studies of labelled DNA 
complexed to Tat-LK15 using confocal microscope showed a dose dependent 
increase 4 hours post transfection. Cellular localisation showed, at least, association 
with cells but more likely intracellular localisation for DNA complexed with Tat-
LK15 at 4 hours and 24 hours. The dose dependent increase in fluorescence intensity 
was also observed 24 hours post transfection which also showed cytoplasmic and 
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nuclear localisation. At 24 hours effective nuclear localisation of the DNA was also 
confirmed by both GFP expression and luciferase expression. DNA complexed to 
Lipofectamine showed a DNA dose dependent increase in fluorescence intensity at 4 
hours, which however was not observed at 24 hours. Confocal experiments for Tat-
LK15/siRNA complexes showed widely punctate localisation both at 4 hours and 24 
hours post transfection and a likely dose dependent increase in uptake.  
 
DNA uptake studies using flow cytometry also showed a DNA dose dependent 
increase in mean fluorescence intensity. Even using low amount of DNA (1µg), the 
percentage of cells that have internalised DNA was 65%, which increased up to 80% 
using 5µg DNA. Similarly, Tat-LK15 based siRNA complexes also showed a siRNA 
dose dependent increase in both the mean fluorescence intensity and the percentage 
of cells that uptake siRNA. In contrast, flow cytometry study using 
Lipofectamine/DNA complexes, the mean fluorescence intensity varies slightly 
between 1µg and 2µg, but increased with 5 µg of DNA used. The percentage of cells 
that have internalised DNA showed no strict pattern of uptake, with an increase 
observed initially (1µg and 2µg) but falls when 5µg of DNA was used. siRNA 
uptake using Lipofectamine, showed no increase in fluorescence intensity and 
percentage of cells between 1µg  and 2µg of siRNA. With 5µg of siRNA, both the 
intensity and number of cells that internalise siRNA increases. Hence, it can be 
concluded from the uptake study that Tat-LK15 clearly shows a dose dependent 
uptake for both DNA and siRNA, contrary to that observed with Lipofectamine 
based complexes.  
 
Effect of shRNA plasmid and siRNA amount on gene silencing: Gene silencing 
mediated by the shRNA plasmid based complexes was studied for varying shRNA 
plasmid amounts and time durations. shRNA plasmid was designed to target bcr-abl 
fusion gene in K562 CML cells. Transfection of K562 cells with shRNA plasmid 
complexed to Tat-LK15 did not lead to any reduction in levels of BCR-ABL at 24 
and 48 hours while, at 96 hours, transfection with Tat-LK15/DNA complexes led to 
protein knockdown to an efficient 80%. However, no significant dose dependent 
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decrease of BCR-ABL was observed between 10µg, 20µg and 30µg shRNA plasmid. 
The reduction in BCR-ABL protein level was also observed with the 30 µg shRNA 
plasmid at 192 hours post transfection. Lipofectamine based complexes also showed 
80% reduction in BCR-ABL protein expression at 96 hours but showed only 40% 
reduction at 192 hours. It is important to note here that these complexes did not show 
any signs of cytotoxicity in K562 cells. Based on these results, it is clear that Tat-
LK15/shRNA plasmid complexes lead to gene silencing with efficiency comparable 
and sometimes better than Lipofectamine.   
 
Transfection of cells with siRNA complexed to Tat-LK15 showed effective 
reduction in BCR-ABL protein levels at a charge ratio of 3:1 compared to 2:1 and 
4:1. The optimum charge ratio of 3:1 is in agreement with the YO-PRO-1 
displacement assay, where maximum displacement or quenching of YO-PRO-1 was 
observed. Hence, at a charge ratio of 3:1, Tat-LK15 based complexes showed a 
constant reduction in expression of BCR-ABL ranging from 70% to 80% using 
siRNA from 1 µg to 30 µg. The cytotoxicity of the Tat-LK15 siRNA complexes 
using 20 µg and 30 µg siRNA resulted in decrease in cell viability. This shows 
effective knockdown of BCR-ABL using 10 µg or less where there is no apparent 
toxicity. Similarly, Lipofectamine based siRNA complexes showed reduction in 
BCR-ABL protein levels up to 70% using 5 µg of siRNA.  Interestingly, the study 
also revealed the transient reduction in protein levels induced by siRNA.  
 
shRNA plasmid versus siRNA mediated gene silencing: shRNA plasmid and 
siRNA have different requirements including cellular localisation, charge ratios, 
optimum amounts and duration of gene silencing. shRNA plasmids should be 
delivered to the nucleus to undergo transcription and synthesise the shRNA which is 
then processed to form the siRNA, whereas, siRNA have to be delivered to the 
cytoplasm for it to be functional. Tat-LK15/DNA complexes achieved nuclear 
localisation as evident from the confocal studies using DNA complexed to Tat-LK15 
observed 24 hours post transfection and also from the expression of luciferase and 
GFP at 24 hours. Tat-LK15/siRNA showed intracellular localisation after 4 hours 
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and 24 hours, however it is unclear whether the complexes were localised in the 
nucleus or cytoplasm. Additionally nothing suggest a possible dissociation of DNA 
or siRNA from the peptide in the cytoplasm. siRNA is likely to dictate the 
cytoplasmic localisation as observed by some (Berezhna et al., 2006, Chiu et al., 
2004) due to the possible interaction of siRNA with RNAi machinery and hence the 
dissociation of siRNA from the vector could take place in the cytoplasm. On the 
other hand, Lipofectamine contains the neutral lipid DOPE that fuses with the cell 
membrane or endosomal membrane to release the DNA or siRNA into the cytoplasm 
(El-Sayed et al., 2009). The membrane fusion leading to cytoplasmic release is useful 
in case of siRNA delivery and hence, efficient siRNA mediated gene silencing was 
observed. However, for DNA complexed to Lipofectamine observed at 24 hours 
using CSLM, there was decrease in fluorescence intensity possibly due to 
degradation of DNA released into the cytosol causing a reduced decreased long term 
gene silencing efficiency using shRNA plasmid mediated gene silencing.  
 
Gene silencing studies suggest that a higher amount shRNA plasmid than siRNA is 
required to mediate gene silencing. shRNA plasmids have various factors involved in 
the gene silencing including nuclear localisation, efficient transcription, transport 
from nucleus to cytoplasm and processing to become the functional siRNA. 
Although the plasmid has an advantage of continuous transcription, all the above 
mentioned factors could play a limiting role for the gene silencing. On the other 
hand, siRNA delivered directly into the cytoplasm is functional immediately and 
does not require modifications. The difference in the number of steps involved before 
achieving functional siRNA plays a key role in determining the amount required to 
produce optimal gene silencing.  
 
Due to continuous transcription of the shRNA plasmid, it is feasible to obtain long 
term gene silencing, as observed for Tat-LK15/shRNA plasmid complexes. 
However, the effect of siRNA mediated gene silencing reduces with the increase in 
cell division. Hence, it is challenging for a single gene delivery system to deliver 
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both shRNA plasmid and siRNA and obtain efficient gene silencing from both the 
systems.  
 
Summary: The current study was aimed at producing peptide based gene delivery 
system capable of forming non-covalent complexes with oligonucleotides, show 
uptake, transfection and gene silencing by the complexes. Finally it was also aimed 
at observing the difference between shRNA plasmid and siRNA mediated gene 
silencing. In this study, Tat-LK15 peptide demonstrated the ability to form non-
covalent complexes with both siRNA and DNA, capable of forming sub micrometer 
complexes with a net positive charge. The peptide/DNA and peptide/siRNA 
exhibited efficient cellular uptake using varying doses of DNA and siRNA 
respectively. Tat-LK15 based shRNA plasmid complexes exhibited efficient gene 
silencing that lasted for long durations. siRNA based complexes exhibited efficient 
gene silencing even at low amounts of siRNA, however the gene silencing was short 
lived. Overall, Tat-LK15 was able to deliver both DNA and siRNA exhibiting high 
gene silencing efficiency comparable and sometimes better than Lipofectamine based 
complexes. 
The majority of the results from this study have been published in the Journal of 
Controlled Release (Arthanari et al., 2010), and is attached in the Appendix section 
3.  
 
6.2 Future work 
Tat-LK15 based siRNA complexes have shown great potential in efficient reduction 
in protein levels even at low amount of siRNA. Studies by Simeoni et al. (2003) with 
the mutant NLS peptides (MPG
∆NLS
) have shown significant increase in the gene 
silencing efficiency when compared to the parent MPG peptide that contains the 
intact NLS sequence. Hence, this concept can also be attempted to further modify 
Tat-LK15 to include a mutation in NLS region of the Tat peptide. A serine scan of 
the amino acids in Tat peptide could result in a Tat peptide that does not have NLS 
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property. Such a mutation would help increase siRNA localisation in the cytoplasm 
thereby leading to further increase in gene silencing efficiency.  
One of the important drawbacks of siRNA mediated gene silencing is the transient 
nature of the reduction in the levels of target protein. In order to sustain the 
reduction, repeated transfection of the cells with the complexes could be attempted 
thereby increasing the duration of the protein knockdown.  
Toxicity of the Tat-LK15 based complexes at a higher siRNA amount (20µg and 
30µg) becomes a point of concern. One of the factors that could play a vital role in 
the toxicity is likely the size of the complexes. Here siRNA complex sizes in the 
range of 660nm, and DNA complex size in the range of 850nm. The size of these 
complexes should be minimised by disrupting the aggregates. This would influence 
higher cellular uptake while minimising the toxicity of the complexes.  
An important part of the future work is to study the efficiency of the Tat-LK15 
peptide to delivery DNA and siRNA in primary cell lines and then eventually test the 
potential of the peptide based delivery system in vivo conditions. The work to test the 
efficiency of Tat-LK15 based complexes to mediate gene silencing in vivo is 
currently under way. To further advance the study using Tat-LK15 into in vivo 
conditions, it is important to consider attaching a ligand to receptors that are widely 
expressed in the target cells. This would greatly improve the specificity as well as 
transfection efficiency of the complexes. Addition of PEG onto the complexes would 
also enhance the half life of the complexes in the systemic circulation.  
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Appendix 1 
Materials for peptide synthesis 
A1.1 Reagents for peptide synthesis 
MBHA resin (substitution 0.5mmol/g) (Novabiochem, UK), 15% v/v 
Dichloromethylsilane in toluene, Dichloromethane (DCM), Dimethylformamide 
(DMF), N,N-diisopropylethylamine (DIPEA), Trifluoroacetic acid (TFA). Amino 
acids are N-Boc protected Boc-Arg(Tos)-OH, Boc-Gln-OH, Boc-Lys(2-Cl-Z)-OH, 
Boc-Cys (pMeOBzl)-OH (Novabiochem, UK). Tat-LK15 of the sequence 
RKKRRQRRRGGGKLLKLLLKLLLKLLK- CONH2 was ordered from Advanced 
Biomedical, UK having >95% purity. 
 
Methods for peptide synthesis 
A1.2 Solid phase peptide synthesis 
The peptide Penetratin was synthesized using solid phase peptide synthesis method 
using Boc chemistry. Tat peptide was synthesized by a colleague and Tat-LK15 
peptide was purchased from Advanced Biomedical Ltd (UK). The list of peptides 
and their sequences used in this study are listed in Table 7.1. 
 
Peptide Peptide Sequence 
Penetratin  RQIKIWFQNRRMKWKK-NH2 
Tat CRKKRRQRRR-NH2 
Tat-LK15 RKKRRQRRRGGGKLLKLLLKLLLKLLK-NH2 
 
Table A1.1: Amino acid sequences of CPPs.  
 
The Tat peptide was synthesized with a Cysteine residue to provide with a C-
terminal sulphhydryl group that could be used later for labelling with a fluorophore. 
The peptide was synthesized on a MBHA resin (0.5-1mmole/g) obtained from 
Novabiochem, UK. The amino acids used were all protected using N-Boc groups. 
The steps involved in the synthesis of peptide are depicted in Figure 7.1. 
 
  
Appendix 1 
187 
 
 
 
Figure A1.1: Steps involved in solid phase peptide synthesis. Diagrammatic 
representation of the steps involved in the solid phase peptide synthesis using Boc 
chemistry. 
 
A1.2.1 Silanisation of the glass vessel  
The peptide synthesis vessel was first silanised, to render the vessel non-adherent to 
the resin and peptides. 15% v/v Dichloromethylsilane in toluene was added to the 
reaction vessel and it was allowed to silanise overnight. Then, in order to swell the 
MBHA resin before the couplings, the resin was soaked in 10 mL of 
Dichloromethane (DCM) for almost 12 hours, followed by a neutralization step. The 
remaining synthesis of the peptide continues in a cycle with steps like deprotection of 
amino acids, neutralisation, and coupling resulting in the final peptide cleavage step. 
These steps are described in detail in the following section. 
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A1.2.2 Deprotection of amino acids 
To remove the Boc protecting group on the N-terminus of the peptide, the N-Boc 
protected amino acids were deprotected using 50% TFA (v/v) in DCM for 2 minutes. 
This was then removed using N2 gas and rinsed with DCM (10 mL). The resin was 
incubated by agitating for 30 minutes with 50% TFA in DCM and then the resin was 
washed with DCM four times, lasting one minute each. 
 
A1.2.3 Neutralization step  
The acid added in the previous step was neutralized using 10 mL of 5% (v/v) N,N-
diisopropylethylamine (DIPEA) in DCM and was agitated for 2 minutes. Similar to 
the deprotection step, the base was washed off using N2 gas and the resin was rinsed 
with 10 mL of DCM twice and then washed using 10 mL DMF lasting for a minute. 
 
A1.2.4 Coupling step 
Three equivalents of amino acid and benzotriazole-1-yloxytris (dimethylamino) 
phophonium hexafluorophosphate (BOP) (coupling agent) were dissolved in 10 mL 
of Dimethylformamide (DMF) containing nine equivalents of DIPEA and sonicated 
for 2 minutes to dissolve the constituents. This mixture was then added to the 
reaction vessel and agitated for 45 minutes. Then, the resin was rinsed with DMF 
twice, followed by DCM twice, each wash step lasting for a minute. Finally, nearly 
0.1 mg of the resin was taken from the reaction vessel and the Keiser test was 
performed on it. If the test results in negative, then the entire cycle was repeated for 
each amino acid.  
 
A1.2.5 Kaiser test 
The Kaiser test was performed to quantify the amount of free amino groups present. 
The test can be performed immediately after the deprotection step to quantify the 
amount of deprotection and also after a coupling step to estimate the efficiency of the 
coupling. The test was done by adding 25 µl of 5% Ninhydrin in ethanol and 100µl 
of pyridine to approximately 0.1 mg of the resin taken separately from the reaction 
mixture. The mixture was then heated using a heating block at 95º C for 10 minutes. 
Once cooled to room temperature, the colour of the mixture was visually determined: 
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blue indicating incomplete coupling reaction ie., free amino groups are exposed and 
yellow to orange indicating efficient coupling or no free amino groups. Coupling 
reactions have to be repeated if the colour of the mixture turns blue until complete 
coupling can be achieved. 
 
A1.2.6 Cleavage from resin using HF 
Once the synthesis was completed, the peptide was cleaved from the resin using 
Hydrogen fluoride (HF). This step also deprotects the protected side chains. Due to 
the hazardous nature of HF, this step was performed by Dr. Harmesh Aojula. Here, 
the dried peptide resin was allowed to react with scanvengers p-cresol, dimethyl 
sulfide, p-thiocresol. These scanvengers help in reducing reactions caused from the 
release of nucleophiles from carbonium ion. The scanvengers have an unfavourable 
reaction at high temperature. Hence, this reaction was done under liquid nitrogen, 
where HF condenses in the reaction vessel and the reaction was allowed to proceed 
for almost 2 hours. The cleaved peptide was then precipitated using Diethyl ether. 
Three washing steps were performed with ether to remove any residual scavengers 
still present in the vessel. 10% Acetic acid was then used to dissolve the peptide and 
was collected in a round-bottomed flask. This was then freeze-dried and the peptide 
was analyzed and purified. 
 
A1.3 Peptide purification 
First, an analytical Reverse Phase High Performance Liquid Chromatography (RP-
HPLC) was run using a C8 RP-HPLC column on a Perkin Elmer liquid 
chromatography system with a diode array detector to estimate the purity of the 
peptide and to determine the solvent gradient to be used for purification. Three 
different solvents were used for the HPLC run: solvent A was 0.1% v/v 
Trifluoroacetic acid (TFA) in water, solvent B was 80% Acetonitrile in water 
containing 0.1% TFA and solvent C was Methanol and the solvents were run at a 
flow rate of 1 mL/min. The column was first washed for several minutes with solvent 
C to equilibrate the column. It was further equilibrated with solvent B followed by 
solvent A. 0.1 mg of peptide was dissolved in 200 µl of 0.1% TFA and the sample 
was injected into the Vydac HPLC column and run for 30 minutes on a linear 
gradient from 100% of Solvent A to 100% Solvent B. Peaks were detected at 220nm.   
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The preparative HPLC was performed after a suitable solvent gradient was chosen 
for purifying the peptide based on the chromatogram obtained in the analytical 
HPLC. The run lasted for 45 minutes at a flow rate of 7 mL/min on a C8 Vydac 
column. Approximately 10 mg of the peptide was dissolved in 0.1% v/v TFA and 
acetic acid was added to a maximum volume of around one third the final volume. 
Acetic acid aids in dissolving any peptide which does not dissolve in 0.1% v/v TFA. 
2 mL of the peptide solution was then injected into the column and the different 
peaks were collected. This was then freeze dried to obtain a dry mass of the solute. 
MALDI-TOF Mass spectrometry was then performed to determine the molecular 
mass of the peptide to confirm the presence of the correct peptide synthesized.  
 
Results 
A1.4 Peptide synthesis and purification 
The crude peptide was purified using Preparative Reverse phase HPLC and the mass 
of the peptide confirmed using MALDI-TOF mass spectrometry. Figure 7.2 shows 
the preparative HPLC chromatogram of Penetratin. A small quantity of the freeze 
dried sample is then given for MALDI-TOF mass Spectrometry. In this case, peak 3 
found to be Penetratin since it had the same molecular mass as 2245.71 as shown in 
Figure 7.3   
   
Figure A1.2: Purification of crude Penetratin. This is a Reverse Phase Preparative 
HPLC chromatogram showing the different peaks when run on a gradient. Here, 
peak 3 was assumed to be the peptide and this was confirmed by performing a mass 
spectrometry. 
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Figure A1.3: Mass spectrometry of the Penetratin. Molecular weight of Penetratin 
is 2245.71. This helps to conclude the peak collected in the Preparative HPLC was 
correct according to the molecular weight of the sample obtained. 
 
TAT was synthesized by a lab member and similar purification was carried out. First 
an analytical run was performed (as shown in Figure 7.4 A) on the RP-HPLC to 
determine the different possible peaks within the sample. Then the Preparative HPLC 
was programmed in such a way that the peaks to be isolated were well separated 
during the run (as shown in Figure 7.4 B). Then peaks 1 and 2 on the Preparative 
HPLC chromatograms were collected and freeze dried and MALDI-TOF Mass 
spectrometry was performed on this sample. Figure 7.5 shows that the mass 
spectrometry of the peak 1 and 2 from the Preparative HPLC revealed the presence 
of correct compound. 
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Figure A1.4: Purification of crude Tat peptide. The chromatograms obtained from 
the RP-HPLC. a) Analytical HPLC run for the crude Tat peptide. b) The Preparative 
HPLC for crude Tat peptide.  
 
 
Figure A1.5: Mass spectrometry of Tat peptide. MALDI-TOF Mass spectrometry of 
Tat peptide peak 1 obtained from the Preparative HPLC column. This image shows 
that the correct peak at the 1443 indicating presence of Tat peptide in the purified 
sample. 
 
Both peaks 1 and 2 (not shown) gave the same MALDI mass spectrometry result. 
The presence of Tat peptide was confirmed by the peak at approximately 1441. 
Hence, sample peak 1 was chosen for further studies.  
 
Peptide Tat-LK15 was also synthesized by a lab member. Similar purifications were 
performed and the mass of the peptide sample was confirmed by MALDI-TOF Mass 
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spectrometry. As shown in Figure 3.5 the peak was observed at 3282, which is the 
molecular mass of the Tat-LK15 peptide. 
 
 
 
 
Figure A1.6: Mass spectrometry of Tat-LK15 peptide. This figure shows the 
MALDI-TOF Mass spectrometry of the Tat-LK15 peptide.  This image shows the 
presence of the correct peptide in the purified sample by showing a peak at 3282. 
 
A1.5 Determining the peptide concentration  
The concentration of Penetratin was determined by measuring its absorbance at 
280nm due to the presence of two Tryptophan residues within the sequence. The 
concentration of the stock solution was found to be10.04 mg/ml.  
 
Since, Tat and Tat LK15 have no Tryptophan or Tyrosine residues in its sequence, 
the concentration of the peptide was found by performing an amino acid analysis 
performed at the University of Cambridge, Department of Biochemistry. The 
concentration of stock solution of the Tat peptide was found to be 58.5mg/ml and 
that of Tat-LK15 was found to be 1.64 mg/ml. 
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A1.6 Determination of transfection efficiency of Penetratin, Tat and 
Tat-LK15 
Preliminary studies were focussed on the determination of transfection efficiencies of 
peptides Penetratin, Tat and Tat-LK15 in K562 suspension cells. Luciferase assays 
were performed on K562 cells 24 hours after transfection with the 
peptide/pEGFPLuc complexes formed at various charge ratios. Figure 7.7 shows that 
the transfection efficiency of Tat-LK15 was 10 to 100 fold higher than Tat peptide 
confirming the same observation made by Saleh et al. (2010). Tat-LK15 peptide also 
showed higher transfection efficiency than Penetratin peptide for all the charge ratios 
tested, indicating that the conjugation of LK15 peptide to Tat peptide has 
significantly increased the transfection efficiency of Tat-LK15.   
 
 
Figure A1.7: Transfection efficiency of peptides Penetratin, Tat and Tat-LK15. 
Luciferase assay performed on K562 cells transfected with the peptides complexed to 
pEGFPLuc at various charge ratios.  
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Appendix 2 
A2.1 Gene Sequencing 
A large amount of the plasmid DNA samples was prepared and then the DNA of 
required concentration was given for DNA sequence analysis. DNA Sequencing was 
carried out to confirm the presence of insert and its location. The DNA sequencing 
was done by the DNA sequencing facility at the university. The results from the 
sequencing reveal the insertion of the correct DNA. There was some error in the 
sequencing due to the failure of the instrument to read with high accuracy of 
sequences which formed hairpin structures. Hence, these minor errors have been 
ignored for the moment. The primers for gene sequencing are listed in section 
3.11.11 was used here. Based on the sequence given in the Ambion instruction 
manual, the sequences obtained from the DNA sequencing results were deciphered 
and verified against the insert sequences. 
 
B3A2 Forward Primer  
GNNNNANNNAATTCCCTCCTAAGGGAGGAGAAGCATGNAATTCCCCAGTGGNAAAGACGCGCAGGCAAAACGCACCACGT 
GACGGAGCGTGACCGCGCGCCGAGCGCGCGCCAAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATATTTG 
CATATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTG 
ACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAA 
CTTGAAAGTATTTCGATTTCTTGGGTTTATATATCTTGTGGAAAGGACGCGGGATCCGCAGAGTTCAAAAGCCCTTCTCA 
AGAGAAAGGGCTTTTGAACTCGGCTTTTTTGGAAAAGCTTGGCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAAC 
CCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGA 
TCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTA 
TTTCACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACA 
CCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCAT 
GTGTCAAAGGTTTTCACCGTCATCACCGAACCGCGCGAGACAAAGGGCCTCGTGATACGCCTATTTTTTATAGGTTAATG 
TCATGATAAAAAATGGTTTCTTANACCTTAAGTGGCACTTTTCGGGGAAATGTGCGCGGAAACCCCTATTTGTTTAATTT 
TCTAAATACTTTAAATNAGTNCCCCCTCAGGAACAAANCCCTGANAAAGGC 
 
B3A2 Reverse Primer  
NNNNNNNGNTTTTCCNTNCNACGTTGTAAAACGACGGCCAGTGCCAAGCTTTTCCAAAAAAGCCGAGTTCAAAAGCCCTT 
TCTCTTGAGAAGGGCTTTTGAACTCTGCGGATCCCGCGTCCTTTCCACAAGATATATAAACCCAAGAAATCGAAATACTT 
TCAAGTTACGGTAAGCATATGATAGTCCATTTTAAAACATAATTTTAAAACTGCAAACTACCCAAGAAATTATTACTTTC 
TACGTCACGTATTTTGTACTAATATCTTTGTGTTTACAGTCAAATTAATTCTAATTATCTCTCTAACAGCCTTGTATCGT 
ATATGCAAATATGAAGGAATCATGGGAAATAGGCCCTCTTCCTGCCCGACCTTGGCGCGCGCTCGGCGCGCGGTCACGCT 
CCGTCACGTGGTGCGTTTTGCCTGCGCGTCTTTCCACTGGGGAATTCATGCTTCTCCTCCCTTTAGTGAGGGTAATTCTC 
TCTCTCTCCCTATAGTGAGTCGTATTAATTCCTTCTCTTCTATAGTGTCACCTAAATCGTTGCAATTCGTAATCATGTCA 
TAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTG 
GGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCC 
AGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGAC 
TCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACNGTTATCCCACAGAATCAG 
GGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCANGAACCGTAAAANGGCCGCGTTGCTGGCGTTT 
TTCCATAGGCCTCCGCCCCCCTGAACGAGCATCACAAAAATCGACGCTCAANTCAGAGTGGCGAAACCCGACAGGACATN 
AAAGATACCA 
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